Government Regulation
Regulation of Clinical Trials
The clinical investigation of new drugs is highly regulated by government agencies. The standard for the conduct of clinical research and development studies is Good Clinical Practice, which stipulates procedures designed to ensure the quality and integrity of data obtained from clinical testing and to protect the rights and safety of clinical subjects.
Regulatory authorities, including the
Food and Drug Administration
(“FDA”), have promulgated regulations and guidelines that pertain to applications to initiate trials of products, the approval and conduct of studies, report and record retention, informed consent, applications for the approval of drugs and post-marketing requirements. Pursuant to these regulations and guidelines, service providers that assume the obligations of a drug sponsor are required to comply with applicable regulations and are subject to regulatory action for failure to comply with such regulations and guidelines. In the United States and Europe, the trend has been in the direction of increased regulation and enforcement by the applicable regulatory authority.
In providing our services in the United States, we are obligated to comply with FDA requirements governing such activities. These include ensuring that the study is approved by an appropriate independent review board (“IRB”)/Ethics Committee, obtaining patient informed consents, verifying qualifications of investigators, reporting patients’ adverse reactions to drugs and maintaining thorough and accurate records. We must maintain critical documents for each study for specified periods, and such documents may be reviewed by the study sponsor and the FDA during audits.
The services we provide outside the United States are ultimately subject to similar regulation by the relevant regulatory authority, including the Medicines and Healthcare products Regulatory Agency Medicines Control Agency in the United Kingdom and the Bundesinstitut für Arzneimittel und Medizinprodukte in Germany. In addition, our activities in Europe are affected by the European Medicines Evaluation Agency, which is based in London, England.
We must retain records for each study for specified periods for inspection by the client and by the applicable regulatory authority during audits. If such audits show that we have failed to comply adequately with applicable regulations and guidelines, it could result in a material adverse effect. In addition, our failure to comply with applicable regulations and guidelines, depending on the extent of the failure, could result in fines, debarment, termination or suspension of ongoing research, the disqualification of data or litigation by clients, any of which could also result in a material adverse effect.
Potential Liability and Insurance
We contract with physicians who serve as investigators in conducting clinical trials to test new drugs on their patients. Such testing creates a risk of liability for personal injury to or death of the patients resulting from adverse reactions to the drugs administered. In addition, although we do not believe that we should be legally accountable for the medical care rendered by third party investigators, it is possible that we could be subject to claims and expenses arising from any professional malpractice of the investigators with whom we contract. We also could be liable for errors and/or omissions in connection with the services we perform and this could result in us being liable to make large payments to sponsor(s) and/or other parties.
From time to time, we are asked to act as the legal representative of a client in certain jurisdictions. As we believe that acting as legal representative of clients might expose us to a higher risk of liability, there is a designated entity within the ICON Group which is generally used to provide this service in relevant jurisdictions subject to certain preconditions being met. The preconditions relate to obtaining protections such as specific insurance and indemnities from the client to cover the nature of the exposure.
We believe that the risk of liability to patients in clinical trials is mitigated by various regulatory requirements, including the role of institutional review boards and the need to obtain each patient’s informed consent. The FDA requires each human clinical trial to be reviewed and approved by the institutional review board at each study site. An institutional review board is an independent committee that includes both medical and non-medical personnel and is obligated to protect the interests of patients enrolled in the trial. After the trial begins, the institutional review board monitors the protocol and measures designed to protect patients, such as the requirement to obtain informed consent.
We further attempt to reduce our risks through seeking contractual indemnification provisions with clients and through insurance maintained by clients, investigators and us. However, the contractual indemnifications from our clients generally do not protect us in certain circumstances or against our own actions such as our negligence or poor performance. The terms and scope of such indemnification vary from client to client and from trial to trial, and the financial performance of these indemnities is not secured. Therefore, we bear the risk that the indemnity may not be sufficient or that the indemnifying party may not have the financial ability to fulfill its indemnification obligations. In addition, we also indemnify our clients where our performance does not reach the required contractual standard, such as our negligence or poor performance. We maintain worldwide professional liability insurance and while we believe that our insurance coverage is adequate there can be no assurance that we will continue to be able to maintain such insurance coverage on terms acceptable to us, if at all, or that the policy will respond and provide cover when we want it to. We could be materially adversely affected if we were required to pay damages or bear the costs of defending any claim outside the scope of or in excess of a contractual indemnification provision or beyond the level of insurance coverage or if our insurance cover does not cover the relevant circumstances or in the event that an indemnifying party does not fulfill its indemnification obligations.
Description of Property
Our principal executive offices are located in South County Business Park, Leopardstown, Dublin, Republic of Ireland, where we own an office facility of approximately 15,000 square meters. We lease all other properties under operating leases.
We maintain three offices in New York, two offices in each of the following US locations: Chicago, San Antonio and Philadelphia and one office in each of the following U.S. locations: Baltimore, Bethesda, Boston, Houston, Los Angles, Morristown, Nashville, Omaha, Raleigh, San Diego, San Francisco and Wilmington.
Our European operations maintain two offices in Amsterdam, Milan, Munich and Stockholm and one office in each of the following locations: Barcelona, Berlin, Brussels, Bucharest, Budapest, Copenhagen, Frankfurt, Helsinki, Kiev, Limerick, London, Madrid, Manchester, Marlow, Moscow, Oxford, Paris, Prague, Riga, Southampton, Tel Aviv, Vilnius, Warsaw and Zurich.
We also maintain two offices in Bangalore and Singapore and one office in each of the following locations: Auckland, Bangkok, Beijing, Bogota, Buenos Aires, Chennai, Hong Kong, Johannesburg, Lima, Manila, Mexico City, Montreal, Osaka, Santiago, Sao Paolo, Seoul, Shanghai, Sydney, Taipei, Tianjin, Tokyo, Toronto, Trivandrum and Vancouver.
Organizational Structure
Details of the Company’s significant operating subsidiaries are as follows:
Name
|
Country of incorporation
|
Group ownership*
|
|
|
|
ICON Clinical Research Limited
|
Republic of Ireland
|
100%
|
|
|
|
ICON Holdings
|
Republic of Ireland
|
100%
|
|
|
|
ICON Holdings Clinical Research International Limited
|
Republic of Ireland
|
100%
|
|
|
|
DOCS Resourcing Limited
|
Republic of Ireland
|
100%
|
|
|
|
Firecrest Clinical Limited
|
Republic of Ireland
|
100%
|
|
|
|
ICON Development Solutions, LLC
|
Delaware, USA
|
100%
|
|
|
|
ICON Development Solutions, LLC
|
Maryland, USA
|
100%
|
|
|
|
ICON Clinical Research, Inc.
|
USA
|
100%
|
|
|
|
ICON Central Laboratories, Inc.
|
USA
|
100%
|
|
|
|
Beacon Bioscience, Inc.
|
USA
|
100%
|
|
|
|
Healthcare Discoveries, LLC
|
USA
|
100%
|
|
|
|
Oxford Outcomes Inc.
|
USA
|
100%
|
|
|
|
PriceSpective LLC
|
USA
|
100%
|
|
|
|
ClinForce LLC
|
USA
|
100%
|
|
|
|
DOCS International Belgium N.V
|
Belgium
|
100%
|
|
|
|
ICON Clinical Research EOOD
|
Bulgaria
|
100%
|
|
|
|
ICON Research Ltd. (Ispitivanja ICON d.o.o)
|
Croatia
|
100%
|
|
|
|
ICON Clinical Research s.r.o.
|
Czech Republic
|
100%
|
|
|
|
DOCS International Nordic Countries A/S
|
Denmark
|
100%
|
|
|
|
DOCS International Finland Oy
|
Finland
|
100%
|
|
|
|
ICON Clinical Research S.A.R.L.
|
France
|
100%
|
|
|
|
DOCS International France S.A.S.
|
France
|
100%
|
|
|
|
ICON Clinical Research GmbH
|
Germany
|
100%
|
|
|
|
DOCS International Germany GmbH
|
Germany
|
100%
|
|
|
|
ICON Clinical Research Kft (ICON Klinikai Kutató Kft)
|
Hungary
|
100%
|
|
|
|
ICON Clinical Research Israel Limited
|
Israel
|
100%
|
The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements, accompanying notes and other financial information, appearing in Item 18. The Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States.
Overview
We are a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. Our vision is to be the Global CRO partner of choice for the Biopharma industry by delivering best in class information, solutions and performance in clinical and outcomes research.
We believe that we are one of a select group of CRO’s with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. At December 31, 2012, we employed approximately 9,500 employees, in 82 locations in 40 countries. During the year ended December 31, 2012 we derived approximately 42.3%, 45.8% and 11.9% our net revenue in the United States, Europe and Rest of World, respectively.
Revenue consists primarily of fees earned under contracts with third-party clients. In most cases, a portion of the contract fee is paid at the time the study or trial is started, with the balance of the contract fee generally payable in installments over the study or trial duration, based on the achievement of certain performance targets or "milestones". Revenue from contracts is recognized on a proportional performance method based on the relationship between time incurred and the total estimated duration of the trial or on a fee-for-service basis according to the particular circumstances of the contract. As is customary in the CRO industry, we contract with third party investigators in connection with clinical trials. All investigator fees and certain other costs, where reimbursed by clients, are, in accordance with industry practice, deducted from gross revenue to arrive at net revenue. As these costs vary from contract to contract, we view net revenue as our primary measure of revenue growth.
As the nature of our business involves the management of projects having a typical duration of one to four years, the commencement or completion of projects in a fiscal year can have a material impact on revenues earned with the relevant clients in such years. In addition, as we typically work with some, but not all, divisions of a client, fluctuations in the number and status of available projects within such divisions can also have a material impact on revenues earned from such clients from year to year.
Termination or delay in the performance of an individual contract may occur for various reasons, including, but not limited to, unexpected or undesired results, production problems resulting in shortages of the drug, adverse patient reactions to the drug, the client’s decision to de-emphasize a particular trial or inadequate patient enrolment or investigator recruitment. In the event of termination the Company is usually entitled to all sums owed for work performed through the notice of termination and certain costs associated with the termination of the study. In addition, contracts generally contain provisions for renegotiation in the event of changes in the scope, nature, duration, or volume of services of the contract. The Company’s results of operations and cash flows are therefore not materially impacted by project cancellations or delays.
Our backlog consists of potential net revenue yet to be earned from projects awarded by clients. At December 31, 2012 we had a backlog of approximately $2.8 billion, compared with approximately $2.3 billion at December 31, 2011. We believe that our backlog as of any date is not necessarily a meaningful predictor of future results, due to the potential for cancellation or delay of the projects underlying the backlog, and no assurances can be given on the extent to which we will be able to realize this backlog as net revenue.
Direct costs consist primarily of compensation, associated fringe benefits and share based compensation expense for project-related employees and other direct project driven costs. Selling, general and administrative expenses comprise primarily of compensation, related fringe benefits and share based compensation expense for non project-related employees, recruitment expenditure, professional service costs, advertising costs and all costs related to facilities and information systems.
Although we are domiciled in Ireland, we report our results in U.S. dollars. As a consequence the results of our non-U.S. based operations, when translated into U.S. dollars, could be materially affected by fluctuations in exchange rates between the U.S. dollar and the currencies of those operations.
In addition to translation exposures, we are also subject to transaction exposures because the currency in which contracts are priced can be different from the currencies in which costs relating to those contracts are incurred. Our operations in the United States are not materially exposed to such currency differences as the majority of our revenues and costs are in U.S. dollars. However, outside the United States the multinational nature of our activities means that contracts are usually priced in a single currency, most often U.S. dollars or Euros, while costs arise in a number of currencies, depending, among other things, on which of our offices provide staff for the contract and the location of investigator sites. Although many such contracts benefit from some degree of natural hedging, due to the matching of contract revenues and costs in the same currency, where costs are incurred in currencies other than those in which contracts are priced, fluctuations in the relative value of those currencies could have a material effect on our results of operations. We regularly review our currency exposures and usually negotiate currency fluctuation clauses in our contracts which allow for price negotiation if changes in the relative value of those currencies exceed predetermined tolerances.
As we conduct operations on a global basis, our effective tax rate has depended and will depend on the geographic distribution of our revenue and earnings among locations with varying tax rates. Our results therefore may be affected by changes in the tax rates of the various jurisdictions. In particular, as the geographic mix of our results of operations among various tax jurisdictions changes, our effective tax rate may vary significantly from period to period.
Operating Results
The following table sets forth for the periods indicated certain financial data as a percentage of net revenue and the percentage change in these items compared to the prior comparable period. The trends illustrated in the following table may not be indicative of future results.
|
|
Year Ended December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
Percentage of Net Revenue
|
|
|
Percentage Increase/(Decrease)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue
|
|
|
100
|
%
|
|
|
100
|
%
|
|
|
17.9
|
%
|
|
|
5.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs
|
|
|
64.4
|
%
|
|
|
64.7
|
%
|
|
|
17.3
|
%
|
|
|
13.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
25.2
|
%
|
|
|
27.1
|
%
|
|
|
9.7
|
%
|
|
|
10.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
3.8
|
%
|
|
|
4.1
|
%
|
|
|
10.7
|
%
|
|
|
14.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations (excluding restructuring and other items)
|
|
|
6.6
|
%
|
|
|
4.1
|
%
|
|
|
87.6
|
%
|
|
|
(57.4
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other items
|
|
|
0.5
|
%
|
|
|
1.0
|
%
|
|
|
(42.6
|
%)
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations (including restructuring and other items)
|
|
|
6.1
|
%
|
|
|
3.1
|
%
|
|
|
131.0
|
%
|
|
|
(68.0
|
%)
|
Year ended December 31, 2012 compared to year ended December 31, 2011
Net revenue for the year increased by $169.3 million, or 17.9%, from $945.7 million for the year ended December 31, 2011 to $1,115.0 million for the year ended December 31, 2012. Net revenue in our clinical research segment increased by $153.3 million, or 17.5%, from $874.2 million for the year ended December 31, 2011 to $1,027.5 million for the year ended December 31, 2012. In our central laboratory business net revenue increased by $16.0 million, or 22.4%, from $71.5 million for the year ended December 31, 2011 to $87.5 million for the year ended December 31, 2012. Net revenue derived from the acquisitions of BeijingWits Medical and PriceSpective amounted to $21.0 million for the year ended December 31, 2012. For the year ended December 31, 2012 we derived approximately 42.3%, 45.8% and 11.9% of our net revenue in the United States, Europe and Rest of World, respectively.
Net revenue in Ireland increased from $88.9 million for the year ended December 31, 2011 to $172.0 million for the year ended December 31, 2012. Net revenue in Ireland is principally a function of the Company’s global transfer pricing model. Significant investment in personnel and related infrastructure in the prior period, to support new strategic partnerships and the expansion into new territories, resulted in an increased proportion of the Company’s net revenue being used to support other Group entities and a corresponding reduction in net revenue in Ireland. Increased revenue flows in the current period, driven by this upfront investment, has led to an increase in net revenue in Ireland in the current period.
Direct costs for the year increased by $105.8 million, or 17.3%, from $611.9 million for the year ended December 31, 2011 to $717.7 million for the year ended December 31, 2012. As a percentage of net revenue, direct costs have decreased from 64.7% for the year ended December 31, 2011 to 64.4% for the year ended December 31, 2012. Direct costs in our clinical research segment have increased by 16.6% or $93.4 million during the year. As a percentage of net revenue direct costs in our clinical research segment have decreased from 64.4% for the year ended December 31, 2011 to 63.9% for the year ended December 31, 2012. In our central laboratory business, direct costs have increased by 25.5% or $12.4 million during the year. As a percentage of net revenue direct costs in our central laboratory business have increased from 68.2% for the year ended December 31, 2011 to 70.0% for the year ended December 31, 2012.
Selling, general and administrative expenses for the year increased by $24.9 million, or 9.7%, from $255.9 million for the year ended December 31, 2011 to $280.8 million for the year ended December 31, 2012. The increase in selling, general and administration expense for the period arose primarily from an increase in personnel related expenditure of $20.4 million and an increase in other general overhead costs of $4.3 million. These increases were offset by the decrease in facilities and related costs of $1.5 million. Selling, general and administrative costs for the year ended December 31, 2011 included the release of $1.7 million in respect of accrued contingent consideration relating to the Timaq acquisition. This amount was released as the Company had assessed the likelihood of the achievement of the earn-out targets related to this consideration as remote. In our clinical research segment, selling, general and administrative expenses increased by $25.4 million or 10.7% during the year. This was offset by a decrease in our central laboratory business, where selling general and administrative expenses decreased by $0.5 million or 2.6%. As a percentage of net revenue, selling, general and administrative expenses, decreased from 27.1% for the year ended December 31, 2011 to 25.2% for the year ended December 31, 2012.
Total share based compensation expense recognized during the years ended December 31, 2012 and December 31, 2011 amounted to $11.5 million and $9.4 million respectively.
Depreciation expense for the period increased by $1.2 million, or 3.5%, from $34.0 million for the year ended December 31, 2011 to $35.2 million for the year ended December 31, 2012, principally as a result of our continued investment in facilities, information systems and equipment to support the Company’s growth. As a percentage of net revenue, depreciation expense decreased from 3.6% of net revenues for the year ended December 31, 2011 to 3.2% for the year ended December 31, 2012. Amortization expense for the year increased by $2.9 million, or 61.7%, from $4.7 million for the year ended December 31, 2011 to $7.6 million for the year ended December 31, 2012. Amortization expense represents the amortization of intangible assets acquired on business combinations. The increase in the amortization expense in the current year is primarily a result of intangible assets acquired from the acquisitions of BeijingWits Medical and PriceSpective in February 2012. As a percentage of net revenue, amortization expense increased from 0.5% of net revenues for the year ended December, 2011 to 0.7% of net revenues for the year ended December 31, 2012.
Restructuring and other items of $5.6 million were recorded during the year ended December 31, 2012 (inclusive of the release of $0.1 million relating to the 2011 Restructuring Plans). During the year ended December 31, 2012 the Company completed a review of its operations to improve resource utilization throughout the business. This review resulted in the adoption of a restructuring plan, to include resource rationalizations in certain areas of the business and a re-organization of available office space at the Company’s Philadelphia facility. A restructuring charge of $4.6 million was recognized during the year ended December 31, 2012; $3.4 million in respect of resource rationalizations and $1.2 million in respect of lease termination and exit costs. The Company also incurred certain other charges in relation to the retirement of Mr. Peter Gray, former Vice Chairman of the Board and former CEO of the Company of $1.1 million for the year ended 31 December 2012 (
see note 14 Restructuring and other non-recurring items for further information).
As a result of the above, income from operations for the year ended December 31, 2012 increased by $38.6 million as follows:
|
|
Operating
Income
|
|
|
Operating Margin
*
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
|
|
|
Clinical research
|
|
$
|
64,116
|
|
|
$
|
31,649
|
|
|
|
6.2
|
%
|
|
|
3.6
|
%
|
Central laboratory
|
|
|
3,901
|
|
|
|
(2,206
|
)
|
|
|
4.5
|
%
|
|
|
(3.1
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
68,017
|
|
|
$
|
29,443
|
|
|
|
6.1
|
%
|
|
|
3.1
|
%
|
* Operating income as a percentage of net revenue
Income from operations excluding the impact of restructuring and other items recognized (adjusted operating income) for the year ended December 31, 2012 increased by $34.4 million as follows:
|
|
Adjusted Operating
Income
|
|
|
Adjusted Operating Margin
*
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
|
|
|
Clinical research
|
|
$
|
69,594
|
|
|
$
|
39,921
|
|
|
|
6.8
|
%
|
|
|
4.6
|
%
|
Central laboratory
|
|
|
4,059
|
|
|
|
(661
|
)
|
|
|
4.6
|
%
|
|
|
(0.9
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
73,653
|
|
|
$
|
39,260
|
|
|
|
6.6
|
%
|
|
|
4.1
|
%
|
* Adjusted operating income as a percentage of net revenue
Losses from operations in Ireland decreased from a loss of $34.7 million for the year ended December 31, 2011, or $33.1 million excluding the impact of restructuring and other items recognized, to a profit of $9.7 million for year ended December 31, 2012, or $11.7 million excluding the impact of restructuring and other non-recurring costs. Income/(losses) from operations in Ireland are impacted by the Group’s global transfer pricing model. In 2011, a significant upfront investment in personnel and related infrastructure in the prior period led to a greater proportion of the Group’s revenue being used to support other Group entities and a corresponding increase in losses from operations in Ireland. Increased revenue flows in the current period, arising from this upfront investment in personnel and related infrastructure, has led to an increase in income from operations in 2012.
Interest expense increased from $1.6 million for the year ended December 31, 2011 to $1.9 million for the year ended December 31, 2012. Interest expense for the year ended December 31, 2012 includes $0.9 million in respect of non-cash finance charges relating to acquisition contingent consideration. Interest income for the period remained at $1.2 million for the year ended December 31, 2011 and the year ended December 31, 2012.
Provision for income taxes for the period increased from $6.1 million for the year ended December 31, 2011 to $11.8 million for the year ended December 31, 2012. The Company’s effective tax rate for the year ended December 31, 2012 was 17.6% compared with 21.1% for the year ended December 31, 2011. Excluding the impact of restructuring and other non-recurring items the Company’s effective tax rate was 17.2% for the year ended December 31, 2012 compared with 18.9% for the year ended December 31, 2011. The Company’s effective tax rate is principally a function of the distribution of pre-tax profits in the territories in which it operates.
Year ended December 31, 2011 compared to year ended December 31, 2010
Net revenue for the year increased by $45.7 million, or 5.1%, from $900.0 million for the year ended December 31, 2010 to $945.7 million for the year ended December 31, 2011. Net revenue in our clinical research segment increased by $38.0 million, or 4.5% from $836.2 million for the year ended December 31, 2010 to $874.2 million for the year ended December 31, 2011. In our central laboratory business net revenue increased by $7.7 million, or 12.1% from $63.8 million for the year ended December 31, 2010 to $71.5 million for the year ended December 31, 2011. Net revenue on the acquisition of Oxford Outcomes Limited and Firecrest Clinical Limited amounted to $29.7 million for the year ended December 31, 2011. For the year ended December 31, 2011 we derived approximately 41.7%, 46.2% and 12.1% of our net revenue in the United States, Europe and Rest of World, respectively.
Net revenue in Ireland decreased from $128.9 million for the year ended December 31, 2010 to $88.9 million for the year ended December 31, 2011. Net revenue in Ireland is principally a function of the Company’s global transfer pricing model. Upfront investment by various group entities in personnel and related infrastructure to support new strategic partnerships and the expansion into new territories has resulted in a greater portion of the Company’s net revenue being used to support these entities and a corresponding reduction in net revenue in Ireland.
Direct costs for the year increased by $70.5 million, or 13.0%, from $541.4 million for the year ended December 31, 2010 to $611.9 million for the year ended December 31, 2011. As a percentage of net revenue, direct costs have increased from 60.1% for the year ended December 31, 2010 to 64.7% for the year ended December 31, 2011. Direct costs in our clinical research segment have increased by 13.9% or $68.5 million during the year. As a percentage of net revenue direct costs in our clinical research segment have increased from 59.1% for the year ended December 31, 2010 to 64.4% for the year ended December 31, 2011. The Company has entered a number of strategic partnerships with sponsors during the year and further expanded operations in certain territories. This has necessitated significant upfront investment in personnel and related infrastructure in advance of anticipated revenue flows from this business. In our central laboratory business, direct costs have increased by 4.2% or $2.0 million during the year. As a percentage of net revenue direct costs in our central laboratory business have decreased from 73.4% for the year ended December 31, 2010 to 68.2% for the year ended December 31, 2011 a result of restructuring activities undertaken in early 2011, together with ongoing cost management and improved resource utilization.
Selling, general and administrative expenses for the year increased by $23.2 million, or 10.0%, from $232.7 million for the year ended December 31, 2010 to $255.9 million for the year ended December 31, 2011. The increase in selling, general and administration expense for the period arose primarily from an increase in facilities and related costs of $13.7 million, an increase in personnel related expenditure of $8.1 million, including increases in recruitment expenditure and travel costs associated with non-project related employees, and an increase in professional services costs of $11.1 million. These increases were offset by the release of certain non-recurring tax related provisions of $6.0 million in both our clinical research and central laboratory business, arising from receipt of additional information in relation to these items, and a decrease in other general overhead costs of $2.0 million. Selling, general and administrative costs for the year ended December 31, 2011 also include the release of $1.7 million in respect of certain milestones pertaining to the Timaq acquisition which were released during the year as the Company has assessed the likelihood of these milestones being achieved as remote. In our clinical research segment, selling, general and administrative expenses increased by $29.5 million or 14.2% during the year. This was offset by a decrease in our central laboratory business, where selling general and administrative expenses decreased by $6.3 million or 25.4%. As a percentage of net revenue, selling, general and administrative expenses, increased from 25.9% for the year ended December 31, 2010 to 27.1% for the year ended December 31, 2011.
Total share based compensation expense recognized during the years ended December 31, 2011 and December 31, 2010 amounted to $9.4 million and $7.4 million respectively.
Depreciation expense for the period increased by $2.6 million, or 8.3%, from $31.4 million for the year ended December 31, 2010 to $34.0 million for the year ended December 31, 2011, principally as a result of our continued investment in facilities, information systems and equipment to support the Company’s growth. As a percentage of net revenue, depreciation expense increased from 3.5% of net revenues for the year ended December 31, 2010 to 3.6% of net revenues for the year ended December 31, 2011. Amortization expense for the year increased by $2.2 million, or 90.0%, from $2.5 million for the year ended December 31, 2010 to $4.7 million for the year ended December 31, 2011. Amortization expense represents the amortization of intangible assets acquired on business combinations. As a percentage of net revenue, amortization expense increased from 0.3% of net revenues for the year ended December, 2010 to 0.5% of net revenues for the year ended December 31, 2011.
During the three months ended March 31, 2011 the Company commenced a review of its operations to improve resource utilization within the business and better align resources to current and future growth opportunities of the business. This review resulted in the adoption of an initial restructuring plan (the “Q1 Restructuring Plan”), the closure of the Company’s facility in Edinburgh, United Kingdom and resource rationalizations in certain of the more mature markets in which it operates. A restructuring charge of $5.0 million in respect of this plan was recognized during the three months ended March 31, 2011, $1.0 million in respect of lease termination and exit costs associated with the closure of the Edinburgh facility and $4.0 million in respect of workforce reductions. $3.5 million of costs recognized under the Q1 Restructuring Plan related to the clinical research segment, while $1.5 million related to our central laboratory business. During the three months ended September 30, 2011 the Company implemented a further restructuring plan (the “Q3 Restructuring Plan”) which resulted in the relocation of the Company’s facility in Maryland, USA; and further resource rationalizations. A restructuring charge of $4.8 million was recognized during the three months ended September 30, 2011 in respect of this plan, $0.9 million in respect of lease termination and exit costs associated with the closure of the existing Maryland facility and $3.9 million in respect of workforce reductions. All costs recognized under the Q3 Restructuring Plan related to the clinical research segment.
As a result of the above, income from operations for the year ended December 31, 2011 decreased by $62.7 million as follows:
|
|
Operating
Income
|
|
|
Operating Margin
*
|
|
|
|
2011
|
|
|
2010
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
Clinical research
|
|
$
|
31,649
|
|
|
$
|
104,854
|
|
|
|
3.6
|
%
|
|
|
12.5
|
%
|
Central laboratory
|
|
|
(2,206
|
)
|
|
|
(12,759
|
)
|
|
|
(3.1
|
)%
|
|
|
(20.0
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
29,443
|
|
|
$
|
92,095
|
|
|
|
3.1
|
%
|
|
|
10.2
|
%
|
* Operating income as a percentage of net revenue
Excluding the impact of restructuring and other items recognized, income from operations for the year ended December 31, 2011 decreased by $52.9 million as follows:
|
|
Adjusted Operating
Income
|
|
|
Adjusted Operating Margin
*
|
|
|
|
2011
|
|
|
2010
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
Clinical research
|
|
$
|
39,921
|
|
|
$
|
104,854
|
|
|
|
4.6
|
%
|
|
|
12.5
|
%
|
Central laboratory
|
|
|
(661
|
)
|
|
|
(12,759
|
)
|
|
|
(0.9
|
)%
|
|
|
(20.0
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
39,260
|
|
|
$
|
92,095
|
|
|
|
4.1
|
%
|
|
|
10.2
|
%
|
* Adjusted operating income as a percentage of net revenue
Income/(loss) from operations in Ireland decreased from income of $36.6 million for the year ended December 31, 2010 to a loss of $34.7 million, or $33.1 million excluding the impact of restructuring and other items recognized, for the year ended December 31, 2011. Income/(loss) from operations in Ireland are impacted by the Group’s global transfer pricing model. This decrease in income/(loss) from operations is principally due to the reduction in net revenue in Ireland during the period together with an increase in personnel and related infrastructure costs to support the Company’s growth.
Interest expense for the period increased from $1.1 million for the year ended December 31, 2010 to $1.6 million for the year ended December 31, 2011. Interest expense for the year ended December 31, 2011 includes $0.8 million in respect of the unwinding of the discount of the Firecrest contingent consideration. Interest income for the period decreased from $1.8 million for the year ended December 31, 2010 to $1.2 million for the year ended December 31, 2011, as a result of lower cash balances during the year ended December 31, 2011.
Provision for income taxes increased from $5.7 million for the year ended December 31, 2010 to $6.1 million for the year ended December 31, 2011. The Company’s effective tax rate for the year ended December 31, 2011 was 21.1% compared with 6.1% for the year ended December 31, 2010. During the year ended December 31, 2011 the Company recognized $2.9 million in unrecognized tax benefits for uncertain tax positions, arising from the expiration of the relevant statute of limitations in certain jurisdictions, thereby allowing for the recognition of these benefits. During the year ended December 31, 2010 the Company recognized $9.7 million in unrecognized tax benefits for uncertain tax positions, arising from both the settlement of positions with the relevant tax authorities and the expiration of the relevant statute of limitations in certain jurisdictions, resulting in the recognition of these benefits. Excluding the impact of the release of uncertain tax provisions the Company would have had an effective tax rate of 31.1% for the year ended December 31, 2011, compared to an effective tax rate of 17.0% for the year ended December 31, 2010.
Liquidity and Capital Resources
The CRO industry is generally not capital intensive. The Group’s principal operating cash needs are payment of salaries, office rents, travel expenditures and payments to investigators. Investing activities primarily reflect capital expenditures for facilities and information systems enhancements, the purchase and sale of short term investments and acquisitions.
Our clinical research and development contracts are generally fixed price with some variable components and range in duration from a few weeks to several years. Revenue from contracts is generally recognized as income on the basis of the relationship between time incurred and the total estimated contract duration or on a fee-for-service basis. The cash flow from contracts typically consists of a small down payment at the time the contract is entered into, with the balance paid in installments over the contract's duration, in some cases on the achievement of certain milestones. Accordingly, cash receipts do not correspond to costs incurred and revenue recognized on contracts.
The Company’s cash and short-term investment balances at December 31, 2012 amounted to $190.2 million, comprising cash and cash equivalents $114.0 million and short-term investments $76.2 million. The Company’s cash and short-term investment balances at December 31, 2011 amounted to $174.1 million, comprising cash and cash equivalents $119.2 million and short-term investments $54.9 million.
Amounts available to the Group under negotiated facilities amounted to $150.0 million at December 31, 2012, compared with $150.0 million at December 31, 2011. On July 20, 2011 the Company entered into a three year committed multi currency revolving credit facility for $150.0 million with Citibank, JP Morgan, Ulster Bank, Deutsche Bank and Barclays Bank. Each bank subject to the agreement has committed $30 million to the facility, with equal terms and conditions in place with all institutions. The facility bears interest at LIBOR plus a margin and includes certain composite guarantees, indemnities and pledges in favor of the banks. The full amount of this facility was available to the Group at December 31, 2012 and December 31, 2011.
Net cash provided by operating activities was $113.4 million for the year ended December 31, 2012 compared with net cash provided by operating activities of $20.2 million for the year ended December 31, 2011. The most significant influence on our operating cash flow is revenue outstanding, which comprises accounts receivable and unbilled revenue, less payments on account. The dollar value of these balances and the related number of days revenue outstanding (i.e. revenue outstanding as a percentage of revenue for the period, multiplied by the number of days in the period) can vary over a study or trial duration. Contract fees are generally payable in installments based on the achievement of certain performance targets or “milestones” (e.g. target patient enrollment rates, clinical testing sites initiated or case report forms completed), such milestones being specific to the terms of each individual contract, while revenues on contracts are recognized as contractual obligations are performed. Days revenue outstanding can vary therefore due to, amongst others, the scheduling of contractual milestones over a study or trial duration, the achievement of a particular milestone during the period or the timing of cash receipts from customers. A decrease in the number of days revenue outstanding during a period will result in cash inflows to the Company while an increase in days revenue outstanding will lead to cash outflows. The number of days revenue outstanding at December 31, 2012 was 40 days compared to 47 days at December 31, 2011. This, together with the increase in income from operations during the year, resulted in the increase in cash inflows from operations during the year ended December 31, 2012.
Net cash used in investing activities was $121.1 million for the year ended December 31, 2012 compared to net cash used in investing activities of $152.4 million for the year ended December 31, 2011. Net cash used in the year ended December 31, 2012 arose principally from cash paid for acquisitions, capital expenditures and the purchase of short-term investments.
During the year ended December 31, 2012 the Company completed the acquisitions of BeijingWits Medical and PriceSpective. The Company acquired BeijingWits Medical for an initial cash consideration of $9.0 million, with $0.6 million in cash received on acquisition. The Company acquired PriceSpective for an initial cash consideration of $37.1 million, with $2.3 million cash received on acquisition. A further $5.0 million was also paid during the period in respect of certain performance milestones to PriceSpective. In addition, a number of payments were made by the company during the period in respect of prior year acquisitions, CHF 0.3 million ($0.3 million) in respect of curtained performance milestones for Timaq Medical Imaging, $4.5 million in respect of certain performance milestones and working capital targets for Oxford Outcomes and $17.0 million in respect of certain performance milestones and working capital targets for Firecrest. Additional amounts payable at December 31, 2012 in relation to acquisitions include $45.9 million potentially payable contingent upon the results of acquired businesses; including PriceSpective ($10.0 million); BeijingWits Medical ($7.0 million); Firecrest ($25.8 million) and Oxford Outcomes ($3.1 million).
(See note 4 Goodwill for further information relating to acquisitions and amounts potentially payable contingent upon the future results of acquired businesses).
Capital expenditure for the year ended December 31, 2012 amounted to $30.8 million, and comprised mainly of expenditure on global infrastructure and information technology systems to support the Company’s growth. During the year ended December 31, 2012 the Company invested a net $20.4 million in short-term investments.
Net cash used by financing activities during the year ended December 31, 2012 amounted to $1.2 million compared with net cash used by financing activities of $3.8 million for the year ended December 31, 2011. Net cash used by financing activities during the year ended December 31, 2012 arose primarily from cash paid to repurchase ordinary shares under the Company’s share repurchase program. During the year ended December 31, 2012 the Company repurchased 738,341 ordinary shares for a total consideration of $15.6 million. As at December 31, 2012 1,283,938 ordinary shares have been repurchased by the Company for a total consideration of $24.6 million.
(see Note 12
Share Capital
for further information).
During the year ended December 31, 2012 the Company received $13.0 million from the exercise of share options compared to $4.7 million from the exercise of share options during the year ended December 31, 2011.
As a result of these cash flows, cash and cash equivalents decreased by $5.2 million for the year ended December 31, 2012 compared to a decrease of $136.5 million for the year ended December 31, 2011.
Contractual obligations table
The following table represents our contractual obligations and commercial commitments as of December 31, 2012:
|
|
Payments due by period
|
|
|
|
Total
|
|
|
Less than
1 year
|
|
|
1 to 3
years
|
|
|
3 to 5
years
|
|
|
More than
5 years
|
|
|
|
(U.S.$ in millions)
|
|
Operating lease obligations
|
|
|
163.9
|
|
|
|
40.4
|
|
|
|
56.0
|
|
|
|
35.2
|
|
|
|
32.3
|
|
Non-current tax liabilities
|
|
|
7.2
|
|
|
|
4.6
|
|
|
|
1.9
|
|
|
|
0.5
|
|
|
|
0.2
|
|
Acquisition contingent consideration
|
|
|
45.9
|
|
|
|
45.9
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total (U.S.$ in millions)
|
|
$
|
217.0
|
|
|
$
|
90.9
|
|
|
$
|
57.9
|
|
|
$
|
35.7
|
|
|
$
|
32.5
|
|
We expect to spend approximately $30 million in the next twelve months on further investments in information technology, the expansion of existing facilities and the addition of new offices. We believe that we will be able to fund our additional foreseeable cash needs for the next twelve months from cash flow from operations, existing cash balances and funds available under negotiated facilities. In the future, we may consider acquiring businesses to enhance our service offerings and global presence. Any such acquisitions could require additional external financing and we may from time to time seek to obtain funds from public or private issues of equity or debt securities. There can be no assurance that such financing will be available on terms acceptable to us.
Critical Accounting Policies
The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and judgments that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period.
We base our estimates and judgments on historical experience and on the other factors that we believe are reasonable under current circumstances. Actual results may differ from these estimates if these assumptions prove to be incorrect or if conditions develop other than as assumed for the purposes of such estimates. The following is a discussion of the accounting policies used by us, which we believe are critical in that they require estimates and judgments by management.
Goodwill
We review our goodwill for impairment annually, or more frequently if facts or circumstances warrant such a review. We evaluate goodwill for impairment by firstly comparing the fair value of each reporting segment to its carrying value. Fair value is determined using the market approach, by assessing the market value of each reporting unit. If the carrying amount exceeds the fair value then a second step is completed which involves the fair value of the reporting unit being allocated to each asset and liability with the excess being implied goodwill. If the implied goodwill is lower than its carrying amount, goodwill is impaired and written down to its implied fair value.
Significant estimates and judgments are required in allocating the fair value of the reporting unit to each asset and liability. If we were to use different estimates or judgments a material impairment charge to the statement of operations could arise. We believe that we have used reasonable estimates and judgments in assessing the carrying value of our goodwill.
Revenue Recognition
Significant management judgments and estimates must be made and used in connection with the recognition of revenue in any accounting period. Material differences in the amount of revenue in any given period may result if these judgments or estimates prove to be incorrect or if management’s estimates change on the basis of development of the business or market conditions. To date there have been no material differences arising from these judgments and estimates.
We earn revenues by providing a number of different services to our clients. These services include clinical trials management, biometric activities, consulting, imaging, contract staffing and laboratory services. Revenue for services, as rendered, are recognized only after persuasive evidence of an arrangement exists, the sales price is fixed or determinable and collectability is reasonably assured.
Clinical trials management revenue is recognized on a proportional performance method. Depending on the contractual terms, revenue is either recognized on the percentage of completion method, based on the relationship between hours incurred and the total estimated hours of the trial, or on the unit of delivery method. Contract costs equate to the product of labor hours incurred and compensation rates. For the percentage of completion method, the input (effort expended) method has been used to measure progress towards completion as there is a direct relationship between input and productivity. Contract revenue is the product of the aggregated labor hours required to complete the specified contract tasks at the agreed contract rates. Where revenue is recognized on the unit of delivery method, the basis applied is the number of units completed as a percentage of the total number of contractual units.
We recognize biometric revenues on a fee-for-service basis as each unit of data is prepared. Imaging revenue is recognized on a fee-for-service basis recognizing revenue for each image completed. Consulting revenue is recognized on a fee-for-service basis recognizing revenue as each hour of the related service is performed. Contract staffing revenue is recognized on a fee-for-service basis, over the time the related service is performed, or in the case of permanent placement, once the candidate has been placed with the client. Informatics revenue is recognized on a fee-for-service basis.
Informatics contracts are treated as multiple element arrangements, with contractual elements comprising licence fee revenue, support fee revenue and revenue from software services, each of which can be sold separately. Sales prices for contractual elements are determined by reference to objective and reliable evidence of their sales price. Licence and support fee revenues are recognized rateably over the period of the related agreement. Revenue from software services is recognized using the percentage of completion method based on the relationship between hours incurred and the total estimated hours required to perform the service.
Laboratory service revenue is recognised on a fee-for-service basis. The Company accounts for laboratory service contracts as multiple element arrangements, with contractual elements comprising laboratory kits and laboratory testing, each of which can be sold separately. Sales prices for contractual elements are determined by reference to objective and reliable evidence of their sales price. Revenues for contractual elements are recognised on the basis of the number of deliverable units completed in the period.
We invoice our customers upon achievement of specified contractual milestones. This mechanism, which allows us to receive payment from our customers throughout the duration of the contract, is not reflective of revenue earned. We recognize revenues over the period from the awarding of the customer’s contract to study completion and acceptance. This requires us to estimate total expected revenue, time inputs, contract costs, profitability and expected duration of the clinical trial. The Company regularly reviews the estimate of total contract time to ensure such estimates remain appropriate taking into account actual contract stage of completion, remaining time to complete and any identified changes to the contract scope. Remaining time to complete depends on the specific contract tasks and the complexity of the contract and can include geographical site selection and initiation, patient enrolment, patient testing and level of results analysis required. While we may routinely adjust time estimates, estimates and assumptions historically have been accurate in all material respects in the aggregate.
If we do not accurately estimate the resources required or the scope of the work to be performed, or do not manage our projects properly within the planned cost or satisfy our obligations under the contracts, then future results may be significantly and negatively affected.
Taxation
Given the global nature of our business and the multiple taxing jurisdictions in which we operate, the determination of the Company’s provision for income taxes requires significant judgments and estimates, the ultimate tax outcome of which may not be certain. Although we believe our estimates are reasonable, the final outcome of these matters may be different than those reflected in our historical income tax provisions and accruals. Such differences could have a material effect on our income tax provision and results in the period during which such determination is made.
Deferred tax assets and liabilities are determined using enacted tax rates for the effects of net operating losses and temporary differences between the book and tax bases of assets and liabilities. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. While management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment, there can be no assurance that these deferred tax assets may be realizable.
In addition, we may also be subject to audits in the multiple taxing jurisdictions in which we operate. These audits can involve complex issues which may require an extended period of time for resolution. Management believe that adequate provisions for income taxes have been made in the financial statements.
Business Combinations
The Group has concluded a number of business combinations in recent years. The cost of a business combination is measured as the aggregate of the fair values at the date of exchange of assets given, liabilities incurred or assumed, and equity instruments issued in exchange for control. The cost of a business combination may include a portion which is contingent upon the achievement of certain future events, such as the achievement of a particular revenue or earnings target. Where a business combination agreement provides for such additional consideration, the amount of the estimated adjustment is recognised on the acquisition date fair value. Any changes to the estimate in subsequent periods will depend on the classification of the contingent consideration. If the contingent consideration is classified as equity it shall not be re-measured and the settlement shall be accounted for within equity. If the contingent consideration is classified as an asset or liability any adjustments will be accounted for through the Consolidated Statement of Operations or other comprehensive income depending on whether the asset or liability is considered a financial instrument.
Significant management judgments and estimates are required in estimating the acquisition date fair value of the additional consideration. Changes in business conditions or the performance of the acquired business could lead to a significant change between our estimate of the acquisition date fair value and amounts payable, which could have a material impact on our results of operations.
Impact of New Accounting Pronouncements
In July 2012, the FASB issued ASU No. 2012-02, Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. ASU 2012-02 allows an organization to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test for indefinite-lived intangible assets. An organization that elects to perform a qualitative assessment is required to perform the quantitative test for indefinite-lived intangible asset if it is more likely than not that the asset is impaired. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company does not expect the adoption of ASU 2012-02 to have a material impact on the financial statements.
In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210
): Disclosures about Offsetting Assets and Liabilities
. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). ASU 2011-11 is effective retrospectively for fiscal years beginning after January 1, 2013. The Company does not expect the adoption of ASU 2011-11 to have a material impact on the financial statements.
In September 2011, the FASB issued ASU No. 2011-08 Intangibles - Goodwill and Other (Topic 350):
Testing Goodwill for Impairment
. ASU 2011-08 permits an entity to make a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount before applying the two-step goodwill impairment test. If an entity concludes it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, it need not perform the two-step impairment test. ASU 2011- 08 is effective for fiscal years beginning after December 15, 2011. The Company does not expect the adoption of ASU 2011-08 to have a material impact on the financial statements.
In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220):
Presentation of Comprehensive Income.
ASU 2011-05 permits an entity to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. ASU 2011-05 is effective for fiscal years ending after December 15, 2012. In December 2011, the FASB decided to defer the effective date of those changes in ASU 2011-05 that relate only to the presentation of reclassification adjustments in the statement of income by issuing ASU 2011-12, Comprehensive Income (Topic 220):
Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive income in Accounting Standards Update 2011-05.
The Company does not expect the adoption of ASU 2011-05 to have a material impact on the financial statements.
In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement (Topic 820):
Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.
ASU 2011-04 provides guidance about how fair value should be applied where it already is required or permitted under IFRS or U.S. GAAP. For U.S. GAAP, most of the changes are clarifications of existing guidance or wording changes to align with IFRS. ASU 2011- 04 is effective prospectively for interim and annual periods beginning after December 15, 2011. The Company does not expect the adoption of ASU 2011-04 to have a material impact on the financial statements.
Inflation
We believe that the effects of inflation generally do not have a material adverse impact on our operations or financial conditions.
Directors and Senior Management
The following table and accompanying biographies set forth certain information concerning each of ICON plc’s directors, officers and other key employees as of
March 6, 2013
.
Name
|
Age
|
Position
|
Thomas Lynch
(2)
(3) (4) (5)
|
56
|
Chairman of the Board, Director
|
Ciaran Murray
(1) (5)
|
50
|
Chief Executive Officer, Director
|
Brendan Brennan
(1) (5)
|
34
|
Chief Financial Officer
|
Dr. John Climax
(6)
|
60
|
Director
|
Dr. Ronan Lambe
(6)
|
73
|
Director
|
Dr. Bruce Given
(2) (4)
|
58
|
Director
|
Professor Dermot Kelleher
(3) (6)
|
57
|
Director
|
Declan McKeon
(3) (4)
|
61
|
Director
|
Cathrin Petty
(2) (4)
|
39
|
Director
|
Professor William Hall
(2) (3) (6)
|
63
|
Director
|
Dr. Steven Cutler
|
52
|
Group President Clinical Research Services
|
Diarmaid Cunningham
|
38
|
General Counsel & Company Secretary
|
(1)
|
Executive Officer of the Company.
|
(2)
|
Member of Compensation and Organization Committee.
|
(3)
|
Member of Audit Committee.
|
(4)
|
Member of Nominating and Governance Committee.
|
(5)
|
Member of Execution Committee.
|
(6)
|
Member of Quality Committee.
|
Thomas Lynch
was appointed Chairman of Board of the Company in January 2013. He has served as an outside director of the Company since January 1996. Mr. Lynch served as Chairman and Chief Executive Officer of Amarin Corporation from December 2007 to December 2009, during which time he re-purposed and refinanced the company towards the development of Vascepa for hypertriglyceridemia and dislipidemia. Mr Lynch retired from the Board of Amarin in October 2010 but continues to serve as Chairman of Amarin Pharmaceuticals Ireland Ltd. Mr. Lynch served in a variety of senior roles in Elan Corporation plc from 1993 to 2004. He was a director of IDA Ireland from 2001 to 2010 and of the Royal Opera House (Covent Garden) from 2001 to 2010. He currently serves as a director of GW Phamaceuticals plc, is Chairman of Dublin Academic Medical Centre and the Queens University of Belfast Foundation. He also serves as a board member of a number of public and privately held pharmaceutical companies.
Ciaran Murray
was appointed Chief Executive Officer of the Company in October 2011. Mr. Murray joined ICON in 2005 as Chief Financial Officer, a position he held until his appointment as Chief Executive Officer. Prior to joining the Company he held a number of senior financial positions in global organisations including Kraft Foods, Novell Inc, Northern Foods and Codec Systems. Mr Murray graduated with a Bachelor of Commerce degree from the University College Dublin and qualified as a Chartered Accountant with PricewaterhouseCoopers in 1988.
Brendan Brennan
has served as Chief Financial Officer since February 2012 having previously served as Acting Chief Financial Officer since October 2011. Prior to this appointment he served in a number of senior finance roles in the Company including the role of Senior Vice President of Corporate Finance. Mr. Brennan has been a senior member of the Company’s finance team since January 2006. Prior to this he developed his corporate finance experience in Cement Roadstone Holdings, a major Irish building materials organization. Mr. Brennan qualified as a chartered accountant with PricewaterhouseCoopers and obtained a bachelors degree in Accounting and Finance from Dublin City University.
Dr. John Climax
, one of the Company’s co-founders, served as Chairman of the Board of the Company from November 2002 to December 2009, and Chief Executive Officer from June 1990 to October 2002. From January 2010 he has held a position as an outside director of the Company. Dr. Climax has over 25 years of experience in the contract research industry. Dr. Climax received his primary degree in pharmacy in 1977 from the University of Singapore, his masters in applied pharmacology in 1979 from the University of Wales and his Ph.D. in pharmacology from the National University of Ireland in 1982. He has authored a significant number of papers and presentations, and holds adjunct professorship at the Royal College of Surgeons of Ireland.
Dr. Ronan Lambe
, one of the Company’s co-founders, served as Chairman of the Board of the Company from June 1990 to November 2002. He has served as an outside director of the Company since January 2008. Dr. Lambe has over 30 years of experience in the contract research industry. Dr. Lambe attended the National University of Ireland where he received his Bachelor of Science degree in chemistry in 1959, his masters in biochemistry in 1962 and his Ph.D. in pharmacology in 1976.
Dr. Bruce Given
has served as an outside director of the Company since September 2004. He served as Chairman of the Board of the Company from January 2010 to December 2012. In October 2011, he was appointed to the position of Chief Operating Officer of Arrowhead Research Corporation. From March 2002 until June 2007 he served as President and Chief Executive Officer of Encysive Pharmaceuticals Inc. Dr. Given previously held various positions in Johnson & Johnson group companies. Dr. Given obtained his doctorate from the University of Chicago in 1980.
Professor Dermot Kelleher
has served as an outside director of the Company since May 2008. Professor Kelleher is currently Principal at the Faculty of Medicine at Imperial College London and Dean of the Lee Kong Chian School of Medicine Singapore, a partnership between Imperial College London and Nanyang Technological University (NTU), which was formed in 2010. From 2004 to 2012 he was Head of the School of Medicine and Vice Provost for Medical Affairs at Trinity College, Dublin, Ireland. His research interests are broad ranging in the fields of Gastroenterology, Immunology and Molecular Biology and over a distinguished thirty year career he has led significant research projects in this field. Alongside his notable academic appointments he has served as a visiting research scientist with a major pharmaceutical company and has been a founder of a number of biotechnology companies.
Declan McKeon
has served as an outside director of the Company since April 2010. Mr. McKeon was a partner in PricewaterhouseCoopers from 1986 to 2007. His roles included leadership of the audit and business advisory team for PricewaterhouseCoopers Ireland, membership on the PwC Europe audit and business advisory services executive and market sector lead for consumer and industrial products. Mr. McKeon is a non-executive director of Ryanair plc, remains a consultant to PricewaterhouseCoopers and sits on the audit committee of the Royal College of Surgeons in Ireland. Mr. McKeon holds a Bachelor of Commerce and Masters in Business Studies from University College Dublin and is a Fellow of The Institute of Chartered Accountants in Ireland.
Cathrin Petty
has served as an outside director of the Company since October 2010. Ms. Petty is a Special Partner at Vitruvian Partners LLP and is an outside director for Healthcare at Home Ltd and Circassia Ltd. Ms. Petty is an advisor to the pharmaceutical industry and formerly served as an outside director for the NHS (Strategic Health Authority for Greater London). Between 2000 and 2010, Ms. Petty was a Healthcare Partner in Apax Partners LLP with responsibility for originating, executing, monitoring and exiting healthcare private equity investments. Her early career included Senior Associate and Research Analyst roles at Schroder Ventures Life Sciences and Schroders Investment Management.
Professor William Hall
has served as an outside Director of the Company since February 2013. He is a renowned expert in infectious diseases and virology, is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism. Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He previously served as an Assistant and Associate Professor of Medicine at Cornell University. Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.
Dr. Steven Cutler
was appointed Group President Clinical Research Services in November 2011. Prior to joining the Company Dr. Cutler held the position of Chief Executive Officer of Kendle, having previously served as Chief Operating Officer.
Prior to Kendle, Dr. Cutler spent 14 years with Quintiles where he served as Senior Vice President, Global Project Management; Senior Vice President, Clinical, Medical and Regulatory; Senior Vice President, Project Management - Europe; and Vice President, Oncology - Europe as well as regional leadership positions in South Africa and Australia. Prior to joining Quintiles Dr. Cutler held positions with Sandoz (now Novartis) in Australia and Europe. He holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).
Diarmaid Cunningham
is the Company’s General Counsel and Company Secretary. Mr. Cunningham joined the Company in November 2009 and was appointed Company Secretary in October 2011. Mr Cunningham spent 10 years with A&L Goodbody, one of Ireland's premier corporate law firms prior to joining the Company. Mr. Cunningham graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997 and qualified as a Solicitor with A&L Goodbody in 2001.
Board Practices
Board of Directors
The business of the Company is managed by the directors who may exercise all the powers of the Company which are not required by the Companies Acts 1963 to 2012 of Ireland or by the Articles of Association of the Company to be exercised by the Company in general meeting. A meeting of directors at which a quorum is present may exercise all powers exercisable by the directors. The directors may delegate (with power to sub-delegate) to any director holding any executive office and to any Committee consisting of one or more directors, together with such other persons as may be appointed to such Committee by the directors, provided that a majority of the members of each Committee appointed by the directors shall at all times consist of directors and that no resolution of any such Committee shall be effective unless a majority of the members of the Committee present at the meeting at which it was passed are directors.
The Board comprises one executive and eight outside-directors at the date of this report. The outside-directors bring independent judgment to bear on issues of strategy, performance, resources, key appointments and standards. The Company considers all of its outside-directors to be of complementary skills, experience and knowledge and each outside-director has specific skills, experience and knowledge that are valuable to the Company. Board members between them have very strong financial, pharmaceutical, CRO, scientific, medical and other skills and knowledge which are harnessed to address the challenges facing the Group. The Board meets regularly throughout the year and all Directors have full and timely access to the information necessary for them to discharge their duties. There is a formal schedule of matters reserved to the Board for consideration and decision including approval of strategic plans, financial statements, acquisitions, material capital expenditures and review of the effectiveness of the Company’s system of internal controls, thereby maintaining control of the Company and its future direction. The Directors have access to the advice and services of the Company Secretary and may seek external independent professional advice where required. The Board considers its current size (9 directors) to be adequate but continues to look for suitable qualified potential candidates to join the Board.
As detailed below, certain other matters are delegated to Board Committees and all Board Committees report to the Board. The Company maintains what it considers an appropriate level of insurance cover in respect of legal action against its Directors. The Board, through the Compensation and Organization Committee, engages in succession planning for the Board and in so doing considers the strength and depth of the Board and the levels of knowledge, skills and experience of the directors necessary for the Company to achieve its objectives. The Board normally meets at least four times each year. During the year ended December 31, 2012 the Board met on four occasions. Additional Board updates were held on 7 occassions, to consider specific issues and provide updates to the Board on various items. All directors allocated sufficient time to the Company during the year ended December 31, 2012 to effectively discharge their responsibilities to the Company.
Directors’ retirement and re-election
The Company’s Articles of Association provide that, unless otherwise determined by the Company at a general meeting, the number of directors shall not be more than 15 nor less than 3. At each annual general meeting, one third of the directors who are subject to retirement by rotation, rounded down to the next whole number if it is a fractional number, shall retire from office. The directors to retire shall be those who have been longest in office, but as between persons who became or were last re-appointed on the same day, those to retire shall be determined, unless otherwise agreed, by lot. Any additional director appointed by the Company shall hold office until the next annual general meeting and will be subject to re-election at that meeting. Accordingly, at the annual general meeting of the Company to be held in 2013, it is anticipated that two directors will retire by rotation and offer themselves for re-election. In addition,
Professor William Hall
, having been appointed a Director by the Company in
February 2013
, will also offer himself for re-election.
Board committees
The Board has delegated some of its responsibilities to Board Committees. There are five permanent Committees. These are the Audit Committee, the Compensation and Organization Committee, the Nominating and Governance Committee, the Execution Committee and the Quality Committee. Each Committee has been charged with specific responsibilities and each has written terms of reference that are reviewed periodically. Minutes of Committee meetings are available to all members of the Board. The Company Secretary is available to act as secretary to each of the Board Committees if required. Appropriate key executives are regularly invited to attend meetings of the Board committees. Each committee Chairman informally evaluated the contribution of each Committee member during the year ended December 31, 2012 and was satisfied with each director’s contribution.
Audit Committee
The Audit Committee meets a minimum of four times a year. It reviews the quarterly and annual financial statements, the effectiveness of the system of internal control (including the arrangement for the Company’s employees to raise concerns in confidence about financial inappropriateness) and recommends the appointment and removal of the external auditors. It monitors the adequacy of internal accounting practices and addresses all issues raised and recommendations made by the external auditors. It pre-approves on an annual basis, the audit and non-audit services provided to the Company by its external auditors. Such annual pre-approval is given with respect to particular services. The Audit Committee, on a case by case basis, may approve additional services not covered by the annual pre-approval, as the need for such services arises. The Audit Committee reviews all services which are provided by the external auditors regularly to review the independence and objectivity of the external auditors taking into consideration relevant professional and regulatory requirements so that these are not impaired by the provisions of permissible non-audit services. The Chief Executive Officer, Chief Financial Officer, the Head of Internal Audit, the General Counsel and the external auditors normally attend all meetings of the Audit Committee and have direct access to the Committee Chairman at all times. During 2012, the Audit Committee comprised Declan McKeon (Chairman), Thomas Lynch and Professor Dermot Kelleher. In February 2013, composition of the Audit Committee was amended to comprise Declan McKeon (Chairman), Thomas Lynch, Professor Dermot Kelleher and Professor William Hall.
Compensation and Organization Committee
The Compensation and Organization Committee is responsible for senior executive remuneration. The committee aims to ensure that remuneration packages are competitive so that individuals are appropriately rewarded relative to their responsibility, experience and value to the Company. Annual bonuses for the executive directors and senior executive management are determined by the committee based on the achievement of the Company’s objectives. The Committee also oversees succession planning for the Company’s senior management.
During 2012, the Compensation and Organization Committee comprised Thomas Lynch (Chairman), Dr. Bruce Given, and Declan McKeon. In February 2013, composition of the Compensation and Organization Committee was amended to comprise Cathrin Petty (Chairperson), Thomas Lynch , Dr. Bruce Given and Professor William Hall.
Nominating and Governance Committee
The Nominating and Governance Committee reviews the membership of the Board of the Company and Board committees on an ongoing basis. As part of this it regularly evaluates the balance of skills, knowledge and experience on the Board and then based on this evaluation, identifies and, if appropriate, recommends individuals to join the Board of the Company. The Committee used in 2012 an external search consultant to assist it in identifying potential new outside directors. Once potential suitable candidates are identified either by the external search consultants or by members of the Nominating Committee, the Committee then discusses and considers the skills, knowledge and experience of the potential candidate. The Committee will assess if the Board of the Company requires and would benefit from the potential candidate’s skills knowledge and experience and if it decides the potential candidate is suitable and would add relevant skills, knowledge and experience to the Board of the Company, the Committee recommends to the Board of the Company that the potential candidate be appointed. The Board of the Company then decides whether or not to appoint the candidate. The Committee considers diversity of the Board members when making recommendations to the Board of the Company. The Committee also reviews and recommends the corporate governance principles of the Company.
During 2012 the Nominating and Governance Committee comprised Dr. Bruce Given (Chairman), Thomas Lynch and Cathrin Petty. In February 2013, composition of the Nomination and Governance Committee was amended to comprise Thomas Lynch (Chairman), Cathrin Petty, Dr. Bruce Given and Declan McKeon.
Execution Committee
The primary function of the Execution Committee is to exercise the powers and authority of the board in intervals between meetings of the board within the limits set out in the Charter of the Execution Committee. The Execution Committee exercises business judgment to act in what the committee members reasonably believe to be in the best interest of the Company and its shareholders. All powers exercised by the Execution Committee are ratified at board meetings. This Committee convenes as often as it determines to be necessary or appropriate. During 2012, the Execution Committee comprised Ciaran Murray (Chairman), Dr. Bruce Given and Brendan Brennan. In February 2013, composition of the Execution Committee was amended to comprise Ciaran Murray (Chairman), Thomas Lynch and Brendan Brennan.
Quality Committee
The purpose of the Quality Committee is to provide oversight of the quality strategy and initiatives in place within the Company. As part of this the Committee is required to review the Company’s strategy in relation to quality and quality management systems and to review continuous improvement initiatives and activities in place within the Company. The Committee is also responsible for reviewing reports and recommendations issued to the Company by such third party consultants and/or auditors retained to evaluate the Company’s quality systems and initiatives and to review reports and results of inspections and/or audits by internal and external auditors or regulatory agencies (including the FDA and European Medicines Agency). During 2012 the Quality Committee comprised Professor Dermot Kelleher (Chairman), Dr. Ronan Lambe and Dr. John Climax. In February 2013, composition of the Quality Committee was amended to comprise Professor Dermot Kelleher (Chairman), Dr. Ronan Lambe, Dr. John Climax and Professor William Hall.
Executive Officers and Directors Remuneration
Compensation Discussion & Analysis
Remuneration policy
The Compensation and Organization Committee seeks to achieve the following goals with the Company’s executive compensation programs: to attract, motivate and retain key executives and to reward executives for value creation. The Committee seeks to foster a performance-oriented environment by ensuring that a significant portion of each executive’s cash and equity compensation is based on the achievement of performance targets that are important to the Company and its shareholders.
The Company’s executive compensation program has three elements: base salary, a bonus plan and equity incentives in the form of share related awards granted under the Company’s equity incentive plans. All elements of key executives compensation are determined by the Committee based on the achievement of the Group’s objectives.
Outside Directors’ remuneration
Outside Directors are remunerated by way of Directors’ fees and are also eligible for participation in the share option scheme. Outside Directors are not eligible for performance related bonuses and no pension contributions are made on their behalf. The Board of Directors as a whole, taking into account input from the Execution Committee of the Board of Directors, sets non-Executive remuneration.
Executive Directors’ and Key Executive Officers’ remuneration
Total cash compensation is divided into a base salary portion and a bonus incentive portion. Base salary is established based on peer group and is adjusted based on individual performance and experience. The Committee targets total cash compensation at the peer group median of comparable Irish companies and peer CRO companies, adjusted upward or downward based on individual performance and experience. The Committee believes that the higher the executive’s level of responsibility within the Company, the greater the percentage of the executive’s compensation that should be tied to the Company’s performance. Target bonus incentive for executive officers range between 60% and 125% of base salary.
An additional bonus was also awarded by the Committee in respect of 2012 to certain key executive officers to reflect their contribution in the successful turnaround in the performance of the Company during the year and the creation of a platform to allow for the delivery of long-term sustainable returns to the Company’s shareholders. This bonus will be payable in either cash or ordinary shares of the Company (at the discretion of the Committee) over the period up to December 31, 2015.
The Company’s executives are eligible to receive equity incentives, including stock options and restricted share units, granted under the Company’s equity incentive plans. If executives receive equity incentive grants, they are normally approved annually at the first regularly scheduled meeting of the Committee in the fiscal year and awarded at the closing price on the second full day following the release of the Company’s prior year results. Newly hired executives may receive sign-on grants, if approved by the Committee. In addition, the Committee may, in its discretion, issue additional equity incentive awards to executives if the Committee determines such awards are necessary to ensure appropriate incentives are in place. The number of equity awards granted to each participant is determined primarily based on an award range determined by the Committee at the start of each year. The extent of existing options is not generally considered in granting equity awards, except that the Company occasionally grants an initial round of equity awards to newly recruited executives to provide them a stake in the Company’s success from the commencement of their employment. The Company granted equity incentive awards to executive officers in its fiscal years ended December 31, 2010, December 31, 2011 and December 31, 2012 (
see Share Ownership section for further information
).
All executive officers are eligible to participate in a defined contribution pension plan. The Company’s contributions are generally a fixed percentage of their annual compensation, supplementing contributions by the executive. The Company has the discretion to make additional contributions if deemed appropriate by the Committee. The Company’s contributions are determined at the peer group median of comparable Irish companies and peer CRO companies. Contributions to this plan are recorded as an expense in the Consolidated Statement of Operations.
Executive Compensation
Summary compensation table - Year ended December 31, 2012
Name & principal position
|
Year
|
|
Salary
|
|
|
Bonus
|
|
|
Pension
contribution
|
|
|
All other compensation
|
|
|
Subtotal
|
|
|
Subtotal
|
|
|
Share-based
compensation
|
|
|
Director’s Fees
|
|
|
Total
compensation
|
|
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
Peter Gray,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vice Chairman of the Board *
|
2012
|
|
|
402
|
|
|
|
194
|
|
|
|
50
|
|
|
|
27
|
|
|
|
673
|
|
|
|
862
|
|
|
|
1,029
|
|
|
|
-
|
|
|
|
1,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ciaran Murray,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer
|
2012
|
|
|
606
|
|
|
4,230***
|
|
|
863
|
|
|
|
28
|
|
|
5,727
|
|
|
7,374
|
|
|
|
1,942
|
|
|
|
-
|
|
|
9,316
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brendan Brennan,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer**
|
2012
|
|
|
262
|
|
|
1,416****
|
|
|
|
32
|
|
|
|
20
|
|
|
1,730
|
|
|
2,228
|
|
|
|
174
|
|
|
|
-
|
|
|
2,402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
2012
|
|
|
1,270
|
|
|
5,840
|
|
|
945
|
|
|
|
75
|
|
|
8,130
|
|
|
10,464
|
|
|
|
3,145
|
|
|
|
-
|
|
|
13,609
|
|
*
|
Retired on July 19, 2012.
|
**
|
Appointed Chief Financial Officer on February 13, 2012.
|
***
|
€4.2 million ($5.5 million) payable up to December 31, 2015 in cash or ordinary shares. The timing and form of the bonus is at the discretion of the Compensation and Organization Committee.
|
****
|
€1.2 million ($1.5 million) payable up to December 31, 2015 in cash or ordinary shares. The timing and form of the bonus is at the discretion of the Compensation and Organization Committee.
|
Summary compensation table - Year ended December 31, 2011
Name & principal position
|
Year
|
|
Salary
|
|
|
Bonus
|
|
|
Pension
contribution
|
|
|
All other compensation
|
|
|
Subtotal
|
|
|
Subtotal
|
|
|
Share-based
compensation
|
|
|
Director’s Fees
|
|
|
Total
compensation
|
|
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
Peter Gray,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vice Chairman of the Board *
|
2011
|
|
|
533
|
|
|
|
187
|
|
|
|
57
|
|
|
|
37
|
|
|
|
814
|
|
|
|
1,139
|
|
|
|
586
|
|
|
|
-
|
|
|
|
1,725
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ciaran Murray,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer *
|
2011
|
|
|
458
|
|
|
|
150
|
|
|
|
196
|
|
|
|
22
|
|
|
|
826
|
|
|
|
1,155
|
|
|
|
564
|
|
|
|
-
|
|
|
|
1,719
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
2011
|
|
|
991
|
|
|
|
337
|
|
|
|
253
|
|
|
|
59
|
|
|
|
1,640
|
|
|
|
2,294
|
|
|
|
1,150
|
|
|
|
-
|
|
|
|
3,444
|
|
*
|
Appointed Vice Chairman and Chief Executive Officer respectively on October 1, 2011.
|
**
|
The above table does not include Brendan Brennan who assumed the role of Acting CFO on October 1, 2011 and was appointed CFO on February 13, 2012.
|
Director Compensation
Summary compensation table
-
Year ended December 31, 2012
Name
|
Year
|
|
Salary
|
|
|
Company
pension
contribution
|
|
|
All other compensation
|
|
Subtotal
|
|
|
Subtotal
|
|
|
Share-based
compensation
|
|
|
Director’s
fees
|
|
|
Total
Compensation
|
|
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
€
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
Bruce Given*
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
29
|
|
|
|
317
|
|
|
|
346
|
|
Peter Gray**
|
2012
|
|
|
402
|
|
|
|
50
|
|
|
|
221
|
|
|
673
|
|
|
|
862
|
|
|
|
1,029
|
|
|
|
-
|
|
|
|
1,891
|
|
Ciaran Murray
|
2012
|
|
|
606
|
|
|
863
|
|
|
4,258***
|
|
5,727
|
|
|
7,374
|
|
|
1,942
|
|
|
|
-
|
|
|
9,316
|
|
John Climax
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
10
|
|
|
|
52
|
|
|
|
62
|
|
Ronan Lambe
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
19
|
|
|
|
53
|
|
|
|
72
|
|
Thomas Lynch
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
19
|
|
|
|
78
|
|
|
|
97
|
|
Dermot Kelleher
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
21
|
|
|
|
73
|
|
|
|
94
|
|
Declan McKeon
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
|
|
73
|
|
|
|
86
|
|
Cathrin Petty
|
2012
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
10
|
|
|
|
51
|
|
|
|
61
|
|
Total
|
2012
|
|
|
1,008
|
|
|
913
|
|
|
4,479
|
|
6,400
|
|
|
8,236
|
|
|
3,092
|
|
|
|
697
|
|
|
12,025
|
|
*
|
Retired as Chairman on December 31, 2012
|
**
|
Retired on July 19, 2012
|
***
|
€
4.2 million ($5.5 million) payable up to December 31, 2015 in cash or ordinary shares. The timing and form of the bonus is at the discretion of the Compensation and Organization Committee
|
Summary compensation table - Year ended December 31, 2011
|
|
|
|
|
|
|
|
|
|
Name
|
Year
|
|
Salary
|
|
|
Company
pension
contribution
|
|
|
All other compensation
|
|
Subtotal
|
|
|
Subtotal
|
|
|
Share-based
compensation
|
|
|
Director’s
fees
|
|
|
Total
compensation
|
|
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
|
€
|
’000
|
|
€
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
|
$
|
’000
|
|
Bruce Given
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
29
|
|
|
|
317
|
|
|
|
346
|
|
Peter Gray
|
2011
|
|
|
533
|
|
|
|
57
|
|
|
|
224
|
|
|
814
|
|
|
|
1,139
|
|
|
|
586
|
|
|
|
-
|
|
|
|
1,725
|
|
Ciaran Murray*
|
2011
|
|
|
134
|
|
|
|
42
|
|
|
|
57
|
|
|
233
|
|
|
|
321
|
|
|
|
273
|
|
|
|
-
|
|
|
|
594
|
|
John Climax
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
6
|
|
|
|
48
|
|
|
|
54
|
|
Ronan Lambe
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
19
|
|
|
|
53
|
|
|
|
72
|
|
Thomas Lynch
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
23
|
|
|
|
71
|
|
|
|
94
|
|
Dermot Kelleher
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
28
|
|
|
|
73
|
|
|
|
101
|
|
Anthony Murphy**
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
10
|
|
|
|
78
|
|
|
|
88
|
|
Declan McKeon
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
9
|
|
|
|
61
|
|
|
|
70
|
|
Cathrin Petty
|
2011
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
-
|
|
|
|
-
|
|
|
|
7
|
|
|
|
59
|
|
|
|
66
|
|
Total
|
2011
|
|
|
667
|
|
|
|
99
|
|
|
|
281
|
|
|
1,047
|
|
|
|
1,460
|
|
|
|
990
|
|
|
|
760
|
|
|
|
3,210
|
|
*
|
Appointed Director of the Company on October 1, 2011 ** Retired on December 31, 2011
|
Disclosure of Compensation Agreements
Employment Contracts, Termination of Employment and Change in Control Arrangements
The Company does not have any termination or change of control agreements with its named executive officers other than as set out below.
Directors’ and Executive Officers’ service agreements and letters of engagement
Mr. Thomas Lynch
Mr. Thomas Lynch has served as Chairman of the Board of the Company since January 2013 and has served as an outside director of the Company since January 1996. The arrangements with Mr. Lynch provide for the payment to him of director fees
of $330,000 p
er annum (pre January 1, 2013: $78,000 per annum) plus reasonable expenses properly incurred in carrying out his duties for the Company. He was previously granted and held at December 31, 2012 17,200 ordinary share options at exercise prices ranging from $11.00 to $35.33 per share.
Mr. Ciaran Murray
Mr. Ciaran Murray is currently Chief Executive Officer of the Company, a position he has held since October 2011. He has served as an Executive Director of the Company since October 2011. He previously served as Chief Financial Officer of the Company from October 2005 until October 2011. The service agreement with Mr. Murray is terminable on 12 months notice by either party. Under the terms of this agreement Mr. Murray is entitled to receive an annual salary of €630,000 ($830,000) and a bonus to be agreed by the Compensation and Organization Committee. He is also entitled to receive a pension contribution, a company car and medical insurance coverage for himself and his dependants. He was previously granted and held at December 31, 2012 345,000 ordinary share options at exercise prices ranging from $10.42 to $35.33 per share and 200,000 Restricted Share Units which vest on various dates between April 2013 and February 2016. His service agreement requires him to devote his full time and attention to his duties for the Company excepting certain outside director positions authorized by the Board. The agreement with Mr. Murray includes termination and change of control provisions and also includes certain post-termination clauses including non-disclosure, non-competition and non-solicitation provisions.
Mr Brendan Brennan
Brendan Brennan
has served as Chief Financial Officer since February 2012 having previously served as acting Chief Financial Officer since October 2011. Prior to this appointment he served in a number of senior finance roles in the Company including the role of Senior Vice President of Corporate Finance. The service agreement with Mr. Brennan is terminable on 12 months notice by either party. Under the terms of this agreement Mr. Brennan is entitled to receive an annual salary of €300,000 ($396,000) and a bonus to be agreed by the Compensation and Organization Committee. He is also entitled to receive a pension contribution, a company car and medical insurance coverage for himself and his dependants. He was previously granted and held at December 31, 2012 29,840 ordinary share options at exercise prices ranging from $20.28 to $35.33 per share and 20,000 Restricted Share Units, which vest on February 21, 2015, the third anniversary of date of grant. His service agreement requires him to devote his full time and attention to his duties for the Company excepting certain outside director positions authorized by the Board. The agreement with Mr. Brennan includes termination and change of control provisions and also includes certain post-termination clauses including non-disclosure, non-competition and non-solicitation provisions.
Dr. John Climax
Dr. John Climax, one of the Company’s co-founders, served as Chairman of the Board of the Company from November 2002 to December 2009. He also served as Chief Executive Officer of the Company from June 1990 to October 2002 and is currently an outside director of the Company. The arrangements with Dr. Climax provide for the payment to him of director fees of $53,000 per annum (pre: February 15, 2013: $53,000 per annum) plus reasonable expenses properly incurred in carrying out his duties for the Company. He was previously granted and held at December 31, 2012 90,000 ordinary share options at exercise prices ranging from $11.00 to $35.33 per share.
Following Dr. Climax’s retirement as Chairman in December 2009, the Company entered a three year agreement with Rotrua Limited, a company controlled by Dr. Climax, for the provision of consultancy services at an agreed fee of €262,500 ($346,000) per annum. Pursuant to the consultancy agreement, Dr. Climax also agreed to certain restrictions that will apply to him after the termination of the consultancy agreement including non-disclosure, non-competition and non-solicitation. The consultancy agreement provided that the Company would provide, during the term of the agreement, permanent disability and life insurance coverage for Dr. Climax and medical insurance coverage for himself and his dependants. The term of the consultancy agreement expired in December 2012.
Dr. Ronan Lambe
Dr. Ronan Lambe, one of the Company’s co-founders, served as Chairman of the Board of the Company from June 1990 to November 2002 and is currently an outside director of the Company. The arrangements with Dr. Lambe provide for the payment to him of director fees of $53,000 per annum (pre: February 15, 2013: $53,000 per annum) plus reasonable expenses properly incurred in carrying out his duties for the Company. He was previously granted and held at December 31, 2012 16,000 ordinary share options at exercise prices ranging from $11.00 to $35.33 per share.
Dr. Bruce Given
Dr. Bruce Given is an outside director of the Company. He served as Chairman of the Board of the Company from January 2009 to December 2012 and has served as an outside director of the Company since September 2004. The arrangements with Dr. Given provide for the payment to him of annual fees of $58,000 per annum (pre January 1, 2013: $316,932 per annum) plus reasonable expenses properly incurred in carrying out his duties for the Company. He was previously granted and held at December 31, 2012 24,000 ordinary share options at exercise prices ranging from $11.00 to $35.33.
Professor Dermot Kelleher
Professor Dermot Kelleher
has served as an outside director of the Company since May 2008. The arrangements with Professor Kelleher provide for the payment to him of director fees of $73,000 per annum (pre: February 15, 2013: $73,000 per annum). He was previously granted and held at December 31, 2012 14,000 ordinary share options at an exercise price ranging from $20.28 to $36.04.
Mr. Declan McKeon
Mr. Declan McKeon has served as an outside director of the Company since April 2010. The arrangements with Mr. McKeon provide for the payment to him of directors fees of $73,000 per annum (pre: February 15, 2013: $73,000 per annum). He was previously granted and held at December 31, 2012 7,000 ordinary share options at exercise prices ranging from $20.28 to $29.45.
Ms Cathrin Petty
Ms. Cathrin Petty has served as an outside director of the Company since October 2010. The arrangements with Ms. Petty provide for the payment to her of directors fees of $73,000 per annum (pre: February 15, 2013: $53,000 per annum). She was previously granted and held at December 31, 2012 7,000 ordinary share options at exercise prices ranging from $19.45 to $22.30.
Professor William Hall
Professor William Hall has served as an outside director of the Company since February 2013. The arrangements with Professor Hall provide for the payment to him of directors fees of $63,000 per annum.
Mr. Peter Gray
Mr. Peter Gray served as an Executive Director of the Company from June 1997 until his retirement in July 2012. From November 2002 to September 2011 he served as Chief Executive Office of the Company, having previously served as Chief Operating Officer from June 2001 until November 2002 and as Chief Financial Officer from June 1997 to June 2001. In September 2011 Mr. Gray announced his intention to retire as Chief Executive Officer of the Company in accordance with the terms of his service agreement which was terminable on 12 months’ notice by either party.
Following this announcement, Mr. Gray served as
Vice Chairman of the Board until his retirement in July 2012.
Under the terms of Mr. Gray’s service agreement he was entitled to receive an annual salary of €535,500 ($695,000) and a bonus to be agreed by the Compensation and Organization Committee. He was also entitled to receive a pension contribution, company car and medical insurance coverage for himself and his dependants. Mr. Gray’s notice period was due to expire on September, 30 2012 during which time his service agreement continued to apply.
In June 2012 the Company entered into an agreement with Mr. Gray whereby he would retire from the Company on July 19, 2012. Under the terms of this agreement Mr. Gray would retire as both an employee and as a Director of the Company and would be entitled to be paid €160,000 ($200,000) in lieu of the balance of his notice period and to receive a discretionary bonus of €194,000 ($243,000) in respect of 2012. In addition, under the terms of the agreement, Mr. Gray’s unvested share options would vest on the date of his retirement. He had previously been granted and held at July 19, 2012 288,000 ordinary share options at exercise prices ranging from $11.00 to $35.33 per share. The Company recognized a share-based compensation charge of $738,000 is respect of the acceleration of vesting on these options during the year ended December 31, 2012.
Following Mr. Gray’s retirement in July 2012, the Company also entered into an agreement with Integritum Limited, a company controlled by Mr. Gray, for the provision of consultancy services for a period of two years from August 1, 2012, at an agreed fee of €265,000 ($350,000) per annum. Mr. Gray also agreed to certain restrictions that will apply to him during the period of the consultancy agreement including non-disclosure, non-competition and non-solicitation.
Employees
We employed approximately 9,500, 8,470 and 7,735 people for the years ended December 31, 2012, December 31, 2011 and December 31, 2010 respectively. Our employees are not unionized and we believe we have a satisfactory relationship with our employees.
Share Ownership
Shares and Restricted Share Units
The following table sets forth certain information as
of March 6, 2013
regarding beneficial ownership of our ordinary shares and restricted share units (“RSU’s”) by all of our current directors and executive officers. Unless otherwise indicated below, to our knowledge, all persons listed below have sole voting and investment power with respect to their ordinary shares, except to the extent authority is shared by spouses under applicable law.
Name of Owner or
Identity of Group
|
|
No. of Shares
(1)
|
|
|
% of total
Shares
|
|
|
No. of RSU’s
(1)
|
|
Vesting Date
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Bruce Given
|
|
|
500
|
|
|
|
-
|
|
|
|
-
|
|
|
Mr. Ciaran Murray
|
|
|
-
|
|
|
|
-
|
|
|
|
50,000
|
|
April 27, 2013
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
October 1, 2014
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
February 10, 2016
|
Mr. Brendan Brennan
|
|
|
-
|
|
|
|
-
|
|
|
|
20,000
|
|
February 21, 2015
|
Dr. John Climax
|
|
|
1,607,568
|
|
|
|
2.7
|
%
|
|
|
-
|
|
|
Dr. Ronan Lambe
|
|
|
400
|
|
|
|
-
|
|
|
|
-
|
|
|
Mr. Thomas Lynch
|
|
|
3,604
|
|
|
|
-
|
|
|
|
-
|
|
|
Professor Dermot Kelleher
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
Mr. Declan McKeon
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
Ms. Cathrin Petty
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
Professor William Hall
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
(1)
|
As used in these tables, each person has the sole or shared power to vote or direct the voting of a security, or the sole or shared investment power with respect to a security (
i.e.
the power to dispose, or direct the disposition, of a security). A person is deemed as of any date to have "beneficial ownership" of any security if that such person has the right to acquire such security within 60 days after such date.
|
Share Options
The following table sets forth certain information as of
March 6, 2013
regarding options to acquire ordinary shares of the Company by all of our current directors and executive officers.
|
Name of Owner or
Identity of Group
|
|
No. of Options
(1)
|
|
|
Exercise price
|
|
Expiration Date
|
Mr. Thomas Lynch
|
|
|
3,200
|
|
|
$
|
11.00
|
|
February 3, 2014
|
|
|
|
4,000
|
|
|
$
|
21.25
|
|
February 16, 2015
|
|
|
|
2,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
2,000
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
2,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
Mr. Ciaran Murray
|
|
|
20,000
|
|
|
$
|
10.42
|
|
January 17, 2014
|
|
|
|
18,000
|
|
|
$
|
11.00
|
|
February 3, 2014
|
|
|
|
16,000
|
|
|
$
|
21.25
|
|
February 16, 2015
|
|
|
|
14,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
17,000
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
30,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
30,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
150,000
|
|
|
$
|
16.80
|
|
October 31, 2019
|
|
|
|
50,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
Name of Owner or
Identity of Group
|
|
No. of Options
(1)
|
|
|
Exercise price
|
|
Expiration Date
|
|
|
|
|
|
|
|
|
Mr. Brendan Brennan
|
|
|
2,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
840
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
3,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
4,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
20,000
|
|
|
$
|
20.59
|
|
February 22, 2020
|
|
|
|
|
|
|
|
|
|
|
Dr. John Climax
|
|
|
12,000
|
|
|
$
|
11.00
|
|
February 3, 2014
|
|
|
|
12,000
|
|
|
$
|
21.25
|
|
February 16, 2015
|
|
|
|
10,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
50,000
|
|
|
$
|
15.84
|
|
April 30, 2017
|
|
|
|
2,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Ronan Lambe
|
|
|
4,000
|
|
|
$
|
11.00
|
|
February 3, 2014
|
|
|
|
2,000
|
|
|
$
|
21.25
|
|
February 16, 2015
|
|
|
|
2,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
2,000
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
2,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
Dr. Bruce Given
|
|
|
4,000
|
|
|
$
|
11.00
|
|
February 3, 2014
|
|
|
|
4,000
|
|
|
$
|
21.25
|
|
February 16, 2015
|
|
|
|
2,000
|
|
|
$
|
35.33
|
|
February 26, 2016
|
|
|
|
2,000
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
4,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
4,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
4,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
Professor Dermot Kelleher
|
|
|
6,000
|
|
|
$
|
36.04
|
|
May 27, 2016
|
|
|
|
2,000
|
|
|
$
|
22.26
|
|
February 25, 2017
|
|
|
|
2,000
|
|
|
$
|
24.46
|
|
March 4, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
Mr. Declan McKeon
|
|
|
3,000
|
|
|
$
|
29.45
|
|
April 29, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
|
|
|
|
|
|
|
|
|
|
Ms. Cathrin Petty
|
|
|
3,000
|
|
|
$
|
19.45
|
|
October 26, 2018
|
|
|
|
2,000
|
|
|
$
|
20.28
|
|
March 3, 2019
|
|
|
|
2,000
|
|
|
$
|
22.30
|
|
April 27, 2020
|
(1) The title of securities covered by all of the above options are non-revenue qualified.
Equity Incentive Schemes
On July 21, 2008 the Company adopted the Employee Share Option Plan 2008 (the “2008 Employee Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any employee, or any director holding a salaried office or employment with the Company or a Subsidiary for the purchase of ordinary shares. On the same date, the Company also adopted the Consultants Share Option Plan 2008 (the “2008 Consultants Plan”), pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any consultant, adviser or non-executive director retained by the Company or any Subsidiary for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008 Consultants Plan (together the “2008 Option Plans”) will be an employee stock option, or NSO, as described in Section 422 or 423 of the Internal Revenue Code. Each grant of an option under the 2008 Options Plans will be evidenced by a Stock Option Agreement between the optionee and the Company. The exercise price will be specified in each Stock Option Agreement, however option prices will not be less than 100% of the fair market value of an ordinary share on the date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved under the 2008 Employee Plan as reduced by any shares issued or to be issued pursuant to options granted under the 2008 Consultants Plan, under which a limit of 400,000 shares applies. Further, the maximum number of ordinary shares with respect to which options may be granted under the 2008 Employee Option Plan, during any calendar year to any employee shall be 400,000 ordinary shares. There is no individual limit under the 2008 Consultants Plan. No options may be granted under the 2008 Option Plans after July 21, 2018.
On July 21, 2008 the Company adopted the 2008 Employees Restricted Share Unit Plan (the “2008 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any director holding a salaried office or employment with the Company or a Subsidiary to receive an award under the plan. An aggregate of 1.0 million ordinary shares have been reserved for issuance under the 2008 RSU Plan.
On January 17, 2003 the Company adopted the Share Option Plan 2003 (the “2003 Share Option Plan”) pursuant to which the Compensation and Organization Committee of the Board may grant options to officers and other employees of the Company or its subsidiaries for the purchase of ordinary shares. Each grant of an option under the 2003 Share Option Plan will be evidenced by a Stock Option Agreement between the employee and the Company. The exercise price will be specified in each Stock Option Agreement.
An aggregate of 6.0 million ordinary shares have been reserved under the 2003 Share Option Plan; and, in no event will the number of ordinary shares that may be issued pursuant to options awarded under the 2003 Share Option Plan exceed 10% of the outstanding shares, as defined in the 2003 Share Option Plan, at the time of the grant, unless the Board expressly determines otherwise. Further, the maximum number of ordinary shares with respect to which options may be granted under the 2003 Share Option Plan during any calendar year to any employee shall be 400,000 ordinary shares. No options can be granted after January 17, 2013.
Share option awards are granted with an exercise price equal to the market price of the Company’s shares at date of grant. Share options typically vest over a period of five years from date of grant and expire eight years from date of grant. The maximum contractual term of options outstanding at December 31, 2012 is eight years.
The following table sets forth certain information regarding beneficial ownership of ICON's ordinary shares as of
March 6, 2013
(i) by each person that beneficially owns more than 5% of the outstanding ordinary shares, based upon publicly available information; and (ii) by all of our current directors, officers and other key employees as a group. Unless otherwise indicated below, to our knowledge, all persons listed below have sole voting and investment power with respect to their ordinary shares, except to the extent authority is shared by spouses under applicable law.
Name of Owner or Identity of Group
|
|
No. of Shares (1)
|
|
|
Percent of Class
|
|
Artisan Partners Limited Partnership (2)
|
|
|
5,799,717
|
|
|
|
9.6
|
%
|
EARNEST Partners, LLC (2)
|
|
|
5,391,736
|
|
|
|
8.9
|
%
|
Neuberger Berman, LLC (2)
|
|
|
5,280,353
|
|
|
|
8.7
|
%
|
Wellington Management Company, LLP (2)
|
|
|
3,158,246
|
|
|
|
5.2
|
%
|
Wasatch Advisors, Inc. (2)
|
|
|
3,107,163
|
|
|
|
5.1
|
%
|
All directors, officers and other key employees as a group (3)
|
|
|
2,534,112
|
|
|
|
4.2
|
%
|
(1)
|
As used in this table, each person has the sole or shared power to vote or direct the voting of a security, or the sole or shared investment power with respect to a security (i.e., the power to dispose, or direct the disposition, of a security). A person is deemed as of any date to have "beneficial ownership" of any security if that such person has the right to acquire such security within 60 days after such date.
|
|
|
(2)
|
Neither the Company nor any of its officers, directors or affiliates holds any voting power in this entity.
|
|
|
(3)
|
Includes 632,040 ordinary shares issuable upon the exercise of stock options granted by the Company and 290,000 RSUs awarded by the Company to directors, officers and other key employees.
|
ICON plc, is not directly or indirectly, owned or controlled by another corporation or by any government.
Related Party Transactions
On July 19, 2012, Mr. Peter Gray retired as a Director and employee of the Company. The Company subsequently entered into an agreement with Integritum Limited, a company controlled by Mr. Gray, for the provision of consultancy services for a period of two years from August 1, 2012, at an agreed fee of €265,000 ($350,000) per annum.
On December 31, 2009, Dr. John Climax retired as Chairman of the Board of the Company. From January 2010 he has held the position as an outside director of the Company. The Company has entered into an agreement with Rotrua Limited, a company controlled by Dr. Climax, for the provision of consultancy services for a period of three years from January 1, 2010, at an agreed fee of €262,500 ($346,000) per annum.
The consultancy agreement has expired but it did provide that the Company would during its term provide permanent disability and life insurance coverage for Dr. Climax and medical insurance cover for himself and his dependants.
Financial Statements
See Item 18.
Legal Proceedings
ICON is not party to any litigation or other legal proceedings that we believe could reasonably be expected to have a material adverse effect on our business, results of operations and financial condition.
Dividends
We have not paid cash dividends on our ordinary shares and do not intend to pay cash dividends on our ordinary shares in the foreseeable future.
ICON’s ordinary shares are traded on the NASDAQ Global Select Market under the symbol “ICLR”. The following table sets forth the trading price for the dates indicated for ICON plc’s ADSs as reported by NASDAQ
,
prior to the termination of ICON plc’s ADR Program. ICON plc’s ADR program was terminated on January 31, 2013 and ICON plc’s ordinary shares began directly trading on NASDAQ on February 4, 2013. Prior to that date, ICON plc’s ADSs were traded on NASDAQ and ICON plc’s Depository for the ADSs was The Bank of New York Mellon.
|
|
High Sales Price
|
|
|
Low Sales Price
|
|
Year Ending
|
|
During Period
|
|
|
During Period
|
|
December 31, 2008
|
|
$
|
44.78
|
|
|
$
|
15.64
|
|
December 31, 2009
|
|
$
|
26.85
|
|
|
$
|
12.17
|
|
December 31, 2010
|
|
$
|
30.31
|
|
|
$
|
18.93
|
|
December 31, 2011
|
|
$
|
26.22
|
|
|
$
|
15.03
|
|
December 31, 2012
|
|
$
|
28.93
|
|
|
$
|
16.73
|
|
Quarter Ending
|
|
High Sales Price
During Period
|
|
|
Low Sales Price
During Period
|
|
Mar 31, 2011
|
|
$
|
24.26
|
|
|
$
|
19.61
|
|
June 30, 2011
|
|
$
|
26.22
|
|
|
$
|
21.03
|
|
Sept 30, 2011
|
|
$
|
25.50
|
|
|
$
|
15.98
|
|
Dec 31, 2011
|
|
$
|
18.28
|
|
|
$
|
15.03
|
|
Mar 31, 2012
|
|
$
|
22.33
|
|
|
$
|
16.73
|
|
June 30, 2012
|
|
$
|
23.81
|
|
|
$
|
20.02
|
|
Sept 30, 2012
|
|
$
|
25.21
|
|
|
$
|
21.71
|
|
Dec 31, 2012
|
|
$
|
28.93
|
|
|
$
|
23.05
|
|
Month Ending
|
|
High Sales Price
During Period
|
|
|
Low Sales Price
During Period
|
|
July 31, 2012
|
|
$
|
24.81
|
|
|
$
|
21.71
|
|
Aug 31, 2012
|
|
$
|
25.03
|
|
|
$
|
22.50
|
|
Sept 30, 2012
|
|
$
|
25.21
|
|
|
$
|
22.43
|
|
Oct 31, 2012
|
|
$
|
25.16
|
|
|
$
|
23.05
|
|
Nov 30, 2012
|
|
$
|
28.06
|
|
|
$
|
23.97
|
|
Dec 31, 2012
|
|
$
|
28.93
|
|
|
$
|
26.96
|
|
Memorandum and Articles of Association
We hereby incorporate by reference our Memorandum and Articles of Association, as amended, located under the heading “Memorandum and Articles of Association of the Company” in exhibit 3.1.
On December 17, 2012 at an Extraordinary General Meeting of the Company, in order to facilitate the conversion to a Direct Listing for the ICON Shares on NASDAQ, the Articles of Association of the Company were amended as follows:
|
●
|
to amend the transfer provisions with respect to the form of instrument of transfer required for the transfer of an ICON Share;
|
|
●
|
to set out the necessary mechanics for stamp duty with respect to any chargeable transfers of ICON Shares;
|
|
●
|
to remove provisions relating to the Irish Stock Exchange which were redundant following the cancellation of the secondary listing from the Irish Stock Exchange;
|
|
●
|
to insert provisions to facilitate future share buy-backs by the Company (including an ability to effect such buy backs by way of redemption);
|
|
●
|
to insert administrative provisions with regard to holding and maintaining share registers; and
|
|
●
|
to update legislative citations and cross-references.
|
The following is a summary of certain provisions of the current Articles of Association of the Company. This summary does not purport to be complete and is qualified in its entirety by reference to the complete text of the Articles of Association of the Company, which are included as an exhibit to this annual report.
Objects
The Company is incorporated under the name ICON plc, and is registered in Ireland under registered number 145835. The Company's objects, which are detailed in the Memorandum of Association of the Company, are broad and include, but are not limited to, the carrying on the business of an investment holding company.
Directors
Subject to certain exceptions, directors may not vote on matters in which they have a material interest. Any director who holds any executive office, serves on any committee or otherwise performs services, which, in the opinion of the directors, are outside the scope of the ordinary duties of a director, may be paid such extra remuneration as the directors may determine. The directors may exercise all the powers of the Company to borrow money. These powers may be amended by special resolution of the shareholders. The directors are not required to retire at any particular age. One-third of the directors retire and offer themselves for re-election at each Annual General Meeting ("AGM") of the Company. The directors to retire by rotation are those who have been longest in office since their last appointment or reappointment. As between persons who became or were appointed directors on the same date, those to retire are determined by agreement between them or, otherwise, by lot. All of the shareholders entitled to attend and vote at the AGM may vote on the re-election of directors. There is no requirement for directors to hold shares.
Rights, Preferences and Dividends Attaching to Shares
The Company has only one class of shares, Ordinary Shares with a par value of €0.06 per share. All such Ordinary Shares rank equally with respect to voting, payment of dividends and on any winding-up of the Company. Any dividend, interest or other sum payable to a shareholder that remains unclaimed for one year after having been declared may be invested by the directors for the benefit of the Company until claimed. If the directors so resolve, any dividend which has remained unclaimed for 12 years from the date of its declaration shall be forfeited and cease to remain owing by the Company. In the event of the Company being wound up, if the assets available for distribution among the Members shall be more than sufficient to repay the whole of the share capital paid up or credited as paid up at the commencement of the winding up, the excess shall be distributed among the Members in proportion to the capital at the commencement of the winding up paid up or credited as paid up on the said Ordinary Shares held by them respectively. An Ordinary Share shall be deemed to be a redeemable share in certain circumstances. The liability of shareholders to invest additional capital is limited to the amounts remaining unpaid on the shares held by them.
Action Necessary to Change the Rights of Shareholders
The rights attaching to shares in the Company may be varied by special resolutions passed at class meetings of that class of shareholders of the Company.
Annual and General Meetings
The AGM shall be held in such place and at such time as shall be determined by the board, but no more than 15 months shall pass between the dates of consecutive AGMs. Directors may call an Extraordinary General Meeting (“EGM”) at any time. The members, in accordance with the Articles of Association of the Company and Irish company law, may also requisition EGM’s. Notice of the AGM or an EGM passing any special resolution must be given at least 21 clear days prior to the scheduled date and, in the case of any other general meeting, not less than 14 clear days’ notice. All holders of Ordinary Shares are entitled to attend, speak at and vote at general meetings of the Company.
Limitations on the Right to Own Shares
There are no limitations on the right to own shares in the Memorandum and Articles of Association of the Company.
Disclosure of Share Ownership
Under Irish law, the Company can require parties to disclose their interests in shares. The Articles of Association of the Company entitle the directors to require parties to provide details regarding their identity and the nature and extent of any interest which such parties hold in Ordinary Shares. Under Irish law, if a party acquires or disposes of Ordinary Shares so as to bring his interest above or below 5% of the total issued share capital of the Company, he must notify the Company of that. The Company would also need to be notified of the acquisition by an existing substantial (i.e. 5% plus) shareholder, of every movement of one whole percentage integer (e.g. 5.9% to 6.1% but not 6.1% to 6.9%) or more.
Other Provisions of the Articles of Association
There are no provisions in the Articles of Association of the Company:
(i) delaying or prohibiting a change in the control of the Company, but which operate only with respect to a merger, acquisition or corporate restructuring;
(ii) discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of shares; or
(iii) governing changes in capital,
in each case, where such provisions are more stringent than those required by law.
Material Contracts
On November 20, 2012 the Company’s subsidiary ICON Clinical Research SARL, entered into a lease agreement with MS Capitole SCI. The lease is for office space at an initial annual rate of of €918,000 per annum, subject to annual inflation adjustments and a statutory revision every 3 years. The term of the lease is 9 years.
Exchange Controls and Other Limitations Affecting Security Holders
Irish exchange control regulations ceased to apply from and after December 31, 1992. Except as indicated below, there are no restrictions on non-residents of Ireland dealing in domestic securities, which includes shares or depository receipts of Irish companies. Except as indicated below, dividends and redemption proceeds also continue to be freely transferable to non-resident holders of such securities.
The Financial Transfers Act, 1992 gives power to the Minister for Finance of Ireland to make provision for the restriction of financial transfers between Ireland and other countries and persons. Financial transfers are broadly defined, and include all transfers which would be movements of capital or payments within the meaning of the treaties governing the European Communities. The acquisition or disposal of shares issued by an Irish incorporated company and associated payments may fall within this definition. In addition, dividends or payments on redemption or purchase of shares and payments on a liquidation of an Irish incorporated company would fall within this definition. At present, the Financial Transfers Act, 1992 prohibits financial transfers involving certain persons connected with the former regime in Iraq, certain persons indicted by the International Criminal Tribunal for the former Yugoslavia and certain associated persons, Zimbabwe,
the Islamic Republic of Iran, the Democratic Peoples Republic of Korea, the Republic of Lebanon,
the Taliban of Afghanistan, certain persons previously connected with the deceased Osama bin Laden and Al-Qaeda, Liberia, Burma/Myanmar, Uzbekistan, Sudan,
Somalia,
Cote D’Ivoire, the Democratic Republic of Congo, President Lukashenko and certain other officials of Belarus, and countries that harbor certain terrorist groups, without the prior permission of the Central Bank of Ireland.
Any transfer of, or payment in respect of shares involving the government of any country or any person which is currently the subject of United Nations sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law. The following countries and persons are currently the subject of such sanctions: Somalia,
Sierra
Leone,
Sudan, Cote D’Ivoire, Democratic Republic of Congo, Liberia,
individuals designated by the international independent investigation Commission or the Government of Lebanon, Democratic Peoples Republic of Korea, the
Islamic Republic of Iran, Iraq,
the Taliban of Afghanistan and Al-Qaeda. There are no restrictions under the Company’s Articles of Association or under Irish Law that limit the right of non-residents or foreign owners to hold the Company’s ordinary shares or vote at general meetings of the Company.
Taxation
General
The following discussion is based on existing Irish tax law, Irish court decisions and the practice of the Revenue Commissioners of Ireland, and the convention between the United States and Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to income and capital gains (the "Treaty"). This discussion does not purport to deal with the tax consequences of owning the ordinary shares for all categories of investors, some of which may be subject to special rules. Prospective purchasers of ordinary shares are advised to consult their own tax advisors concerning the overall tax consequences arising in their own particular situations under Irish law. Each prospective investor should understand that future legislative, administrative and judicial changes could modify the tax consequences described below, possibly with retroactive effect.
As used herein, the term "U.S. Holder" means a beneficial owner of ordinary shares that (i) owns the ordinary shares as capital assets; (ii) is a U.S. citizen or resident, a U.S. corporation, an estate the income of which is subject to U.S. federal income taxation regardless of its source or a trust that meets the following two tests: (A) a U.S. court is able to exercise primary supervision over the administration of the trust, and (B) one or more U.S. persons have the authority to control all substantial decisions of the trust; and for the purpose of the discussion under Irish Taxation of U.S. Holders (A) is not a resident of, or ordinarily resident in, Ireland for the purposes of Irish tax; and (B) is not engaged in trade or business in Ireland through a permanent establishment.
AS USED HEREIN, REFERENCES TO THE ORDINARY SHARES SHALL INCLUDE SHARES HELD IN THE ACCOUNTS OF PARTICIPANTS THROUGH THE DEPOSITARY TRUST COMPANY (“THE DTC”).
Irish Taxation
Irish corporation tax on income
ICON is a public limited company incorporated and resident for tax purposes in Ireland.
For Irish tax purposes, the residence of a company is generally in the jurisdiction where the place of central management and control of the company is located. Subject to certain exceptions, all Irish incorporated companies are deemed to be Irish tax resident. Companies which are resident in the Republic of Ireland are subject to Irish corporation tax on their total profits (wherever arising and, generally, whether or not remitted to the Republic of Ireland). The question of residence, by virtue of management and control, is essentially one of fact. It is the present intention of the Company's management to continue to manage and control the Company from the Republic of Ireland, so that the Company will continue to be resident in the Republic of Ireland.
The standard rate of Irish corporation tax on trading income (with certain exceptions) is currently 12.5%.
A research and development tax credit is available in Ireland where an Irish resident company incurs qualifying expenditure on research and development activities. Qualifying expenditure incurred in a particular account period, which exceeds the qualifying expenditure incurred by the company in 2003 results in a tax credit of 25% of that expenditure. With effect from 1 January 2012 the incremental test does not apply to the first €100,000 of qualifying expenditure as such expenditure automatically qualifies for a tax credit of 25%. It is expected that legislative changes will be enacted in March 2013 which will provide that the incremental test will no longer apply to the first €200,000 of qualifying expenditure. These proposed legislation changes will likely apply retrospectively from 1 January 2013.
Corporation tax is charged at the rate of 25% on a company's non-trading income and certain types of trading income not eligible for the lower rate of 12.5% referred to above.
Capital gains arising to an Irish resident company are liable to tax at 33% (30% for disposals made on or before 5 December 2012). However, a capital gains tax exemption is available in Ireland for qualifying Irish resident companies in respect of disposals of certain qualifying shareholdings.
The exemption from capital gains tax on the disposal of shares by an Irish resident company will apply where certain conditions are met. These conditions principally are:
●
|
The company claiming the exemption must hold (directly or indirectly) at least 5% of the ordinary share capital of the company in which the interest is being disposed of, throughout the period of at least 12 months, within the two year period prior to disposal
|
●
|
The shares being disposed of must be in a company, which at the date of disposal, is resident in a
Member State of the European Communities or in a country with which Ireland has signed or made specific arrangements to sign a double tax agreement (together a “Relevant Territory”)
|
●
|
The shares must be in a company which is primarily a trading company or the company making the disposal together with its “5% plus subsidiaries” should be primarily a trading group
|
●
|
The shares must not derive the greater part of their value from land or mineral rights in the State.
|
Irish withholding tax on dividends
Unless specifically exempted, all dividends paid by the Company, will be subject to Irish withholding tax at the standard rate of income tax in force at the time the dividend is paid, which is currently 20%.
An individual shareholder who is neither resident nor ordinarily resident for tax purposes in Ireland, but is resident in a country with which Ireland has a double tax treaty, or in a member state of the European Union, other than Ireland (together, a Relevant Territory), will be exempt from withholding tax provided he or she makes the requisite declaration.
Non-Irish resident corporate shareholders that:
|
●
|
are resident in a Relevant Territory and are not controlled (directly or indirectly) by Irish residents
|
|
●
|
are ultimately controlled (directly or indirectly) by residents of a Relevant Territory or
|
|
●
|
have the principal class of their shares, or shares of a 75% parent, substantially and regularly traded on one or more recognized stock exchanges in a Relevant Territory (including Ireland) or Territories; or
|
|
●
|
are wholly owned by two or more companies, each of whose principal class of shares is substantially and regularly traded on one or more recognized stock exchanges in a Relevant Territory (including Ireland) or Territories
|
will be exempt from withholding tax on the production of the appropriate certificates and declarations.
U.S. Holders of ordinary shares should note, however, that detailed documentation requirements may need to be complied with. Special arrangements are available in the case of an interest in shares held in Irish companies through a depositary or in accounts of participants through the DTC. In certain cases the depositary or the DTC can receive and pass on a dividend from an Irish company without deducting withholding tax, provided the depositary or the DTC is a qualifying intermediary, and provided the person beneficially entitled to the distribution would meet the same conditions outlined above for the withholding tax exemption to apply and has provided the qualifying intermediary with the appropriate declarations. The depositary or the DTC shall be regarded as a qualifying intermediary provided the following conditions are met:
|
●
|
the depositary or the DTC is resident in a Relevant Territory and
|
|
●
|
the depositary or the DTC have entered into a qualifying intermediary agreement with the Irish tax authorities and
|
|
●
|
the depositary or the DTC have been authorized by the Irish Revenue Commissioners as a qualifying intermediary and such authorization has not expired or been revoked;
|
Irish income tax on dividends
Irish resident or ordinarily resident shareholders will generally be liable to Irish income tax on dividend income at their marginal rate of tax. This income may also be liable to Pay Related Social Insurance (“PRSI”) of up to 4% and the Universal Social Charge (“USC”) of up to 10% (up to 14% in total).
Under certain circumstances, non-Irish resident shareholders will be subject to Irish income tax on dividend income. This liability is limited to tax at the standard rate of 20% and therefore, where withholding tax has been deducted, this will satisfy the tax liability. No PRSI or USC should apply in these circumstances.
However, a non-Irish resident shareholder will not have an Irish income tax liability on dividends from the Company if the holder is neither resident nor ordinarily resident in the Republic of Ireland and the holder is
|
●
|
an individual resident in the U.S. or in a Relevant Territory;
|
|
●
|
a corporation that is ultimately controlled by persons resident in the U.S. or in a Relevant Territory;
|
|
●
|
a corporation whose principal class of shares (or its 75% or greater parent’s principal class of shares) is substantially and regularly traded on a recognized stock exchange in an EU country or in a Relevant Territory;
|
|
●
|
a corporation resident in another EU member state or in a Relevant Territory, which is not controlled directly or indirectly by Irish residents; or
|
|
●
|
a corporation that is wholly owned by two or more corporations each of whose principal class of shares is substantially and regularly traded on a recognized stock exchange in an EU country or in a Relevant Territory.
|
U.S. Holders who do not qualify for the above income tax exemption may be able to obtain treaty benefits under the double tax treaty.
Irish domicile levy
Certain non-Irish resident individuals that are domiciled in Ireland will be subject to an annual levy of €200,000 if their Irish-located property exceeds €5,000,000, their worldwide annual income exceeds €1,000,000 and their liability to Irish Income Tax in that year is less than €200,000.
Irish capital gains tax on disposal of shares
Irish resident or ordinarily resident shareholders will be liable to capital gains tax at 33% (30% in respect of disposals made up to 5 December 2012) on gains arising from the disposal or part disposal of their shareholding.
A person who is not resident or ordinarily resident in Ireland, who has not been an Irish resident within the past five years and who does not carry on a trade in Ireland through a branch or agency will not be subject to Irish capital gains tax on the disposal of ordinary shares or shares held in accounts of participants through the DTC, so long as the shares are either quoted on a stock exchange or do not derive the greater part of their value from Irish land or mineral rights.
There are provisions to subject a person who disposes of an interest in a company while temporarily being non-Irish resident, to Irish capital gains tax. This treatment will apply to Irish domiciled individuals -:
|
●
|
who cease to be Irish resident;
|
|
●
|
who beneficially own the shares when they cease to be resident;
|
|
●
|
if there are not more than 5 years of assessment between the last year of Irish tax residence prior to becoming temporarily non-resident and the tax year that he/she resumes Irish tax residency;
|
|
●
|
who dispose of an interest in a company during this temporary non-residence; and
|
|
●
|
the interest disposed of represents 5% or greater of the issued share capital of the company or is worth at least €500,000.
|
In these circumstances the person will be deemed, for Irish capital gains tax purposes, to have sold and immediately reacquired the interest in the company on the date of his or her departure and will be subject to tax at 33% (30% up to 5 December 2012) of the taxable gain.
Irish capital acquisitions tax
Irish capital acquisitions tax (referred to as CAT) applies to gifts and inheritances. Subject to certain tax – free thresholds, gifts and inheritances are liable to tax at 33% (30% up to 6 December 2012).
Where a gift or inheritance is taken under a disposition made after December 1, 1999, it will be within the charge to CAT:
|
●
|
to the extent that the property of which the gift or inheritance consists is situated in the Republic of Ireland at the date of the gift or inheritance;
|
|
●
|
where the person making the gift or inheritance is or was resident or ordinarily resident in the Republic of Ireland at the date of the disposition under which the gift or inheritance is taken;
|
|
●
|
in the case of a gift taken under a discretionary trust where the person from whom the gift is taken was resident or ordinarily resident in the Republic of Ireland at the date he made the settlement, or at the date of the gift or, if he is dead at the date of the gift, at the date of his death; or
|
|
●
|
where the person receiving the gift or inheritance is resident or ordinarily resident in the Republic of Ireland at the date of the gift or inheritance.
|
For these purposes a non-Irish domiciled individual will not be regarded as resident or ordinarily resident in the Republic of Ireland on a particular date unless they are resident or ordinarily resident in the Republic of Ireland on that date and have been resident for the 5 consecutive tax years immediately preceding the year of assessment in which the date falls.
The person who receives the gift or inheritance (“the beneficiary”) is primarily liable for CAT. In the case of an inheritance, where a beneficiary and personal representative of the deceased are both non-residents, a solicitor must be appointed to be responsible for paying inheritance tax. Taxable gifts or inheritances received by an individual since December 5, 1991 from donors in the same threshold class are aggregated and only the excess over a specified tax-free threshold is taxed. The tax-free threshold is dependent on the relationship between the donor and the donees and the aggregation since December 5, 1991 of all previous gifts and inheritances, within the same tax threshold.
The tax-free threshold amounts that apply with effect from 5 December 2012 are:
|
●
|
€15,075 (€16,750 pre December 6, 2012) in the case of persons who are not related to one another;
|
|
●
|
€30,150 (€33,500 pre December 6, 2012) in the case of gifts or inheritances received from inter alia a brother or sister or from a brother or sister of a parent or from a grandparent; and
|
|
●
|
€225,000 (€250,000 pre December 5, 2012) in the case of gifts and inheritances received from a parent (or from a grandparent by a minor child of a deceased child) and specified inheritances received by a parent from a child.
|
Gifts and inheritances passing between spouses are exempt from CAT.
A gift or inheritance of ordinary shares or ADSs will be within the charge to Irish capital acquisitions tax, notwithstanding that the person from whom or by whom the gift or inheritance is received is domiciled or resident outside Ireland.
The Estate Tax Convention between Ireland and the United States generally provides for Irish capital acquisitions tax paid on inheritances in Ireland to be credited against U.S. Federal Estate tax payable in the United States and for tax paid in the United States to be credited against tax payable in Ireland, based on priority rules set forth in the Estate Tax Convention. The Estate Tax Convention does not apply to Irish capital acquisitions tax paid on gifts.
Irish stamp duty
Irish stamp duty, which is a tax on certain documents, is payable on all transfers of ordinary shares (other than between spouses) whenever a document of transfer is executed. Where the transfer is attributable to a sale, stamp duty will be charged at a rate of 1%, rounded to the nearest Euro. The stamp duty is calculated on the amount or value of the consideration (i.e. purchase price) or, if the transfer is by way of a gift (subject to certain exceptions) or for consideration less than the market value, on the market value of the shares. Where the consideration for the sale is expressed in a currency other than Euro, the duty will be charged on the Euro equivalent calculated at the rate of exchange prevailing on the date of the transfer.
Transfers through the DTC of book entry interests in shares are not subject to Irish stamp duty.
A transfer of ordinary shares by a shareholder to a depositary or custodian for deposit and a transfer of ordinary shares from the depositary or the custodian for the purposes of the withdrawal of the underlying ordinary shares in accordance with the terms of a deposit agreement will be stampable at the ad valorem rate if the transfer relates to a sale, a contemplated sale, a gift or any other change in the beneficial ownership of such ordinary shares. However transfers of ordinary shares into or out of the DTC are not be subject to Irish stamp duty provided that no change in beneficial ownership of the shares has occurred and provided a contract for sale in respect of the transferring shares is not in place.
The person accountable for payment of stamp duty is normally the transferee or, in the case of a transfer by way of gift, or for a consideration less than the market value, all parties to the transfer.
Transfers of ordinary shares between associated companies (broadly, companies within a 90% group relationship and subject to the satisfaction of certain conditions) are exempt from stamp duty in the Republic of Ireland. In the case of transfers of ordinary shares where no beneficial interest passes (e.g. a transfer of shares from a beneficial owner to his nominee), no stamp duty arises.
No stamp duty shall arise on the transfer of ordinary shares where the consideration for the transfer does not exceed €1,000, provided the instrument contains a statement certifying that the transaction does not form part of a larger transaction or a series of larger transactions, in respect of which the amount of the total consideration attributable to the shares would exceed €1,000.
Documents on Display
We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and file reports and other information with the SEC. The SEC maintains a web site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC at http://www.sec.gov.
We “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this report and more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this report. Our SEC file number for Exchange Act reports is 333-08704.
As a foreign private issuer, we are exempt from certain rules under the Exchange Act, prescribing the furnishing and content of proxy statements to shareholders.
We will provide without charge to each person, including any beneficial owner, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this report (not including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: ICON plc, South County Business Park, Leopardstown, Dublin 18, Ireland, Attention: Sam Farthing, telephone number: (353) 1 291 2000.
Exemptions From Corporate Governance Listing Requirements Under the NASDAQ Marketplace Rules
NASDAQ may provide exemptions from certain NASDAQ corporate governance standards to a foreign private issuer if, among other reasons those standards are contrary to a law, rule or regulation of a public authority exercising jurisdiction over such issuer or contrary to generally accepted business practices in the issuer’s home country of domicile, provided, that, the foreign private issuer properly notifies NASDAQ and makes the required disclosure except to the extent that such exemptions would be contrary to United States federal securities laws. The Company, as a foreign private issuer, was granted an exemption in 1998 from provisions set forth in NASDAQ Rule 4350(f), which requires each issuer to provide for a quorum in its by-laws for any meeting of the holders of common stock, which shall in no case be less than 33.33% of the outstanding shares of the issuer’s outstanding voting stock. The Company’s Articles of Association require that only 3 members be present, in person or by proxy, at a shareholder meeting to constitute a quorum. This quorum requirement is in accordance with Irish law and generally accepted business practices in Ireland.
The principal market risks (i.e. risk of loss arising from adverse changes in market rates and prices) to which we are exposed include foreign currency risk and interest rate risk.
Foreign Currency Exchange Risk
We are subject to a number of foreign currency risks given the global nature of our operations. The principal foreign currency risks to which the business is subject to includes both foreign currency translation risk and foreign currency transaction risk.
Although domiciled in Ireland, we report our results in U.S. dollars. As a consequence the results of our non-U.S. based operations, when translated into U.S. dollars, could be affected by fluctuations in exchange rates between the U.S. dollar and the currencies of those operations.
We are also subject to foreign currency transaction exposures as the currency in which our contracts are priced can be different from the currencies in which costs relating to those contracts are incurred. Our operations in the United States are not materially exposed to such currency differences as the majority of revenues and costs are in U.S. dollars. However, outside the United States the multinational nature of our activities means that contracts are usually priced in a single currency, most often U.S. dollars, or Euros, while costs arise in a number of currencies, depending, among other things, on which of our offices provide staff for the contract, and the location of investigator sites. Although many such contracts benefit from some degree of natural hedging due to the matching of contract revenues and costs in the same currency, where costs are incurred in currencies other than those in which contracts are priced, fluctuations in the relative value of those currencies could have a material effect on our results of operations. We regularly review our foreign currency exposures and usually negotiate currency fluctuation clauses in our contracts which allow for price negotiation if certain exchange rate triggers occur.
The following significant exchange rates applied during the year:
|
|
Average Rate
|
|
|
Closing Rate
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro:USD
|
|
|
1.2876
|
|
|
|
1.3991
|
|
|
|
1.3193
|
|
|
|
1.2961
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pound Sterling:USD
|
|
|
1.5832
|
|
|
|
1.6050
|
|
|
|
1.6255
|
|
|
|
1.5413
|
|
Interest Rate Risk
We are exposed to interest rate risk in respect of our cash and cash equivalents and short term investments – available for sale. Our treasury function actively manages our available cash resources and invests significant cash balances in various financial instruments to try to ensure optimum returns for the Company’s surplus cash balances. Financial instruments are classified either as cash and cash equivalents or short term investments –available for sale depending upon the maturity of the related investment. Funds may be invested in the form of floating rate notes and medium term minimum “A” rated corporate securities. We may be subject to interest rate risk in respect of interest rate changes on amounts invested. Our treasury function manages interest rate risk in respect of these balances by monitoring the composition of the Company’s investment portfolio on an ongoing basis having regard to current market interest rates and future trends.
The sensitivity analysis below represents the hypothetical change in our interest income based on an immediate 1% movement in market interest rates.
|
|
Interest Income
for the year ended
December 31, 2012
|
|
|
Interest Income
Change 1% increase in
market interest rate
|
|
|
Interest Income
Change 1% decrease in
market interest rate
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Interest Income
|
|
$
|
1,151
|
|
|
$
|
2,987
|
|
|
$
|
-
|
|
Not applicable.
None.
None.
(a) Disclosure controls and procedures
An evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), of the effectiveness of our disclosure controls and procedures as at December 31, 2012. Based on that evaluation, the CEO and CFO have concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.
(b) Management’s Annual Report on Internal Accounting Control over Financial Reporting
Reference is made to page 71 of this Form 20-F.
(c) Attestation Report of Independent Registered Public Accounting Firm
Reference is made to page 73 of this Form 20-F.
(d) Changes in Internal Controls over Financial Reporting
There were no changes in our internal controls over financial reporting that occurred during the period covered by this Form 20-F that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.
Mr. Declan McKeon acts as the Audit Committee financial expert serving on our Audit Committee and Board of Directors. Mr. McKeon is an independent Board member and serves as one of our non-executive directors.
Our Board of Directors adopted a new code of ethics on March 22, 2011, which replaced our previous Code of Ethics. The new Code of Ethics applies to all ICON employees.
There are no material modifications to, or waivers from, the provisions of such code, which are required to be disclosed.
This code is available on our website at the following address:
http://investor.iconplc.com/governance.cfm
Our principal accountants for the years ended December 31, 2012 and December 31, 2011, were KPMG.
The table below summarizes the fees for professional services rendered by KPMG for the audit of our annual financial statements for the years ended December 31, 2012 and December 31, 2011 and fees billed for other services rendered by KPMG.
|
|
12 month period ended
December 31, 2012
|
|
|
12 month period ended
December 31, 2011
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
Audit fees (1)
|
|
$
|
1,597
|
|
|
|
73
|
%
|
|
$
|
1,629
|
|
|
|
66
|
%
|
Audit related fees (2)
|
|
|
23
|
|
|
|
1
|
%
|
|
|
160
|
|
|
|
7
|
%
|
Tax fees (3)
|
|
|
570
|
|
|
|
26
|
%
|
|
|
662
|
|
|
|
27
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,190
|
|
|
|
100
|
%
|
|
$
|
2,451
|
|
|
|
100
|
%
|
(1)
|
Audit fees include annual audit fees for the Company and its subsidiaries.
|
(2)
|
Audit related fees principally consisted of fees for financial due diligence services and fees for audit of the financial statements of employee benefit plans.
|
(3)
|
Tax fees are fees for tax compliance and tax consultation services.
|
The Audit Committee pre-approves on an annual basis the audit and non-audit services provided to the Company by its auditors.
Such annual pre-approval is given with respect to particular services. The Audit Committee, on a case-by-case basis, may approve additional services not covered by the annual pre-approval, as the need for such services arises.
Not applicable.
|
|
Total Number
of Shares (incl.
ADS’s)
Purchased
|
|
|
Average Price
Paid per Share
|
|
|
Total Number
of Shares (incl.
ADS’s)
Purchased as
Part of a
Publicly
Announced
Plan
|
|
|
Total Price
Paid for shares
purchased
(incl. ADS’s)
Purchased as
Part of a
Publicly
Announced
Plan
|
|
|
Maximum
Approximate
Value of Shares
that may yet be
purchased under
the Plans
|
|
|
|
(in thousands, except per share data)
|
|
|
|
|
|
January 1/1 - 1/31
|
|
|
82,100
|
|
|
$
|
17.25
|
|
|
|
82,100
|
|
|
$
|
1,417
|
|
|
$
|
8,583
|
|
February 2/1 – 2/29
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
20,000
|
|
March 3/1 – 3/31
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
20,000
|
|
April 4/1 – 4/30
|
|
|
40,700
|
|
|
$
|
22.00
|
|
|
|
40,700
|
|
|
|
895
|
|
|
$
|
19,105
|
|
May 5/1 – 5/31
|
|
|
300,838
|
|
|
$
|
21.80
|
|
|
|
300,838
|
|
|
|
6,559
|
|
|
$
|
12,546
|
|
June 6/1 – 6/30
|
|
|
314,703
|
|
|
$
|
21.42
|
|
|
|
314,703
|
|
|
|
6,734
|
|
|
$
|
5,805
|
|
July 7/1 – 7/31
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
10,000
|
|
August 8/1 – 8/31
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
10,000
|
|
September 9/1 – 9/30
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
10,000
|
|
October 10/1 – 10/26
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
738,341
|
|
|
$
|
21.14
|
|
|
|
738,341
|
|
|
$
|
15,605
|
|
|
|
-
|
|
On October 27, 2011 the Company announced its intention to commence a share repurchase program of up to $50 million. On November 22, 2011 the Company entered into two separate share repurchase plans of up to $10 million each, covering the periods November 23, 2011 to December 31, 2011 and January 1, 2012 to February 20, 2012 respectively. On February 21, 2012 the Company entered into a further share repurchase plan of up to $20 million, covering the period February 22, 2012 to April 22, 2012. On April 27, 2012 the Company entered into a fourth share repurchase plan of up to $20 million, covering the period April 27, 2012 to July 18, 2012
.
On July 30, 2012 the Company entered into a fifth share repurchase plan of up to $10 million, covering the period July 30, 2012 to October 26, 2012
.
Under the repurchase program, a broker purchased the Company’s shares from time to time on the open market or in privately negotiated transactions in accordance with agreed terms and limitations. The program was designed to allow share repurchases during periods when the Company would ordinarily not be permitted to do so because it may be in possession of material non-public or price-sensitive information, applicable insider trading laws or self-imposed trading blackout periods. The
Company’s instructions to the broker were irrevocable and the
trading decisions in respect of the repurchase program were made independently of and uninfluenced by the Company. The Company confirms that on entering the share repurchase plans it had no material non-public
,
price-sensitive
or inside
information regarding the Company or its securities. Furthermore, the Company will not enter into additional plans whilst in possession of such information.
Not applicable.
See Item 10 “Exemptions from Corporate Governance Listing Requirements under the NASDAQ Marketplace Rules”.
Not applicable.
See item 18.
Reference is made to pages 71 to 122 of this Form 20-F.
Financial statements of ICON plc and subsidiaries
Management's Report on Internal Control over Financial Reporting
Reports of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as at December 31, 2012 and December 31, 2011
Consolidated Statements of Operations for the years ended December 31, 2012, December 31, 2011 and December 31, 2010
Consolidated Statements of Comprehensive Income for the years ended December 31, 2012, December 31, 2011 and December 31, 2010
Consolidated Statements of Shareholders’ Equity and Comprehensive Income for the years ended December 31, 2012, December 31, 2011 and December 31, 2010
Consolidated Statements of Cash Flows for the years ended December 31, 2012, December 31, 2011 and December 31, 2010
Notes to the Consolidated Financial Statements
Exhibits of ICON plc and subsidiaries
Exhibit
Number
|
|
Title
|
|
|
|
3.1*
|
|
Description of the Memorandum and Articles of Association of the Company (Amended as of December 17, 2012).
|
|
|
|
10.1*
|
|
Office Space Lease, dated November 20, 2012, between ICON Clinical Research SARLand MS Capitole SCI.
|
|
|
|
12.1*
|
|
Section 302 certifications.
|
|
|
|
12.2*
|
|
Section 906 certifications.
|
|
|
|
21.1
|
|
List of Subsidiaries (incorporated by reference to Item 4 of Form 20-F filed herewith).
|
|
|
|
23.1*
|
|
Consent of KPMG, Independent Registered Public Accounting Firm
|
|
|
|
101.1*
|
|
Interactive Data Files (XBRL – Related Documents)
|
* Filed herewith
Management's Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934.
The Company’s internal control over financial reporting is a process designed by, or under the supervision of, the Company’s executive and financial officers and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles.
A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of the inherent limitation due to, for example, the potential for human error or circumvention of control, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2012. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework. Based upon the assessment performed, we determined that, as of December 31, 2012 the Company’s internal control over financial reporting was effective. In addition, there have been no changes in the Company’s internal control over financial reporting during 2012 that have materially affected, or are reasonably likely to affect materially, the Group’s internal control over financial reporting.
KPMG, which has audited the consolidated financial statements of the Company for the year ended December 31, 2012, has also audited the effectiveness of the Company’s internal control over financial reporting under Auditing Standard No. 5 of the Public Company Accounting Oversight Board (United States) and their report is included at page 73.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Directors and Shareholders of ICON plc:
We have audited the accompanying consolidated balance sheets of ICON plc and subsidiaries (“the Company”) as of December 31, 2012 and 2011 and the related consolidated statements of operations, shareholders’ equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2012. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of ICON plc and subsidiaries as of December 31, 2012 and 2011 and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2012, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), ICON plc’s internal control over financial reporting as of December 31, 2012 based on criteria established in
Internal Control — Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report
dated March 6, 2013
expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.
KPMG
Dublin, Ireland
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Directors and Shareholders of ICON plc:
We have audited ICON plc’s internal control over financial reporting as of December 31, 2012 based on criteria established in
Internal Control - Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). ICON plc’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying
Management Report on Internal Control over Financial Reporting
. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, ICON plc maintained, in all material respects, effective internal control over financial reporting as of December 31, 2012 based on criteria established in
Internal Control - Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of ICON plc and subsidiaries as of December 31, 2012 and 2011 and the related consolidated statements of operations, shareholders’ equity and comprehensive income, and cash flows for each of the years in the three-year period ended December 31, 2012 and our report dated
March 6, 2013
expressed an unqualified opinion on those consolidated financial statements.
KPMG
Dublin, Ireland
March 6, 2013
ICON plc
CONSOLIDATED BALANCE SHEETS
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
ASSETS
|
|
(in thousands)
|
|
Current Assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
114,047
|
|
|
$
|
119,237
|
|
Short term investments - available for sale (Note 3)
|
|
|
76,183
|
|
|
|
54,940
|
|
Accounts receivable, net
|
|
|
285,419
|
|
|
|
201,338
|
|
Unbilled revenue
|
|
|
112,483
|
|
|
|
126,850
|
|
Other receivables
|
|
|
13,387
|
|
|
|
13,788
|
|
Deferred tax asset (Note 13)
|
|
|
20,574
|
|
|
|
13,812
|
|
Prepayments and other current assets
|
|
|
23,155
|
|
|
|
21,424
|
|
Income taxes receivable (Note 13)
|
|
|
18,500
|
|
|
|
8,183
|
|
Total current assets
|
|
|
663,748
|
|
|
|
559,572
|
|
Other Assets:
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net (Note 6)
|
|
|
168,373
|
|
|
|
168,461
|
|
Goodwill (Note 4)
|
|
|
315,441
|
|
|
|
253,393
|
|
Non-current other assets
|
|
|
5,584
|
|
|
|
4,583
|
|
Non-current income taxes receivable (Note 13)
|
|
|
9,506
|
|
|
|
10,272
|
|
Non-current deferred tax asset (Note 13)
|
|
|
5,009
|
|
|
|
2,976
|
|
Intangible assets (Note 5)
|
|
|
34,447
|
|
|
|
28,260
|
|
Total Assets
|
|
$
|
1,202,108
|
|
|
$
|
1,027,517
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current Liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
8,149
|
|
|
$
|
5,340
|
|
Payments on account
|
|
|
219,467
|
|
|
|
150,792
|
|
Other liabilities (Note 7)
|
|
|
181,092
|
|
|
|
145,963
|
|
Deferred tax liability (Note 13)
|
|
|
144
|
|
|
|
333
|
|
Income taxes payable (Note 13)
|
|
|
4,570
|
|
|
|
3,630
|
|
Total current liabilities
|
|
|
413,422
|
|
|
|
306,058
|
|
Other Liabilities:
|
|
|
|
|
|
|
|
|
Non-current other liabilities (Note 8)
|
|
|
14,312
|
|
|
|
20,038
|
|
Non-current government grants (Note 11)
|
|
|
1,427
|
|
|
|
1,351
|
|
Non-current income taxes payable (Note 13)
|
|
|
5,650
|
|
|
|
5,231
|
|
Non-current deferred tax liability (Note 13)
|
|
|
12,722
|
|
|
|
13,295
|
|
Shareholders' Equity:
|
|
|
|
|
|
|
|
|
Ordinary shares, par value 6 euro cents per share;
100,000,000 shares authorized, (Note 12)
|
|
|
|
|
|
|
|
|
60,287,498 shares issued and outstanding at December 31, 2012 and
60,135,603 shares issued and outstanding at December 31, 2011.
|
|
|
5,067
|
|
|
|
5,055
|
|
Additional paid-in capital
|
|
|
237,217
|
|
|
|
211,549
|
|
Capital redemption reserve (Note 12)
|
|
|
100
|
|
|
|
44
|
|
Accumulated other comprehensive income (Note 19)
|
|
|
(8,776
|
)
|
|
|
(16,446
|
)
|
Retained earnings
|
|
|
520,967
|
|
|
|
481,342
|
|
Total Shareholders’ Equity
|
|
|
754,575
|
|
|
|
681,544
|
|
Total Liabilities and Shareholders’ Equity
|
|
$
|
1,202,108
|
|
|
$
|
1,027,517
|
|
The accompanying notes are an integral part of these consolidated financial statements.
ICON plc
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Year Ended
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share and per share data)
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
Gross revenue
|
|
$
|
1,503,993
|
|
|
$
|
1,296,509
|
|
|
$
|
1,263,147
|
|
Reimbursable expenses
|
|
|
(388,987
|
)
|
|
|
(350,780
|
)
|
|
|
(363,103
|
)
|
Net revenue
|
|
|
1,115,006
|
|
|
|
945,729
|
|
|
|
900,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs
|
|
|
717,750
|
|
|
|
611,923
|
|
|
|
541,388
|
|
Selling, general and administrative
|
|
|
280,780
|
|
|
|
255,864
|
|
|
|
232,688
|
|
Depreciation and amortization
|
|
|
42,823
|
|
|
|
38,682
|
|
|
|
33,873
|
|
Restructuring and other items, net (Note 14)
|
|
|
5,636
|
|
|
|
9,817
|
|
|
|
-
|
|
Total costs and expenses
|
|
|
1,046,989
|
|
|
|
916,286
|
|
|
|
807,949
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations
|
|
|
68,017
|
|
|
|
29,443
|
|
|
|
92,095
|
|
Interest income
|
|
|
1,151
|
|
|
|
1,194
|
|
|
|
1,761
|
|
Interest expense
|
|
|
(1,947
|
)
|
|
|
(1,642
|
)
|
|
|
(1,132
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes
|
|
|
67,221
|
|
|
|
28,995
|
|
|
|
92,724
|
|
Provision for income taxes (Note 13)
|
|
|
(11,801
|
)
|
|
|
(6,115
|
)
|
|
|
(5,653
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
55,420
|
|
|
$
|
22,880
|
|
|
$
|
87,071
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per ordinary share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.92
|
|
|
$
|
0.38
|
|
|
$
|
1.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
0.92
|
|
|
$
|
0.37
|
|
|
$
|
1.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of ordinary shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic (Note 2)
|
|
|
59,968,174
|
|
|
|
60,379,338
|
|
|
|
59,718,934
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (Note 2)
|
|
|
60,450,706
|
|
|
|
61,070,686
|
|
|
|
60,637,103
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
|
|
ICON plc
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
|
Year Ended
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
55,420
|
|
|
$
|
22,880
|
|
|
$
|
87,071
|
|
Currency translation adjustment
|
|
|
4,494
|
|
|
|
(11,347
|
)
|
|
|
(9,701
|
)
|
Currency impact on long-term funding
|
|
|
1,982
|
|
|
|
(802
|
)
|
|
|
(1,080
|
)
|
Tax on currency impact of long term funding
|
|
|
(356
|
)
|
|
|
294
|
|
|
|
(198
|
)
|
Unrealized capital gain/(loss) – investments
|
|
|
861
|
|
|
|
(622
|
)
|
|
|
-
|
|
Actuarial gain/(loss) on defined benefit pension plan
|
|
|
689
|
|
|
|
(4,365
|
)
|
|
|
(1,209
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
$
|
63,090
|
|
|
$
|
6,038
|
|
|
$
|
74,883
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
|
|
ICON plc
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Capital
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid-in
|
|
|
Redemption
|
|
|
Comprehensive
|
|
|
Retained
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Reserve
|
|
|
Income
|
|
|
Earnings
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
59,007,565
|
|
|
$
|
4,965
|
|
|
$
|
174,188
|
|
|
$
|
-
|
|
|
$
|
12,584
|
|
|
$
|
380,509
|
|
|
$
|
572,246
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
87,071
|
|
|
$
|
87,071
|
|
Currency translation adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(9,701
|
)
|
|
|
-
|
|
|
|
(9,701
|
)
|
Currency impact on long-term
funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,080
|
)
|
|
|
-
|
|
|
|
(1,080
|
)
|
Tax on currency impact of long
term
funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(198
|
)
|
|
|
-
|
|
|
|
(198
|
)
|
Actuarial loss on defined benefit
pension plan
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,209
|
)
|
|
|
-
|
|
|
|
(1,209
|
)
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74,883
|
|
Exercise of share options
|
|
|
1,237,015
|
|
|
|
98
|
|
|
|
13,070
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13,168
|
|
Issue of restricted share units
|
|
|
2,512
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Share based compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
7,408
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
7,408
|
|
Share issue costs
|
|
|
-
|
|
|
|
-
|
|
|
|
(51
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(51
|
)
|
Excess tax benefit on exercise
of options
|
|
|
-
|
|
|
|
-
|
|
|
|
2,345
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,345
|
|
Balance at December 31, 2010
|
|
|
60,247,092
|
|
|
$
|
5,063
|
|
|
$
|
196,960
|
|
|
$
|
-
|
|
|
$
|
396
|
|
|
$
|
467,580
|
|
|
$
|
669,999
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
22,880
|
|
|
$
|
22,880
|
|
Currency translation adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(11,347
|
)
|
|
|
-
|
|
|
|
(11,347
|
)
|
Currency impact on long-term
funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(802
|
)
|
|
|
-
|
|
|
|
(802
|
)
|
Tax on currency impact of long
term funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
294
|
|
|
|
-
|
|
|
|
294
|
|
Unrealized capital gain/loss -
investments
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(622
|
)
|
|
|
-
|
|
|
|
(622
|
)
|
Actuarial loss on defined benefit
pension plan
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,365
|
)
|
|
|
-
|
|
|
|
(4,365
|
)
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,038
|
|
Exercise of share options
|
|
|
430,340
|
|
|
|
36
|
|
|
|
4,629
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,665
|
|
Issue of restricted share units
|
|
|
3,768
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Share based compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
9,355
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
9,355
|
|
Share issue costs
|
|
|
-
|
|
|
|
-
|
|
|
|
(76
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(76
|
)
|
Repurchase of ordinary shares
|
|
|
(545,597
|
)
|
|
|
(44
|
)
|
|
|
-
|
|
|
|
44
|
|
|
|
-
|
|
|
|
(9,005
|
)
|
|
|
(9,005
|
)
|
Share repurchase costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(113
|
)
|
|
|
(113
|
)
|
Excess tax benefit on exercise
of options
|
|
|
-
|
|
|
|
-
|
|
|
|
681
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
681
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2011
|
|
|
60,135,603
|
|
|
$
|
5,055
|
|
|
$
|
211,549
|
|
|
$
|
44
|
|
|
$
|
(16,446
|
)
|
|
$
|
481,342
|
|
|
$
|
681,544
|
|
ICON plc
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Capital
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid-in
|
|
|
Redemption
|
|
|
Comprehensive
|
|
|
Retained
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Reserve
|
|
|
Income
|
|
|
Earnings
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2011
|
|
|
60,135,603
|
|
|
$
|
5,055
|
|
|
$
|
211,549
|
|
|
$
|
44
|
|
|
$
|
(16,446
|
)
|
|
$
|
481,342
|
|
|
$
|
681,544
|
|
Comprehensive Income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
$
|
55,420
|
|
|
$
|
55,420
|
|
Currency translation adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,494
|
|
|
|
-
|
|
|
|
4,494
|
|
Currency impact on long-term
funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,982
|
|
|
|
-
|
|
|
|
1,982
|
|
Tax on currency impact of long
term funding
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(356
|
)
|
|
|
-
|
|
|
|
(356
|
)
|
Unrealized capital loss -
investments
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
861
|
|
|
|
-
|
|
|
|
861
|
|
Actuarial gain on defined benefit pension plan
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
689
|
|
|
|
-
|
|
|
|
689
|
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,090
|
|
Exercise of share options
|
|
|
890,236
|
|
|
|
68
|
|
|
|
12,947
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13,015
|
|
Share based compensation expense
|
|
|
-
|
|
|
|
-
|
|
|
|
11,521
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
11,521
|
|
Share issue costs
|
|
|
-
|
|
|
|
-
|
|
|
|
(74
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(74
|
)
|
Repurchase of ordinary shares
|
|
|
(738,341
|
)
|
|
|
(56
|
)
|
|
|
-
|
|
|
|
56
|
|
|
|
-
|
|
|
|
(15,605
|
)
|
|
|
(15,605
|
)
|
Share repurchase costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(190
|
)
|
|
|
(190
|
)
|
Excess tax benefit on exercise
of options
|
|
|
-
|
|
|
|
-
|
|
|
|
1,274
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,274
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2012
|
|
|
60,287,498
|
|
|
$
|
5,067
|
|
|
$
|
237,217
|
|
|
$
|
100
|
|
|
$
|
(8,776
|
)
|
|
$
|
520,967
|
|
|
$
|
754,575
|
|
The accompanying notes are an integral part of these consolidated financial statements.
ICON plc
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
Year Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
|
Year Ended
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
55,420
|
|
|
$
|
22,880
|
|
|
$
|
87,071
|
|
Adjustments to reconcile net income to net cash
|
|
|
|
|
|
|
|
|
|
|
|
|
provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on disposal of property, plant and equipment
|
|
|
233
|
|
|
|
136
|
|
|
|
136
|
|
Depreciation expense
|
|
|
35,210
|
|
|
|
34,030
|
|
|
|
31,425
|
|
Amortization of intangibles
|
|
|
7,613
|
|
|
|
4,652
|
|
|
|
2,448
|
|
Amortization of government grants
|
|
|
(154
|
)
|
|
|
(115
|
)
|
|
|
(220
|
)
|
Stock compensation expense
|
|
|
11,521
|
|
|
|
9,355
|
|
|
|
7,408
|
|
Deferred taxes
|
|
|
(10,430
|
)
|
|
|
(6,121
|
)
|
|
|
2,334
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
(Increase)/decrease in accounts receivable
|
|
|
(79,155
|
)
|
|
|
(32,081
|
)
|
|
|
18,267
|
|
Decrease/(increase) in unbilled revenue
|
|
|
13,227
|
|
|
|
(27,164
|
)
|
|
|
(4,887
|
)
|
Decrease/(increase) in other receivables
|
|
|
1,125
|
|
|
|
(1,669
|
)
|
|
|
469
|
|
(Increase)/decrease in prepayments and other current assets
|
|
|
682
|
|
|
|
(1,345
|
)
|
|
|
(783
|
)
|
Increase in other non current assets
|
|
|
(861
|
)
|
|
|
(233
|
)
|
|
|
(1,271
|
)
|
Increase/(decrease) in payments on account
|
|
|
68,654
|
|
|
|
9,494
|
|
|
|
(29,191
|
)
|
Increase/(decrease) in other current liabilities
|
|
|
17,035
|
|
|
|
20,390
|
|
|
|
(13,848
|
)
|
Increase/(decrease) in other non current liabilities
|
|
|
189
|
|
|
|
(613
|
)
|
|
|
999
|
|
Decrease in income taxes payable
|
|
|
(7,916
|
)
|
|
|
(2,753
|
)
|
|
|
(13,576
|
)
|
Increase/(decrease) increase in accounts payable
|
|
|
1,038
|
|
|
|
(8,652
|
)
|
|
|
647
|
|
Net cash provided by operating activities
|
|
|
113,431
|
|
|
|
20,191
|
|
|
|
87,428
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment
|
|
|
(30,791
|
)
|
|
|
(35,284
|
)
|
|
|
(30,952
|
)
|
Purchase of subsidiary undertakings and acquisition costs
|
|
|
(72,508
|
)
|
|
|
(69,836
|
)
|
|
|
(3,693
|
)
|
Cash acquired with subsidiary undertaking
|
|
|
2,572
|
|
|
|
8,300
|
|
|
|
-
|
|
Sale of short term investments
|
|
|
82,193
|
|
|
|
438
|
|
|
|
79,487
|
|
Purchase of short term investments
|
|
|
(102,575
|
)
|
|
|
(56,000
|
)
|
|
|
(30,260
|
)
|
Net cash (used in)/provided by investing activities
|
|
|
(121,109
|
)
|
|
|
(152,382
|
)
|
|
|
14,582
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Drawdown of credit lines and facilities
|
|
|
20,000
|
|
|
|
-
|
|
|
|
-
|
|
Repayment of credit lines and facilities
|
|
|
(20,000
|
)
|
|
|
-
|
|
|
|
-
|
|
Proceeds from the exercise of share options
|
|
|
13,015
|
|
|
|
4,665
|
|
|
|
13,168
|
|
Share issuance costs
|
|
|
(74
|
)
|
|
|
(76
|
)
|
|
|
(51
|
)
|
Excess tax benefit from the exercise of share options
|
|
|
1,274
|
|
|
|
681
|
|
|
|
2,345
|
|
Repurchase of ordinary shares
|
|
|
(15,605
|
)
|
|
|
(9,005
|
)
|
|
|
-
|
|
Share repurchase costs
|
|
|
(190
|
)
|
|
|
(113
|
)
|
|
|
-
|
|
Receipt of government grant
|
|
|
340
|
|
|
|
-
|
|
|
|
-
|
|
Repayment of other liabilities and finance lease obligations
|
|
|
-
|
|
|
|
-
|
|
|
|
(166
|
)
|
Net cash (used in)/provided by financing activities
|
|
|
(1,240
|
)
|
|
|
(3,848
|
)
|
|
|
15,296
|
|
Effect of exchange rate movements on cash
|
|
|
3,728
|
|
|
|
(430
|
)
|
|
|
(6,401
|
)
|
Net (decrease)/increase in cash and cash equivalents
|
|
|
(5,190
|
)
|
|
|
(136,469
|
)
|
|
|
110,905
|
|
Cash and cash equivalents at beginning of year
|
|
|
119,237
|
|
|
|
255,706
|
|
|
|
144,801
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
114,047
|
|
|
$
|
119,237
|
|
|
$
|
255,706
|
|
ICON plc
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
1. Description of business
ICON plc and its subsidiaries (“the Company” or “ICON”) is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process from compound selection to Phase I-IV clinical studies. Our vision is to be the Global CRO partner of choice for the Biopharma industry by delivering best in class information, solutions and performance in clinical and outcomes research.
We believe that we are one of a select group of CRO’s with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution At December 31, 2012 we had approximately 9,500 employees, in 82 locations in 40 countries. During the year ended December 31, 2012, we derived approximately 42.3%, 45.8% and 11.9% of our net revenue in the United States, Europe and Rest of World, respectively.
We began operations in 1990 and have expanded our business predominately through internal growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process. We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, Republic of Ireland. The contact telephone number of this office is 353 (1) 291 2000.
2. Significant Accounting Policies
The accounting policies noted below were applied in the preparation of the accompanying financial statements of the Company and are in conformity with accounting principles generally accepted in the United States.
(a) Basis of consolidation
The consolidated financial statements include the financial statements of the Company and all of its subsidiaries. All significant intercompany profits, transactions and account balances have been eliminated. The results of subsidiary undertakings acquired in the period are included in the consolidated statement of operations from the date of acquisition.
(b) Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The principle management estimates and judgements used in preparing the financial statements relate to revenue recognition, taxation, goodwill and business combinations.
(c) Revenue recognition
The Company primarily earns revenues by providing a number of different services to its customers. These services, which are integral elements of the clinical development process, include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. Contracts range in duration from a number of months to several years. Revenue for services, as rendered, is recognized only after persuasive evidence of an arrangement exists, the sales price is fixed or determinable and collectability is reasonably assured.
Clinical trials management revenue is recognized on a proportional performance method. Depending on the contractual terms revenue is either recognized on the percentage of completion method based on the relationship between hours incurred and the total estimated hours of the trial or on the unit of delivery method. Contract costs equate to the product of labor hours incurred and compensation rates. For the percentage of completion method, the input (effort expended) method has been used to measure progress towards completion as there is a direct relationship between input and productivity. Contract revenue is the product of the aggregated labor hours required to complete the specified contract tasks at the agreed contract rates. The Company regularly reviews the estimate of total contract time to ensure such estimates remain appropriate taking into account actual contract stage of completion, remaining time to complete and any identified changes to the contract scope. Remaining time to complete depends on the specific contract tasks and the complexity of the contract and can include geographical site selection and initiation, patient enrolment, patient testing and level of results analysis required. While the Company may routinely adjust time estimates, the Company’s estimates and assumptions historically have been accurate in all material respects in the aggregate. Where revenue is recognized on the unit of delivery method, the basis applied is the number of units completed as a percentage of the total number of contractual units.
Biometrics revenue is recognized on a fee-for-service method as each unit of data is prepared on the basis of the number of units completed in a period as a percentage of the total number of contracted units. Imaging revenue is recognized on a fee-for-service basis recognizing revenue for each image completed. Consulting revenue is recognized on a fee-for-service basis as each hour of the related service is performed.
Contract staffing revenue is recognized on a fee-for-service basis, over the time the related service is performed, or in the case of permanent placement, once the candidate has been placed with the client. Informatics revenue is recognized on a fee-for-service basis.
Informatics contracts are treated as multiple element arrangements, with contractual elements comprising licence fee revenue, support fee revenue and revenue from software services, each of which can be sold separately. Sales prices for contractual elements are determined by reference to objective and reliable evidence of their sales price. Licence and support fee revenues are recognized rateably over the period of the related agreement. Revenue from software services is recognized using the percentage of completion method based on the relationship between hours incurred and the total estimated hours required to perform the service.
Laboratory service revenue is recognized on a fee-for-service basis. The Company accounts for laboratory service contracts as multiple element arrangements, with contractual elements comprising laboratory kits and laboratory testing, each of which can be sold separately. Sales prices for contractual elements are determined by reference to objective and reliable evidence of their sales price. Revenues for contractual elements are recognised on the basis of the number of deliverable units completed in the period.
Contracts generally contain provisions for renegotiation in the event of changes in the scope, nature, duration, or volume of services of the contract. Renegotiated amounts are recognised as revenue by revision to the total contract value arising as a result of an authorised customer change order.
The difference between the amount of revenue recognized and the amount billed on a particular contract is included in the balance sheet as unbilled revenue or payments on account. Normally, amounts become billable upon the achievement of certain milestones, for example, target patient enrollment rates, clinical testing sites initiated or case report forms completed. Once the milestone target is reached, amounts become billable in accordance with pre-agreed payment schedules included in the contract or on submission of appropriate billing detail. Such cash payments are not representative of revenue earned on the contract as revenues are recognized over the period in which the specified contractual obligations are fulfilled. Amounts included in unbilled revenue are expected to be collected within one year and are included within current assets. Advance billings to customers, for which revenue has not been recognized, are recognized as payments on account within current liabilities.
In the event of contract termination, if the value of work performed and recognized as revenue is greater than aggregate milestone billings at the date of termination, cancellation clauses ensure that the Company is paid for all work performed to the termination date.
(d) Reimbursable expenses
Reimbursable expenses comprise investigator payments and certain other costs which are reimbursed by clients under terms specific to each contract and are deducted from gross revenue in arriving at net revenue. Investigator payments are accrued based on patient enrollment over the life of the contract. Investigator payments are made based on predetermined contractual arrangements, which may differ from the accrual of the expense.
(e) Direct costs
Direct costs consist of compensation, associated employee benefits and share-based payments for project-related employees and other direct project-related costs.
(f) Advertising costs
All costs associated with advertising and promotion are expensed as incurred. The advertising and promotion expense was $3,679,000, $2,905,000 and $3,431,000 for the years ended December 31, 2012, December 31, 2011 and December 31, 2010 respectively.
(g) Foreign currencies and translation of subsidiaries
The Company's financial statements are prepared in United States dollars. Transactions in currencies other than United States dollars are recorded at the rate ruling at the date of the transactions. Monetary assets and liabilities denominated in currencies other than United States dollars are translated into United States dollars at exchange rates prevailing at the balance sheet date. Adjustments resulting from these translations are charged or credited to income. Amounts credited or charged to the statement of operations for the years ended December 31, 2012, December 31, 2011 and December 31, 2010 were as follows:
|
|
Year ended
December 31,
|
|
|
|
(in thousands)
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Amounts (credited)/charged
|
|
$
|
(1,231
|
)
|
|
$
|
391
|
|
|
$
|
3,731
|
|
The financial statements of subsidiaries with other functional currencies are translated at period end rates for the balance sheet and average rates for the statement of operations. Translation gains and losses arising are reported as a movement on accumulated other comprehensive income.
(h) Disclosure about fair value of financial instruments
The following methods and assumptions were used to estimate the fair value of each material class of financial instrument:
Cash, cash equivalents, unbilled revenue, other receivables, short term investments, prepayments and other current assets, accounts receivable, accounts payable, investigator payments, payments on account, accrued liabilities, accrued bonuses and income taxes payable have carrying amounts that approximate fair value due to the short term maturities of these instruments. Other liabilities’ carrying amounts approximate fair value based on net present value of estimated future cash flows.
(i) Business combinations
The cost of a business combination is measured as the aggregate of the fair values at the date of exchange of assets given, liabilities incurred or assumed and equity instruments issued in exchange for control. Where a business combination agreement provides for an adjustment to the cost of the acquisition which is contingent upon future events, the amount of the estimated adjustment is recognised on the acquisition date at the acquisition date fair value of this contingent consideration. Any changes to this estimate in subsequent periods will depend on the classification of the contingent consideration. If the contingent consideration is classified as equity it shall not be re-measured and the settlement shall be accounted for within equity. If the contingent consideration is classified as an asset or liability any adjustments will be accounted for through the Consolidated Statement of Operations or other comprehensive income depending on whether the asset or liability is considered a financial instrument.
The assets, liabilities and contingent liabilities of businesses acquired are measured at their fair values at the date of acquisition. In the case of a business combination which is completed in stages, the fair values of the identifiable assets, liabilities and contingent liabilities are determined at the date of each exchange transaction. When the initial accounting for a business combination is determined provisionally, any subsequent adjustments to the provisional values allocated to the identifiable assets, liabilities and contingent liabilities are made within twelve months of the acquisition date and presented as adjustments to the original acquisition accounting.
(j) Goodwill and Impairment
Goodwill represents the excess of the cost of acquired entities over the net amounts assigned to assets acquired and liabilities assumed. Goodwill primarily comprises acquired workforce in place which does not qualify for recognition as an asset apart from goodwill. Goodwill is stated net of any provision for impairment. The Company tests goodwill annually for any impairments or whenever events occur which may indicate impairment. The first step is to compare the carrying amount of the reporting unit’s assets to the fair value of the reporting unit. If the carrying amount exceeds the fair value then a second step is completed which involves the fair value of the reporting unit being allocated to each asset and liability with the excess being implied goodwill. The impairment loss is the amount by which the recorded goodwill exceeds the implied goodwill. No impairment was recognized as a result of the impairment testing carried out for the years ended December 31, 2012, December 31, 2011 and December 31, 2010.
(k) Intangible assets
Intangible assets are amortized on a straight line basis over their estimated useful life.
(l) Cash and cash equivalents
Cash and cash equivalents include cash and highly liquid investments with initial maturities of three months or less and are stated at cost, which approximates market value.
(m) Short term investments - available for sale
The Company classifies short-term investments as available for sale in accordance with the terms of FASB ASC 320,
Investments – Debt and Equity Securities
. Realized gains and losses are determined using specific identification. The investments are reported at fair value, with unrealized gains or losses reported in a separate component of shareholders’ equity. Any differences between the cost and fair value of the investments are represented by accrued interest.
(n) Inventory
Inventory is valued at the lower of cost and net market value and after provisions for obsolescence. Cost of inventories comprises the purchase price and attributable costs, less trade discounts. At December 31, 2012 the carrying value of inventory, included within prepayments and other current assets on the balance sheet, was $3.0 million (2011: $2.8 million).
(o) Property, plant and equipment
Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation of property, plant and equipment is computed using the straight line method based on the estimated useful lives of the assets as listed below:
|
|
Years
|
Building
|
|
40
|
Office furniture and fixtures
|
|
8
|
Laboratory equipment
|
|
5
|
Motor vehicles
|
|
5
|
Computer equipment and software
|
|
2-8
|
Leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter.
(p) Leased assets
Costs in respect of operating leases are charged to the statement of operations on a straight line basis over the lease term.
Assets acquired under capital finance leases are included in the balance sheet at the present value of the future minimum lease payments and are depreciated over the shorter of the lease term and their remaining useful lives. The corresponding liabilities are recorded in the balance sheet and the interest element of the capital lease rental is charged to interest expense.
(q) Income taxes
The Company applies FASB ASC 740,
Income Taxes
(“ASC 740”), which requires the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which these temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. ASC 740 requires that the Company recognizes the largest amount of tax benefit that is greater than 50% likely of being realized upon effective settlement when considering uncertain tax positions.
(r) Government grants
Government grants received relating to capital expenditure are shown as deferred income and credited to income on a basis consistent with the depreciation policy of the relevant assets. Grants relating to categories of operating expenditures are credited to income in the period in which the expenditure to which they relate is charged.
Under the grant agreements amounts received may become repayable in full should certain circumstances specified within the grant agreements occur, including downsizing by the Company, disposing of the related assets, ceasing to carry on its business or the appointment of a receiver over any of its assets. The Company has not recognized any loss contingency having assessed as remote the likelihood of these events arising.
(s) Research and development credits
Research and development credits are available to the Company under the tax laws in certain jurisdictions, based on qualifying research and development spend as defined under those tax laws. Research and development credits are generally recognized as a reduction of income tax expense. However, certain tax jurisdictions provide refundable credits that are not wholly dependent on the Company’s ongoing income tax status or income tax position. In these circumstances the benefit of these credits is not recorded as a reduction to income tax expense, but rather as a reduction of the operating expenditure to which the credits relate.
(t) Pension costs
The Company contributes to defined contribution plans covering all eligible employees. The Company contributes to these plans based upon various fixed percentages of employee compensation and such contributions are expensed as incurred.
The Company operates, through a subsidiary, a defined benefit plan for certain of its United Kingdom employees. The Company accounts for the costs of this plan using actuarial models required by FASB ASC 715-30 and the plan is presented in accordance with the requirements of FASB ASC 715-60
Defined Benefit Plans – Other Postretirement
.
(u) Net income per ordinary share
Basic net income per ordinary share has been computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income per ordinary share is computed by adjusting the weighted average number of ordinary shares outstanding during the period for all potentially dilutive ordinary shares outstanding during the period and adjusting net income for any changes in income or loss that would result from the conversion of such potential ordinary shares.
There is no difference in net income used for basic and diluted net income per ordinary share. The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows:
|
|
Year Ended December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
Weighted average number of ordinary shares outstanding for
basic net income per ordinary share
|
|
|
59,968,174
|
|
|
|
60,379,338
|
|
|
|
59,718,934
|
|
Effect of dilutive share options outstanding
|
|
|
482,532
|
|
|
|
691,348
|
|
|
|
918,169
|
|
Weighted average number of ordinary shares outstanding for
diluted net income per ordinary share
|
|
|
60,450,706
|
|
|
|
61,070,686
|
|
|
|
60,637,103
|
|
(v) Share-based compensation
The Company accounts for its share options and restricted share units (“RSU’s”) in accordance with the provisions of FASB ASC 718,
Compensation – Stock Compensation.
Share-based compensation expense for equity-settled awards made to employees and directors is measured and recognized based on estimated grant date fair values. These awards include employee stock options and RSU’s.
Share-based compensation expense for stock options awarded to employees and directors is estimated at the grant date based on each option’s fair value as calculated using the Black-Scholes option-pricing model. Share-based compensation for RSU’s awarded to employees and directors is calculated based on the market value of the Company’s shares on the date of award of the RSU’s. The value of awards expected to vest is recognized as an expense over the requisite service periods.
Estimating the fair value of share-based awards as of the grant date using an option-pricing model, such as the Black-Scholes model, is affected by the Company’s share price as well as assumptions regarding a number of complex variables. These variables include, but are not limited to, the expected share price volatility over the term of the awards, risk-free interest rates, and the expected term of the awards.
(w) Impairment of long-lived assets
Long lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less selling costs.
(x) Reclassifications
Certain amounts in the consolidated financial statements have been reclassified where necessary to conform to the current year presentation.
3. Short term investments - available for sale
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
At start of year
|
|
$
|
54,940
|
|
|
$
|
-
|
|
Additions
|
|
|
102,575
|
|
|
|
56,000
|
|
Disposals
|
|
|
(82,193
|
)
|
|
|
(438
|
)
|
Unrealized capital gain/(loss) - investments
|
|
|
861
|
|
|
|
(622
|
)
|
|
|
|
|
|
|
|
|
|
At end of year
|
|
$
|
76,183
|
|
|
$
|
54,940
|
|
The Company classifies its short term investments as available for sale. Short term investments comprise highly liquid investments with maturities of greater than three months and minimum “A” rated fixed and floating rate securities. The investments are reported at fair value with unrealized gains or losses reported in a separate component of shareholders’ equity. Any differences between the cost and fair value of investments are represented by accrued interest. The fair value of short term investments are represented by level 1 fair value measurements – quoted prices in active markets for identical assets.
4. Goodwill
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Opening goodwill
|
|
$
|
253,393
|
|
|
$
|
175,860
|
|
Current year acquisitions
|
|
|
55,759
|
|
|
|
83,656
|
|
Prior year acquisitions
|
|
|
1,382
|
|
|
|
-
|
|
Foreign exchange movement
|
|
|
4,907
|
|
|
|
(6,123
|
)
|
Closing goodwill
|
|
$
|
315,441
|
|
|
$
|
253,393
|
|
The Company has made a number of strategic acquisitions since its inception to enhance its capabilities and experience in certain areas of the clinical development process. Goodwill arising on acquisition represents the excess of the cost of acquired entities over the net amounts assigned to assets acquired and liabilities assumed. Goodwill primarily comprises acquired workforce in place which does not qualify for recognition as an asset apart from goodwill.
The Company tests goodwill annually for any impairments or whenever events occur which may indicate impairment. The results of the Company’s goodwill impairment testing during the year ended December 31, 2012, indicated the existence of sufficient headroom such that a reasonably possible change to the key assumptions used would be unlikely to result in an impairment of the related goodwill.
(a) Acquisition of PriceSpective
On February 28, 2012 the Company acquired 100% of the common stock of PriceSpective LLC (PriceSpective) strategy consulting company for an initial cash consideration of $37.1 million. Headquartered in Philadelphia, and with offices in London, Los Angeles, San Diego, Raleigh and Boston, PriceSpective is a premier consultancy that has a strong reputation for excellence in strategic pricing, market access, Health Economics and Outcomes Research (“HEOR”), due diligence support and payer engagement services. Since PriceSpective’s incorporation in 2003, it has developed strategies for dozens of new product launches, and hundreds of development and in-market products, across 40+ disease areas. Further consideration of up to $15.0 million was payable if certain performance milestones were achieved in respect of periods up to December 31, 2012. On August 13, 2012 the Company paid $5.0 million in relation to performance milestones for the year ended December 31, 2011.
At December 31, 2012 the Company has recorded a liability of $10.0 million in respect of the milestones for the year ended December 31, 2012.
The following table summarizes the Company’s estimates of the fair values of assets acquired and the liabilities assumed:
|
|
February 28
|
|
|
|
2012
|
|
|
|
(in thousands)
|
|
Property, plant and equipment
|
|
$
|
256
|
|
Goodwill*
|
|
|
42,247
|
|
Intangible asset – customer relationships
|
|
|
10,237
|
|
Intangible asset – order backlog
|
|
|
405
|
|
Intangible asset – non-compete arrangements
|
|
|
392
|
|
Cash and cash equivalents
|
|
|
2,311
|
|
Accounts receivable
|
|
|
2,662
|
|
Unbilled revenue
|
|
|
1,140
|
|
Other current assets
|
|
|
236
|
|
Current liabilities
|
|
|
(7,788
|
)
|
Liability arising from contingent consideration arrangement
|
|
|
(15,000
|
)
|
Net assets acquired
|
|
$
|
37,098
|
|
Cash consideration
|
|
$
|
37,199
|
|
Working capital adjustment
|
|
|
(101
|
)
|
Contingent consideration
|
|
|
15,000
|
|
Amount of total consideration
|
|
|
52,098
|
|
Liabilities included in preliminary purchase price allocation re
contingent consideration
|
|
|
(15,000
|
)
|
Net assets acquired
|
|
$
|
37,098
|
|
* Goodwill represents the acquisition of an established workforce with experience in strategic pricing, market access, HEOR, due diligence support and payer engagement services. Goodwill related to the US portion of the business acquired is tax deductible.
The proforma effect of the PriceSpective acquisition if completed on January 1, 2011 would have resulted in net revenue, net income and earnings per share for the fiscal years ended December 31, 2011 and December 31, 2012 as follows:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Net revenue
|
|
$
|
1,118,410
|
|
|
$
|
964,388
|
|
Net income
|
|
$
|
55,931
|
|
|
$
|
25,363
|
|
Basic earnings per share
|
|
$
|
0.93
|
|
|
$
|
0.42
|
|
Diluted earnings per share
|
|
$
|
0.93
|
|
|
$
|
0.42
|
|
(b) Acquisition of BeijingWits Medical
On February 15, 2012 the Company acquired 100% of the common stock of BeijingWits Medical Consulting Co. Limited (BeijingWits Medical), a leading Chinese CRO, for an initial cash consideration of $9.0 million. BeijingWits Medical offers full-service clinical development capabilities and has a strong track record in clinical trial execution in China. It is a renowned expert in Chinese regulatory processes and a leading advocate of International Conference on Harmonisation Good Clinical Practice (“ICH GCP”) in China. In addition to boosting the Company’s service capabilities in the region, BeijingWits Medical will also strengthen the Company’s presence through the addition of over 100 highly qualified and experienced professionals in Beijing, Shanghai, Chengdu, Guangzhou, Wuhan and Hong Kong. Further consideration of up to $7.0 million may become payable if certain performance milestones are achieved in respect of periods up to December 31, 2013. At December 31, 2012 the Company has recorded a liability of $7.0 million in respect of the additional consideration.
The following table summarizes the Company’s estimates of the fair values of assets acquired and the liabilities assumed:
|
|
February 15
|
|
|
|
2012
|
|
|
|
(in thousands)
|
|
Property, plant and equipment
|
|
$
|
172
|
|
Goodwill*
|
|
|
13,512
|
|
Intangible asset – customer relationships
|
|
|
1,761
|
|
Intangible asset – order backlog
|
|
|
376
|
|
Intangible asset – non-compete arrangements
|
|
|
97
|
|
Cash and cash equivalents
|
|
|
587
|
|
Accounts receivable
|
|
|
657
|
|
Unbilled revenue
|
|
|
176
|
|
Other current assets
|
|
|
228
|
|
Deferred tax liability
|
|
|
(559
|
)
|
Current liabilities
|
|
|
(1,007
|
)
|
Liability arising from contingent consideration arrangement
|
|
|
(7,000
|
)
|
Net assets acquired
|
|
$
|
9,000
|
|
Cash consideration
|
|
$
|
9,000
|
|
Contingent consideration
|
|
|
7,000
|
|
Amount of total consideration
|
|
|
16,000
|
|
Liabilities included in preliminary purchase price allocation re
contingent consideration
|
|
|
(7,000
|
)
|
Net assets acquired
|
|
$
|
9,000
|
|
* Goodwill represents the acquisition of an established workforce with experience in clinical trial execution and regulatory processes in China and is not tax deductible.
The proforma effect of the BeijingWits acquisition if completed on January 1, 2011 would have resulted in net revenue, net income and earnings per share for the fiscal years ended December 31, 2011 and December 31, 2012 as follows:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Net revenue
|
|
$
|
1,115,355
|
|
|
$
|
989,942
|
|
Net income
|
|
$
|
55,349
|
|
|
$
|
22,549
|
|
Basic earnings per share
|
|
$
|
0.92
|
|
|
$
|
0.37
|
|
Diluted earnings per share
|
|
$
|
0.92
|
|
|
$
|
0.37
|
|
(c) Acquisition of Firecrest Clinical
On July 14, 2011 the Company acquired 100% of the common stock of Firecrest Clinical Limited (“Firecrest”), a market leading provider of technology solutions that boost investigator site performance and study management, for an initial cash consideration of €17.0 million ($24.5 million). Headquartered in Limerick, Ireland, Firecrest Clinical provides a comprehensive site performance management system that is used to improve compliance consistency and execution of activities at investigative sites. The acquisition agreement provided that further consideration of up to €33.0 million ($46.8 million) may become payable if certain performance milestones are achieved in respect of periods up to June 30, 2013. At the date of acquisition the Company recorded a liability of €31.3 million ($44.0 million) in relation to these performance milestones. In March 2012 €3.0 million ($4.0million) was paid by the Company in relation to performance milestones for the six months ended June 30, 2011 and in July 2012 a further €10 million ($12.5 million) was paid by the Company in relation to performance milestones for the year ended December 31, 2011, both amounts representing the full amount of additional consideration potentially payable. At December 31, 2012 the Company has recorded a liability of €19.5 million ($25.8 million) in relation to the remaining performance milestones.
The acquisition agreement also provided for certain working capital targets to be achieved by Firecrest Clinical on completion. In March 2012 the Company paid €0.4 million ($0.5 million) on completion of this review.
The acquisition of Firecrest has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations. The following table summarizes the estimated fair values of the assets acquired and the liabilities assumed:
|
|
July 14
|
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Property, plant and equipment
|
|
$
|
687
|
|
Goodwill*
|
|
|
48,073
|
|
Intangible asset – technology asset
|
|
|
11,169
|
|
Intangible asset – customer relationships
|
|
|
5,243
|
|
Intangible asset – order backlog
|
|
|
1,172
|
|
Intangible asset - trade name
|
|
|
1,357
|
|
Cash and cash equivalents
|
|
|
1,965
|
|
Other current assets
|
|
|
3,713
|
|
Deferred tax liability
|
|
|
(2,367
|
)
|
Other liabilities
|
|
|
(2,521
|
)
|
Liability arising from contingent consideration arrangement
|
|
|
(44,028
|
)
|
Net assets acquired
|
|
$
|
24,463
|
|
Cash consideration
|
|
$
|
24,463
|
|
Contingent consideration
|
|
|
44,028
|
|
Amount of total consideration
|
|
|
68,491
|
|
Liabilities included in preliminary purchase price allocation re
contingent consideration
|
|
|
(44,028
|
)
|
Net assets acquired
|
|
$
|
24,463
|
|
*
|
Goodwill represents the cost of an established workforce with experience in the development of site performance and study management systems and process related efficiencies expected to be generated from the use of the Firecrest site performance management system and is not tax deductible.
|
The proforma effect of the Firecrest acquisition if completed on January 1, 2010 would have resulted in net revenue, net income and earnings per share for the fiscal years ended December 31, 2010 and December 31, 2011 as follows:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Net revenue
|
|
$
|
952,729
|
|
|
$
|
906,311
|
|
Net income
|
|
$
|
25,851
|
|
|
$
|
86,127
|
|
Basic earnings per share
|
|
$
|
0.43
|
|
|
$
|
1.44
|
|
Diluted earnings per share
|
|
$
|
0.42
|
|
|
$
|
1.42
|
|
(d) Acquisition of Oxford Outcomes
On January 14, 2011 the Company acquired approximately 80% of the common stock of Oxford Outcomes Limited (“Oxford Outcomes”), an international health outcomes consultancy business, for an initial cash consideration of £18.1 million ($28.1 million). Headquartered in Oxford, United Kingdom, and with offices in the USA and Canada, Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation. On the same day a put and call option was agreed between the Company and the selling shareholders for the acquisition of the remaining common stock of Oxford Outcomes during the year ended December 31, 2011 for cash consideration of £3.8 million ($6.0 million). This option was exercised in October 2011.
Additional consideration of up to £8.0 million ($12.6 million) was potentially payable if certain performance milestones were achieved by Oxford Outcomes in respect of periods up to March 31, 2012; £4.0 million ($6.3 million) in respect of the year ended March 31, 2011 and £4.0 million ($6.3 million) in respect of the year ended March 31, 2012. Performance milestones in respect of both periods have been achieved. £4.0 million ($6.3 million) was paid during the year ended December 31, 2011 in respect of the milestone for the year ended March 31, 2011. A part payment of £2.0 million ($3.3 million) in respect of March 31, 2012 milestone was made by the Company in October 2012. At December 31, 2012, the Company has recorded a liability of £2.0 million ($3.1 million) in relation to the milestone for the year ended March 31, 2012.
The acquisition agreement also provided for certain working capital targets to be achieved by Oxford Outcomes on completion. In May 2011 the Company paid an additional £3.3 million ($5.1 million) in respect of certain elements of this review and in March 2012 paid a further £0.8 million ($1.2 million) on completion of the review.
The acquisition of Oxford Outcomes has been accounted for as a business combination in accordance with FASB ASC 805
Business Combinations.
The following table summarizes the estimated fair values of the assets acquired and the liabilities assumed:
|
|
January 14
|
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Property, plant and equipment
|
|
$
|
490
|
|
Goodwill*
|
|
|
36,432
|
|
Intangible asset – customer relationships
|
|
|
6,648
|
|
Intangible asset – order backlog
|
|
|
618
|
|
Cash and cash equivalents
|
|
|
6,015
|
|
Other current assets
|
|
|
6,792
|
|
Deferred tax liability
|
|
|
(2,003
|
)
|
Other liabilities
|
|
|
(2,128
|
)
|
Liability arising from contingent consideration arrangement
|
|
|
(12,474
|
)
|
Net assets acquired
|
|
$
|
40,390
|
|
Cash consideration
|
|
$
|
28,114
|
|
Working capital adjustment
|
|
|
6,383
|
|
Put and call option
|
|
|
5,893
|
|
Contingent consideration
|
|
|
12,474
|
|
Amount of total consideration
|
|
|
52,864
|
|
Liabilities included in preliminary purchase price allocation
re contingent consideration
|
|
|
(12,474
|
)
|
Net assets acquired
|
|
$
|
40,390
|
|
*
|
Goodwill represents the cost of established workforce with experience in specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation and is not tax deductible.
|
The proforma effect of the Oxford Outcomes acquisition if completed on January 1, 2010 would have resulted in net revenue, net income and earnings per share for the fiscal years ended December 31, 2010 and December 31, 2011 as follows:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Net revenue
|
|
$
|
945,729
|
|
|
$
|
919,524
|
|
Net income
|
|
$
|
22,880
|
|
|
$
|
91,524
|
|
Basic earnings per share
|
|
$
|
0.38
|
|
|
$
|
1.53
|
|
Diluted earnings per share
|
|
$
|
0.37
|
|
|
$
|
1.51
|
|
5. Intangible Assets
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
Cost
|
|
(in thousands)
|
|
Customer relationships acquired
|
|
$
|
33,951
|
|
|
$
|
22,193
|
|
Technology asset acquired
|
|
|
11,169
|
|
|
|
11,169
|
|
Order backlog
|
|
|
2,571
|
|
|
|
3,260
|
|
Tradenames acquired
|
|
|
1,357
|
|
|
|
1,357
|
|
Volunteer list acquired
|
|
|
1,325
|
|
|
|
1,325
|
|
Non-compete arrangements
|
|
|
489
|
|
|
|
-
|
|
Foreign exchange movement
|
|
|
(1,001
|
)
|
|
|
(1,728
|
)
|
Total cost
|
|
|
49,861
|
|
|
|
37,576
|
|
Accumulated amortization
|
|
|
(15,363
|
)
|
|
|
(9,467
|
)
|
Foreign exchange movement
|
|
|
(51
|
)
|
|
|
151
|
|
|
|
|
|
|
|
|
|
|
Net book value
|
|
$
|
34,447
|
|
|
$
|
28,260
|
|
On February 28, 2012 the Company acquired PriceSpective a strategy consulting company. The value of certain customer relationships identified of $10.2 million is being amortized over approximately 10 years, the estimated period of benefit. The value of order backlog and certain non-compete arrangements identified of $0.4 million and $0.4 million respectively are being amortized over approximately 0.8 and 3 years, the estimated period of benefit. $1,367,000 has been amortized in the period since the date of acquisition.
On February 15, 2012 the Company acquired BeijingWits Medical, a Chinese CRO. The value of certain customer relationships and order backlog identified of $1.8 million and $0.4 million respectively are being amortized over approximately 10 and 4 years, the estimated period of benefit. The value of certain non-compete arrangements identified of $0.01 million are being amortized over approximately 5 years, the estimated period of benefit. $253,000 has been amortized in the period since the date of acquisition.
On July 14, 2011 the Company acquired Firecrest Clinical Limited, a provider of technology solutions that boost investigator site performance and study management. The value of certain technology assets and customer relationships identified of $11.2 million and $5.2 million respectively are being amortized over approximately 7.5 years, the estimated period of benefit. The value of the Firecrest tradename and order backlog identified of $1.4 million and $1.2 million respectively are being amortized over approximately 4.5 and 1.2 years, the estimated period of benefit. $4,482,000 has been amortized in the period since the date of acquisition.
On January 14, 2011 the Company acquired Oxford Outcomes Limited, an international health outcomes consultancy business. The value of certain customer relationships and order backlog identified of $6.6 million and $0.6 million respectively are being amortized over approximately 6.5 and 2 years, the estimated period of benefit. $2,666,000 has been amortized in the period since the date of acquisition. A put and call option was also agreed between the Company and the selling shareholders for the acquisition of the remaining common stock of Oxford Outcomes Limited. This option was exercised in October 2011.
On May 17, 2010 the Company acquired Timaq Medical Imaging, a European provider of advanced imaging services. The value of certain client relationships identified of $0.8 million is being amortized over approximately 3 years, the estimated period of benefit. $674,000 has been amortized in the period since the date of acquisition.
During the year ended December 31, 2009 the Company completed the acquisitions of Qualia Clinical Services, Inc, a US provider of Phase I clinical trial services and Veeda Laboratories Limited, a specialist provider of biomarker laboratory services. The value of certain client relationships identified of $0.4 million is being amortized over 3 years, the estimated period of benefit. $352,000 has been amortized in the period since the date of acquisition.
On November 14, 2008 the Company acquired Prevalere Life Sciences, a US provider
of bioanalytical and immunoassay laboratory services.
The value of certain customer relationships identified of $7.4 million is being amortized over periods ranging from approximately 7 to 11 years, the estimated period of the benefit. $3,347,000 has been amortized in the period since the date of acquisition.
On February 11, 2008 the Company acquired Healthcare Discoveries, a US provider of Phase I clinical trial services. The value of certain client relationships identified of $1.6 million is being amortized over periods ranging from approximately 2 to 9 years, the estimated periods of benefit. The value of certain volunteer lists identified of $1.3 million is being amortized over approximately 6 years, the estimated period of benefit. $2,222,000 has been amortized in the period since the date of acquisition.
Future intangible asset amortization expense for the years ended December 31, 2013 to December 31, 2017 is as follows:
|
|
Year ended
December 31
(in thousands)
|
|
2013
|
|
$
|
6,078
|
|
2014
|
|
|
5,800
|
|
2015
|
|
|
5,642
|
|
2016
|
|
|
5,048
|
|
2017
|
|
|
4,182
|
|
|
|
|
|
|
|
|
$
|
26,750
|
|
6. Property, Plant and Equipment, net
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Cost
|
|
|
|
|
|
|
Land
|
|
$
|
3,325
|
|
|
$
|
3,323
|
|
Building
|
|
|
94,395
|
|
|
|
92,859
|
|
Computer equipment and software
|
|
|
189,455
|
|
|
|
179,850
|
|
Office furniture and fixtures
|
|
|
66,351
|
|
|
|
62,458
|
|
Laboratory equipment
|
|
|
32,724
|
|
|
|
32,156
|
|
Leasehold improvements
|
|
|
10,482
|
|
|
|
9,462
|
|
Motor vehicles
|
|
|
69
|
|
|
|
70
|
|
|
|
|
396,801
|
|
|
|
380,178
|
|
Less accumulated depreciation and asset write off
|
|
|
(228,428
|
)
|
|
|
(211,717
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment (net)
|
|
$
|
168,373
|
|
|
$
|
168,461
|
|
7. Other Liabilities
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
Personnel related liabilities
|
|
$
|
90,902
|
|
|
$
|
62,017
|
|
Facility related liabilities
|
|
|
15,393
|
|
|
|
14,776
|
|
General overhead liabilities
|
|
|
22,776
|
|
|
|
24,520
|
|
Other liabilities
|
|
|
5,010
|
|
|
|
1,823
|
|
Short term government grants (note 11)
|
|
|
235
|
|
|
|
79
|
|
Restructuring and other items (note 14)
|
|
|
926
|
|
|
|
3,874
|
|
Acquisition consideration payable
|
|
|
45,850
|
|
|
|
37,615
|
|
Share repurchase program
|
|
|
-
|
|
|
|
1,259
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
181,092
|
|
|
$
|
145,963
|
|
8. Other Non-Current Liabilities
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
Personnel related liabilities
|
|
$
|
6,920
|
|
|
$
|
-
|
|
Defined benefit pension obligations, net (note 9)
|
|
$
|
4,720
|
|
|
$
|
4,903
|
|
Acquisition consideration payable
|
|
|
-
|
|
|
|
11,903
|
|
Other non-current liabilities
|
|
|
2,672
|
|
|
|
3,232
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
14,312
|
|
|
$
|
20,038
|
|
9. Employee Benefits
Certain Company employees are eligible to participate in a defined contribution plan (the "Plan"). Participants in the Plan may elect to defer a portion of their pre-tax earnings into a pension plan, which is run by an independent party. The Company matches participant's contributions typically at 6% of the participant's annual compensation. Contributions to this plan are recorded, as an expense in the Consolidated Statement of Operations. Contributions for the years ended December 31, 2010, December 31, 2011 and December 31, 2012 were $14,206,000, $16,644,000 and $18,187,000 respectively.
The Company's United States operations maintain a retirement plan (the "U.S. Plan") that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Participants in the U.S. Plan may elect to defer a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. The Company matches 50% of each participant's contributions; each participant can contribute up to 6% of their annual compensation. Contributions to this U.S. Plan are recorded, in the year contributed, as an expense in the Consolidated Statement of Operations. Contributions for the years ended December 31, 2010, December 31, 2011 and December 31, 2012 were $6,603,000, $7,064,000 and $8,442,000 respectively.
One of the Company’s subsidiaries which was acquired during the 2003 fiscal year, ICON Development Solutions Limited, operates a defined benefit pension plan in the United Kingdom for its employees. The plan is managed externally and the related pension costs and liabilities are assessed in accordance with the advice of a professionally qualified actuary. Plan assets at December 31, 2012, December 31, 2011 and December 31, 2010, consist of units held in independently administered funds. The pension costs of this plan are presented in the following tables in accordance with the requirements of ASC 715-60,
Defined Benefit Plans – Other Postretirement
. The plan has been closed to new entrants with effect from July 1, 2003.
Change in benefit obligation
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
|
(in thousands)
|
|
Benefit obligation at beginning of year
|
|
$
|
19,924
|
|
|
$
|
16,482
|
|
Service cost
|
|
|
242
|
|
|
|
212
|
|
Interest cost
|
|
|
964
|
|
|
|
931
|
|
Plan participants’ contributions
|
|
|
101
|
|
|
|
134
|
|
Benefits paid
|
|
|
(237
|
)
|
|
|
(109
|
)
|
Actuarial loss
|
|
|
405
|
|
|
|
2,621
|
|
Foreign currency exchange rate changes
|
|
|
1,128
|
|
|
|
(347
|
)
|
|
|
|
|
|
|
|
|
|
Benefit obligation at end of year
|
|
$
|
22,527
|
|
|
$
|
19,924
|
|
Change in plan assets
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
|
(in thousands)
|
|
Fair value of plan assets at beginning of year
|
|
$
|
15,021
|
|
|
$
|
15,499
|
|
Actual return on plan assets
|
|
|
1,810
|
|
|
|
(604
|
)
|
Employer contributions
|
|
|
239
|
|
|
|
273
|
|
Plan participants’ contributions
|
|
|
101
|
|
|
|
135
|
|
Benefits paid
|
|
|
(237
|
)
|
|
|
(109
|
)
|
Foreign currency exchange rate changes
|
|
|
873
|
|
|
|
(173
|
)
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets at end of year
|
|
$
|
17,807
|
|
|
$
|
15,021
|
|
The fair values of the assets above do not include any of the Company’s own financial instruments, property occupied by, or other assets used by, the Company.
Funded status
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
|
(in thousands)
|
|
Projected benefit obligation
|
|
$
|
(22,527
|
)
|
|
$
|
(19,924
|
)
|
Fair value of plan assets
|
|
|
17,807
|
|
|
|
15,021
|
|
|
|
|
|
|
|
|
|
|
Funded status
|
|
$
|
(4,720
|
)
|
|
$
|
(4,903
|
)
|
|
|
|
|
|
|
|
|
|
Non-current other liabilities
|
|
$
|
(4,720
|
)
|
|
$
|
(4,903
|
)
|
The following amounts were recorded in the consolidated statement of operations as components of the net periodic benefit cost/(credit)
|
|
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
December 31,
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Service cost
|
|
$
|
242
|
|
|
$
|
212
|
|
|
$
|
184
|
|
Interest cost
|
|
|
964
|
|
|
|
931
|
|
|
|
746
|
|
Expected return on plan assets
|
|
|
(895
|
)
|
|
|
(1,141
|
)
|
|
|
(980
|
)
|
Amortization of net (gain)/loss
|
|
|
179
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net periodic benefit (credit)/cost
|
|
$
|
490
|
|
|
$
|
2
|
|
|
$
|
(50
|
)
|
The following assumptions were used at the commencement of the year in determining the net periodic pension benefit cost/(credit) for the years ended December 31, 2010, December 31, 2011 and December 31, 2012:
|
|
Year ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
Discount rate
|
|
|
4.7
|
%
|
|
|
5.4
|
%
|
|
|
5.7
|
%
|
Rate of compensation increase
|
|
|
3.5
|
%
|
|
|
4.0
|
%
|
|
|
4.0
|
%
|
Expected rate of return on plan assets
|
|
|
5.8
|
%
|
|
|
7.1
|
%
|
|
|
7.4
|
%
|
Accumulated other comprehensive income
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
December 31,
2010
|
|
|
|
(in thousands)
|
|
Actuarial loss - benefit obligation
|
|
$
|
405
|
|
|
$
|
2,621
|
|
|
$
|
2,232
|
|
Actuarial (gain)/loss – plan assets
|
|
|
(915
|
)
|
|
|
1,744
|
|
|
|
(1,023
|
)
|
Actuarial loss recognized in net periodic
benefit cost
|
|
|
(179
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
(689
|
)
|
|
$
|
4,365
|
|
|
$
|
1,209
|
|
The estimated net gain and prior service cost for the defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next year are $135,000 and $nil respectively.
Amounts recognized in accumulated other comprehensive income that has not yet been recognized as components of net periodic benefit cost are as follows:
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
|
December 31,
2010
|
|
|
|
(in thousands)
|
|
Net actuarial (gain)/loss
|
|
$
|
3,371
|
|
|
$
|
4,060
|
|
|
$
|
(305
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
3,371
|
|
|
$
|
4,060
|
|
|
$
|
(305
|
)
|
Benefit Obligation
The following assumptions were used in determining the benefit obligation at December 31, 2012:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
Discount rate
|
|
|
4.6
|
%
|
|
|
4.7
|
%
|
Rate of compensation increase
|
|
|
3.4
|
%
|
|
|
3.5
|
%
|
The discount rate is determined by reference to UK long dated government and corporate bond yields at the balance sheet date. This is represented by the iboxx corporate bond over 15 year index plus 50 basis points. At December 31, 2012 the Company, with input from its actuarial advisors, refined its estimate of the discount rate used in calculating the benefit obligation and applied an additional 50 basis points to the iboxx corporate bond over 15 year index to reflect the long term nature of the benefit obligation. Had this not been applied and a discount rate of 4.1% used, the benefit obliation at December 31, 2012 would have been $25,577,000.
Plan Assets
The assets of the scheme are invested in the Legal and General Global Equity and Fixed Index Fund. The aim of this fund is to capture the returns on UK and overseas equity markets with a more even investment in UK and overseas equities than would be provided by reference to market capitalization or consensus weights. The expected long-term rate of return on assets at December 31, 2012 of 5.7% was calculated as the value of the fund after application of a market value reduction factor. The expected long term rates of return on different asset classes over the long term are as follows:
Asset Category
|
|
Expected long-term
return per annum
|
|
Equity
|
|
|
5.8
|
%
|
Bonds
|
|
|
4.6
|
%
|
At December 31, 2012 UK gilts were yielding around 2.7% per annum. This is often referred to as the risk free rate of return as UK gilts have a negligible risk of default and the income payments and capital on redemption are guaranteed by the UK Government. The long-term expected return on equities has been determined by setting appropriate risk premiums above the yield on UK gilts. A long term equity “risk-premium” of 3.1% per annum has been assumed, this being the expected long-term out-performance of equities over UK gilts. The long-term expected return on bonds is determined by reference to UK long dated government and corporate bond yields at the balance sheet date. This is represented by the iboxx AA 15 index plus 50 basis points.
The underlying asset split of the fund is shown below.
Asset Category
|
|
December 31,
2012
|
|
|
December 31,
2011
|
|
Equity
|
|
|
90
|
%
|
|
|
90
|
%
|
Bonds
|
|
|
10
|
%
|
|
|
10
|
%
|
|
|
|
100
|
%
|
|
|
100
|
%
|
Applying the above expected long term rates of return to the asset distribution at December 31, 2012, gives rise to an expected overall rate of return of scheme assets of approximately 5.7% per annum.
Plan Asset Fair Value Measurements
|
|
Quoted Prices in Active
Markets for Identical
Assets
|
|
|
|
Level 1
|
|
|
|
(in thousands)
|
|
|
|
|
|
Cash
|
|
$
|
13
|
|
|
|
|
|
|
Equity Securities
|
|
|
|
|
Legal and General UK Equity Index
|
|
|
6,404
|
|
Legal and General North America Equity Index
|
|
|
3,082
|
|
Legal and General Europe (ex UK) Equity Index
|
|
|
3,303
|
|
Legal and General Japan Equity Index
|
|
|
1,637
|
|
Legal and General Asia Pac (ex Japan) Equity Index
|
|
|
1,630
|
|
|
|
|
|
|
Fixed Income Securities
|
|
|
|
|
Legal and General over 15 year Gilts Index
|
|
|
564
|
|
Legal and General AAA-AA-A Bonds Over 15 year Index
|
|
|
597
|
|
Legal and General over 5 year Index-Linked Gilts Index
|
|
|
577
|
|
|
|
|
|
|
|
|
$
|
17,807
|
|
Cash Flows
The Company expects to contribute $0.3 million to its pension fund in the year ending December 31, 2013.
The following annual benefit payments, which reflect expected future service as appropriate, are expected to be paid.
|
|
(in thousands)
|
|
|
|
|
|
2013
|
|
$
|
81
|
|
2014
|
|
|
81
|
|
2015
|
|
|
81
|
|
2016
|
|
|
81
|
|
2017
|
|
|
81
|
|
Years 2018 - 2022
|
|
$
|
406
|
|
The expected cash flows are estimated figures based on the members expected to retire over the next 10 years assuming no early retirements plus an additional amount in respect of recent average withdrawal experience. At the present time it is not clear whether annuities will be purchased when members reach retirement or whether pensions will be paid each month out of scheme assets. The cash flows above have been estimated on the assumption that pensions will be paid monthly out of scheme assets. If annuities are purchased, then the expected benefit payments will be significantly different from those shown above.
10. Equity Incentive Schemes and Stock Compensation Charges
Share Options
On July 21, 2008 the Company adopted the Employee Share Option Plan 2008 (the “2008 Employee Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any employee, or any director holding a salaried office or employment with the Company or a Subsidiary for the purchase of ordinary shares. On the same date, the Company also adopted the Consultants Share Option Plan 2008 (the “2008 Consultants Plan”), pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any consultant, adviser or non-executive director retained by the Company or any Subsidiary for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008 Consultants Plan (together the “2008 Option Plans”) will be an employee stock option, or NSO, as described in Section 422 or 423 of the Internal Revenue Code. Each grant of an option under the 2008 Options Plans will be evidenced by a Stock Option Agreement between the optionee and the Company. The exercise price will be specified in each Stock Option Agreement, however option prices will not be less than 100% of the fair market value of an ordinary share on the date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved under the 2008 Employee Plan as reduced by any shares issued or to be issued pursuant to options granted under the 2008 Consultants Plan, under which a limit of 400,000 shares applies. Further, the maximum number of ordinary shares with respect to which options may be granted under the 2008 Employee Option Plan, during any calendar year to any employee shall be 400,000 ordinary shares. There is no individual limit under the 2008 Consultants Plan. No options may be granted under the 2008 Option Plans after July 21, 2018.
On January 17, 2003 the Company adopted the Share Option Plan 2003 (the “2003 Share Option Plan”) pursuant to which the Compensation and Organization Committee of the Board may grant options to officers and other employees of the Company or its subsidiaries for the purchase of ordinary shares. Each grant of an option under the 2003 Share Option Plan will be evidenced by a Stock Option Agreement between the employee and the Company. The exercise price will be specified in each Stock Option Agreement.
An aggregate of 6.0 million ordinary shares have been reserved under the 2003 Share Option Plan; and, in no event will the number of ordinary shares that may be issued pursuant to options awarded under the 2003 Share Option Plan exceed 10% of the outstanding shares, as defined in the 2003 Share Option Plan, at the time of the grant, unless the Board expressly determines otherwise. Further, the maximum number of ordinary shares with respect to which options may be granted under the 2003 Share Option Plan during any calendar year to any employee shall be 400,000 ordinary shares. No options can be granted after January 17, 2013.
Share option awards are granted with an exercise price equal to the market price of the Company’s shares at date of grant. Share options typically vest over a period of five years from date of grant and expire eight years from date of grant. The maximum contractual term of options outstanding at December 31, 2012 is eight years.
The following table summarizes the transactions for the Company’s share option plans for the years ended December 31, 2012, December 31, 2011 and December 31, 2010:
|
|
Options Granted
Under Plans
|
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weighted
Average Grant
Date Fair
Value
|
|
Outstanding at December 31, 2009
|
|
|
5,408,222
|
|
|
|
5,408,222
|
|
|
$
|
18.99
|
|
|
$
|
7.60
|
|
Granted
|
|
|
1,038,327
|
|
|
|
1,038,327
|
|
|
$
|
24.34
|
|
|
$
|
9.08
|
|
Exercised
|
|
|
(1,237,015
|
)
|
|
|
(1,237,015
|
)
|
|
$
|
10.64
|
|
|
$
|
4.69
|
|
Cancelled
|
|
|
(410,857
|
)
|
|
|
(410,857
|
)
|
|
$
|
25.86
|
|
|
$
|
9.91
|
|
Outstanding at December 31, 2010
|
|
|
4,798,677
|
|
|
|
4,798,677
|
|
|
$
|
21.71
|
|
|
$
|
8.47
|
|
Granted
|
|
|
989,449
|
|
|
|
989,449
|
|
|
$
|
19.66
|
|
|
$
|
8.20
|
|
Exercised
|
|
|
(430,340
|
)
|
|
|
(430,340
|
)
|
|
$
|
10.84
|
|
|
$
|
4.80
|
|
Cancelled
|
|
|
(454,968
|
)
|
|
|
(454,968
|
)
|
|
$
|
25.77
|
|
|
$
|
9.87
|
|
Outstanding at December 31, 2011
|
|
|
4,902,818
|
|
|
|
4,902,818
|
|
|
$
|
21.87
|
|
|
$
|
8.61
|
|
Granted
|
|
|
842,273
|
|
|
|
842,273
|
|
|
$
|
22.01
|
|
|
$
|
9.59
|
|
Exercised
|
|
|
(890,236
|
)
|
|
|
(890,236
|
)
|
|
$
|
14.62
|
|
|
$
|
6.16
|
|
Cancelled
|
|
|
(504,224
|
)
|
|
|
(504,224
|
)
|
|
$
|
25.14
|
|
|
$
|
9.76
|
|
Outstanding at December 31, 2012
|
|
|
4,350,631
|
|
|
|
4,350,631
|
|
|
$
|
23.01
|
|
|
$
|
9.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and exercisable at December 31, 2012
|
|
|
2,256,098
|
|
|
|
2,256,098
|
|
|
$
|
23.54
|
|
|
$
|
9.07
|
|
The weighted average remaining contractual life of options outstanding and options exercisable at December 31, 2012, was 4.67 years and 3.34 years respectively. 756,637 options are expected to vest during the year ended December 31, 2013.
The intrinsic value of options exercised during the year ended December 31, 2012 amounted to $11.7 million. The intrinsic value of options outstanding and options exercisable at December 31, 2012 amounted to $26.0 million and $13.8 million respectively. Intrinsic value is calculated based on the market value of the Company’s shares at December 31, 2012.
Non vested shares outstanding as at December 31, 2012 are as follows:
|
|
Options
Outstanding
Number of Shares
|
|
|
Weighted Average Exercise Price
|
|
|
Weighted Average
Fair Value
|
|
|
|
|
|
|
|
|
|
|
|
Non vested outstanding at December 31, 2011
|
|
|
2,534,310
|
|
|
$
|
23.30
|
|
|
$
|
9.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
842,273
|
|
|
|
22.01
|
|
|
|
9.59
|
|
Vested
|
|
|
(985,264
|
)
|
|
|
23.95
|
|
|
|
9.04
|
|
Forfeited
|
|
|
(296,786
|
)
|
|
|
23.60
|
|
|
|
9.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non vested outstanding at December 31, 2012
|
|
|
2,094,533
|
|
|
$
|
22.43
|
|
|
$
|
9.17
|
|
Outstanding and exercisable share options:
The following table summarizes information concerning outstanding and exercisable share options as of December 31, 2012:
Options Outstanding
|
|
|
Options Exercisable
|
|
Range
Exercise
Price
|
|
|
Number of
Shares
|
|
|
Weighted
Average
Remaining
Contractual Life
|
|
|
Weighted
Average
Exercise Price
|
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
$8.60
|
|
|
|
12,940
|
|
|
|
0.13
|
|
|
$
|
8.60
|
|
|
|
12,940
|
|
|
$
|
8.60
|
|
$10.42
|
|
|
|
20,000
|
|
|
|
1.04
|
|
|
$
|
10.42
|
|
|
|
20,000
|
|
|
$
|
10.42
|
|
$11.00
|
|
|
|
274,767
|
|
|
|
1.09
|
|
|
$
|
11.00
|
|
|
|
274,767
|
|
|
$
|
11.00
|
|
$15.47
|
|
|
|
630
|
|
|
|
4.33
|
|
|
$
|
15.47
|
|
|
|
270
|
|
|
$
|
15.47
|
|
$15.84
|
|
|
|
103,000
|
|
|
|
4.33
|
|
|
$
|
15.84
|
|
|
|
81,800
|
|
|
$
|
15.84
|
|
$16.80
|
|
|
|
150,000
|
|
|
|
6.83
|
|
|
$
|
16.80
|
|
|
|
30,000
|
|
|
$
|
16.80
|
|
$17.17
|
|
|
|
30,000
|
|
|
|
6.85
|
|
|
$
|
17.17
|
|
|
|
6,000
|
|
|
$
|
17.17
|
|
$18.00
|
|
|
|
58,000
|
|
|
|
1.83
|
|
|
$
|
18.00
|
|
|
|
58,000
|
|
|
$
|
18.00
|
|
$18.98
|
|
|
|
9,000
|
|
|
|
3.87
|
|
|
$
|
18.98
|
|
|
|
7,200
|
|
|
$
|
18.98
|
|
$19.45
|
|
|
|
21,000
|
|
|
|
5.82
|
|
|
$
|
19.45
|
|
|
|
1,200
|
|
|
$
|
19.45
|
|
$20.16
|
|
|
|
2,000
|
|
|
|
5.87
|
|
|
$
|
20.16
|
|
|
|
800
|
|
|
$
|
20.16
|
|
$20.28
|
|
|
|
600,547
|
|
|
|
6.17
|
|
|
$
|
20.28
|
|
|
|
149,058
|
|
|
$
|
20.28
|
|
$20.59
|
|
|
|
185,000
|
|
|
|
7.14
|
|
|
$
|
20.59
|
|
|
|
-
|
|
|
$
|
20.59
|
|
$21.25
|
|
|
|
462,831
|
|
|
|
2.12
|
|
|
$
|
21.25
|
|
|
|
462,831
|
|
|
$
|
21.25
|
|
$21.76
|
|
|
|
1,000
|
|
|
|
2.31
|
|
|
$
|
21.76
|
|
|
|
1,000
|
|
|
$
|
21.76
|
|
$22.10
|
|
|
|
800
|
|
|
|
4.56
|
|
|
$
|
22.10
|
|
|
|
-
|
|
|
$
|
22.10
|
|
$22.26
|
|
|
|
415,953
|
|
|
|
4.15
|
|
|
$
|
22.26
|
|
|
|
229,621
|
|
|
$
|
22.26
|
|
$22.30
|
|
|
|
608,073
|
|
|
|
7.32
|
|
|
$
|
22.30
|
|
|
|
-
|
|
|
$
|
22.30
|
|
$22.60
|
|
|
|
2,000
|
|
|
|
2.65
|
|
|
$
|
22.60
|
|
|
|
2,000
|
|
|
$
|
22.60
|
|
$23.20
|
|
|
|
4,000
|
|
|
|
5.70
|
|
|
$
|
23.20
|
|
|
|
1,600
|
|
|
$
|
23.20
|
|
$23.66
|
|
|
|
9,580
|
|
|
|
7.57
|
|
|
$
|
23.66
|
|
|
|
-
|
|
|
$
|
23.66
|
|
$24.25
|
|
|
|
150,000
|
|
|
|
5.18
|
|
|
$
|
24.25
|
|
|
|
150,000
|
|
|
$
|
24.25
|
|
$24.46
|
|
|
|
507,728
|
|
|
|
5.17
|
|
|
$
|
24.46
|
|
|
|
196,667
|
|
|
$
|
24.46
|
|
$26.20
|
|
|
|
2,400
|
|
|
|
5.38
|
|
|
$
|
26.20
|
|
|
|
960
|
|
|
$
|
26.20
|
|
$26.27
|
|
|
|
2,000
|
|
|
|
3.81
|
|
|
$
|
26.27
|
|
|
|
1,600
|
|
|
$
|
26.27
|
|
$26.71
|
|
|
|
12,450
|
|
|
|
7.70
|
|
|
$
|
26.71
|
|
|
|
-
|
|
|
$
|
26.71
|
|
$27.91
|
|
|
|
2,000
|
|
|
|
5.41
|
|
|
$
|
27.91
|
|
|
|
800
|
|
|
$
|
27.91
|
|
$29.45
|
|
|
|
8,000
|
|
|
|
5.32
|
|
|
$
|
29.45
|
|
|
|
3,200
|
|
|
$
|
29.45
|
|
$35.33
|
|
|
|
685,932
|
|
|
|
3.15
|
|
|
$
|
35.33
|
|
|
|
555,384
|
|
|
$
|
35.33
|
|
$36.05
|
|
|
|
6,000
|
|
|
|
3.40
|
|
|
$
|
36.05
|
|
|
|
6,000
|
|
|
$
|
36.05
|
|
$36.20
|
|
|
|
2,000
|
|
|
|
3.33
|
|
|
$
|
36.20
|
|
|
|
1,600
|
|
|
$
|
36.20
|
|
$41.25
|
|
|
|
1,000
|
|
|
|
3.67
|
|
|
$
|
41.25
|
|
|
|
800
|
|
|
$
|
41.25
|
|
$8.60 - $41.25
|
|
|
|
4,350,631
|
|
|
|
4.67
|
|
|
$
|
23.01
|
|
|
|
2,256,098
|
|
|
$
|
23.54
|
|
Options outstanding include both vested and unvested options as at December 31, 2012. Options excercisable represent options which have vested at December 31, 2012. From the date of grant, substantially all options vest over a five year period at 20% per anum.
Fair value of Stock Options Assumptions
The weighted average fair value of options granted during the years ended December 31, 2012, December 31, 2011 and December 31, 2010 was calculated using the Black-Scholes option pricing model. The weighted average fair values and assumptions were as follows:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average fair value
|
|
$
|
9.59
|
|
|
$
|
8.20
|
|
|
$
|
9.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
Expected volatility
|
|
|
50
|
%
|
|
|
45
|
%
|
|
|
45
|
%
|
Dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
|
|
0
|
%
|
Risk-free interest rate
|
|
|
0.83
|
%
|
|
|
1.4
|
%
|
|
|
1.5
|
%
|
Expected life
|
|
5.0 years
|
|
|
5.0 years
|
|
|
4.05 years
|
|
Expected volatility is based on the historical volatility of our common stock over a period equal to the expected term of the options; the expected life represents the weighted average period of time that options granted are expected to be outstanding given consideration to vesting schedules, and our historical experience of past vesting and termination patterns. The risk-free rate is based on the U.S. government zero-coupon bonds yield curve in effect at time of the grant for periods corresponding with the expected life of the option.
Restricted Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted Share Unit Plan (the “2008 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan. An aggregate of 1.0 million ordinary shares have been reserved for issuance under the 2008 RSU Plan. Restricted Share Units (“RSU’s”) typically vest over periods ranging from one to five years. The Company issues new ordinary shares on the date of vesting of the RSU.
The Company has awarded RSU’s to certain key executives of the Group. The following table summarizes RSU activity for the year ended December 31, 2012:
|
|
RSU Outstanding
Number of Shares
|
|
|
Weighted
Average
Fair Value
|
|
|
Weighted
Average
Remaining
Contractual Life
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2011
|
|
|
365,000
|
|
|
$
|
19.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awarded
|
|
|
281,000
|
|
|
$
|
21.64
|
|
|
|
|
Ordinary shares issued
|
|
|
-
|
|
|
|
-
|
|
|
|
|
Forfeited
|
|
|
(150,000
|
)
|
|
$
|
20.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2012
|
|
|
496,000
|
|
|
$
|
20.26
|
|
|
|
1.96
|
|
The fair value of RSU’s vested for the year ended December 31, 2012 totaled $0.0 million (2011: $0.1 million).
Non-cash stock compensation expense
Income from operations for the year ended December 31, 2012 is stated after charging $11.5 million in respect of non-cash stock compensation expense. Non-cash stock compensation expense for the year ended December 31, 2012 has been allocated as follows:
|
|
Year ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
Direct costs
|
|
$
|
6,007
|
|
|
$
|
5,155
|
|
|
$
|
4,049
|
|
Selling, general and administrative
|
|
$
|
4,894
|
|
|
$
|
4,200
|
|
|
$
|
3,359
|
|
Restructuring and other non-recurring items (note 14)
|
|
$
|
620
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total compensation costs
|
|
$
|
11,521
|
|
|
$
|
9,355
|
|
|
$
|
7,408
|
|
Total non-cash stock compensation expense not yet recognized at December 31, 2012 amounted to $19.7 million. The weighted average period over which this is expected to be recognized is 2.87 years. Total tax benefit recognized in additional paid in capital related to the non-cash compensation expense amounted to $1.3 million for the year ended December 31, 2012 (2011: $0.7 million, 2010: $2.3 million).
11. Government Grants
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Received
|
|
$
|
3,473
|
|
|
$
|
3,133
|
|
Less accumulated amortization
|
|
|
(2,148
|
)
|
|
|
(1,994
|
)
|
Foreign exchange translation adjustment
|
|
|
337
|
|
|
|
291
|
|
|
|
|
1,662
|
|
|
|
1,430
|
|
Less current portion
|
|
|
(235
|
)
|
|
|
(79
|
)
|
|
|
$
|
1,427
|
|
|
$
|
1,351
|
|
Capital grants received may be refundable in full if certain events occur. Such events, as set out in the related grant agreements, include sale of the related asset, liquidation of the Company or failure to comply with other conditions of the grant agreements. No loss contingency has been recognized as the likelihood of such events arising has been assessed as remote. Government grants amortized to the profit and loss account amounted to $154,000 and $115,000 for the years ended December 31, 2012 and December 31, 2011 respectively. As at December 31, 2012 the Company had $1.9 million in restricted retained earnings, pursuant to the terms of grant agreements.
12. Share Capital
Holders of ordinary shares will be entitled to receive such dividends as may be recommended by the board of directors of the Company and approved by the shareholders and/or such interim dividends as the board of directors of the Company may decide. On liquidation or a winding up of the Company, the par value of the ordinary shares will be repaid out of the assets available for distribution among the holders of the ordinary shares of the Company. Holders of ordinary shares have no conversion or redemption rights. On a show of hands, every holder of an ordinary share present in person or proxy at a general meeting of shareholders shall have one vote, for each ordinary share held with no individual having more than one vote.
During the year ended December 31, 2012, 890,236 options were exercised by employees at an average exercise price of $14.62 per share for total proceeds of $13.0 million.
During the year ended December 31, 2011, 430,340 options were exercised by employees at an average exercise price of $10.84 per share for total proceeds of $4.7 million. During the year ended December 31, 2011 3,768 ordinary shares were issued in respect of certain RSU’s previously awarded by the Company.
During the year ended December 31, 2010, 1,237,015 options were exercised by employees at an average exercise price of $10.64 per share for total proceeds of $13.2 million. During the year ended December 31, 2010 2,512 ordinary shares were issued in respect of certain RSU’s previously awarded by the Company.
Share Repurchase Program
On October 27, 2011 the Company announced its intention to commence a share repurchase program of up to $50 million. On November 22, 2011 the Company entered into two separate share repurchase plans of up to $10 million each, covering the periods November 23, 2011 to December 31, 2011 and January 1, 2012 to February 20, 2012 respectively. On February 21, 2012 the Company entered into a further share repurchase plan of up to $20 million, covering the period February 22, 2012 to April 22, 2012. On April 27, 2012 the Company entered into a fourth share repurchase plan of up to $20 million, covering the period April 27, 2012 to July 18, 2012
.
On July 30, 2012 the Company entered into a fifth share repurchase plan of up to $10 million, covering the period July 30, 2012 to October 26, 2012
.
Under the repurchase program, a broker purchased the Company’s shares from time to time on the open market or in privately negotiated transactions in accordance with agreed terms and limitations. The program was designed to allow share repurchases during periods when the Company would ordinarily not be permitted to do so because it may be in possession of material non-public or price-sensitive information, applicable insider trading laws or self-imposed trading blackout periods. The
Company’s instructions to the broker were irrevocable and the
trading decisions in respect of the repurchase program were made independently of and uninfluenced by the Company. The Company confirms that on entering the share repurchase plans it had no material non-public
,
price-sensitive
or inside
information regarding the Company or its securities. Furthermore, the Company will not enter into additional plans whilst in possession of such information.
During the year ended December 31, 2012 738,341 ordinary shares were repurchased by the Company for a total consideration of $15.6 million. During the year ended December 31, 2011 545,597 ordinary shares were repurchased by the Company for a total consideration of $9.0 million. As at December 31, 2012 1,283,938 ordinary shares have been repurchased by the Company for a total consideration of $24.6 million. All ordinary shares repurchased by the Company were cancelled, and the nominal value of these shares transferred to a capital redemption reserve fund as required under Irish Company Law.
13. Income Taxes
The Company’s United States and Irish based subsidiaries file tax returns in the United States and Ireland respectively. Other foreign subsidiaries are taxed separately under the laws of their respective countries.
The components of income before provision for income tax expense are as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
12,157
|
|
|
$
|
(33,732
|
)
|
|
$
|
37,298
|
|
United States
|
|
|
11,371
|
|
|
|
13,317
|
|
|
|
12,276
|
|
Other
|
|
|
43,693
|
|
|
|
49,410
|
|
|
|
43,150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income taxes
|
|
$
|
67,221
|
|
|
$
|
28,995
|
|
|
$
|
92,724
|
|
The components of total income tax expense are as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Provision for income taxes:
|
|
|
|
|
|
|
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
Ireland
|
|
$
|
1,684
|
|
|
$
|
351
|
|
|
$
|
4,522
|
|
United States
|
|
|
12,290
|
|
|
|
6,367
|
|
|
|
(1,915
|
)
|
Other
|
|
|
8,257
|
|
|
|
5,518
|
|
|
|
712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current tax
|
|
|
22,231
|
|
|
|
12,236
|
|
|
|
3,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred expense/(benefit):
|
|
|
|
|
|
|
|
|
|
|
|
|
Ireland
|
|
|
(287
|
)
|
|
|
(3,825
|
)
|
|
|
788
|
|
United States
|
|
|
(9,715
|
)
|
|
|
(1,711
|
)
|
|
|
1,322
|
|
Other
|
|
|
(428
|
)
|
|
|
(585
|
)
|
|
|
224
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax expense/(benefit)
|
|
|
(10,430
|
)
|
|
|
(6,121
|
)
|
|
|
2,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
11,801
|
|
|
|
6,115
|
|
|
|
5,653
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact on shareholders equity & OCI of the tax consequence of :
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
|
(1,274
|
)
|
|
|
(681
|
)
|
|
|
(2,345
|
)
|
Currency impact of long term funding
|
|
|
356
|
|
|
|
(294
|
)
|
|
|
198
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
10,883
|
|
|
$
|
5,140
|
|
|
$
|
3,506
|
|
Ireland’s statutory income tax rate is 12.5%. The Company’s consolidated effective tax rate differed from the statutory rate as set forth below;
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Taxes at Irish statutory rate of 12.5% (2011:12.5%; 2012: 12.5%)
|
|
$
|
8,401
|
|
|
$
|
3,625
|
|
|
$
|
11,590
|
|
Foreign and other income taxed at higher/(reduced) rates
|
|
|
7,873
|
|
|
|
5,373
|
|
|
|
(4,765
|
)
|
Research & development tax incentives
|
|
|
(4,954
|
)
|
|
|
(6,341
|
)
|
|
|
(1,927
|
)
|
Movement in valuation allowance
|
|
|
1,557
|
|
|
|
4,362
|
|
|
|
822
|
|
Prior year over provision in respect of foreign taxes
|
|
|
(678
|
)
|
|
|
(83
|
)
|
|
|
(285
|
)
|
Effects of permanent items
|
|
|
(26
|
)
|
|
|
(615
|
)
|
|
|
97
|
|
Other
|
|
|
(372
|
)
|
|
|
(206
|
)
|
|
|
121
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
11,801
|
|
|
$
|
6,115
|
|
|
$
|
5,653
|
|
The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are presented below:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment
|
|
$
|
6,631
|
|
|
$
|
7,331
|
|
|
$
|
6,645
|
|
Goodwill
|
|
|
11,467
|
|
|
|
9,443
|
|
|
|
8,055
|
|
Other intangible assets
|
|
|
2,707
|
|
|
|
3,525
|
|
|
|
223
|
|
Accruals
|
|
|
77
|
|
|
|
1,185
|
|
|
|
149
|
|
Other
|
|
|
88
|
|
|
|
97
|
|
|
|
835
|
|
Unrealised FX
|
|
|
1,160
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities recognized
|
|
|
22,130
|
|
|
|
21,581
|
|
|
|
15,907
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net operating loss carry forwards
|
|
|
25,116
|
|
|
|
21,981
|
|
|
|
16,580
|
|
Property, plant and equipment
|
|
|
2,345
|
|
|
|
1,324
|
|
|
|
882
|
|
Accrued expenses and payments on account
|
|
|
19,382
|
|
|
|
11,652
|
|
|
|
6,607
|
|
Stock options
|
|
|
5,586
|
|
|
|
4,818
|
|
|
|
3,522
|
|
Deferred compensation expense
|
|
|
1,136
|
|
|
|
1,197
|
|
|
|
1,349
|
|
Other
|
|
|
-
|
|
|
|
214
|
|
|
|
90
|
|
Unrealised FX
|
|
|
98
|
|
|
|
-
|
|
|
|
-
|
|
Total deferred tax assets
|
|
|
53,663
|
|
|
|
41,186
|
|
|
|
29,030
|
|
Valuation allowance for deferred tax assets
|
|
|
(18,817
|
)
|
|
|
(16,445
|
)
|
|
|
(12,290
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets recognized
|
|
$
|
34,846
|
|
|
$
|
24,741
|
|
|
$
|
16,740
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax asset
|
|
$
|
12,716
|
|
|
$
|
3,160
|
|
|
$
|
833
|
|
$13.1 million (2011:$10.1 million) of the deferred tax asset of $34.8 million (2011:$24.7 million) above is non-current.
$20.8 million (2011:$20.4 million) of the deferred tax liability of $22.1 million (2011:$21.6 million) is non-current.
At December 31, 2012 non-U.S subsidiaries had operating loss carry forwards for income tax purposes that may be carried forward indefinitely, available to offset against future taxable income, if any, of approximately $94.4 million (2011:$83.1 million). At December 31, 2012 non-U.S. subsidiaries also had additional operating loss carry forwards of $5.8 million which are due to expire between 2013 and 2015.
At December 31, 2012 U.S. subsidiaries, had U.S. Federal and State net operating loss (“NOL”) carry forwards of approximately $9.6 million and $17.9 million, respectively. These net operating losses are available for offset against future taxable income and expire between 2013 and 2032. Of the $9.6 million U.S. Federal and $17.9 million State net operating losses, approximately $8.7 million and $17.0 million are currently available for offset against future U.S. Federal and State taxable income respectively. Annual utilization of these state net operating losses may be limited by specific state rules. The subsidiary’s ability to use the remaining U.S. Federal and State net operating loss carry forwards of $0.9 million and $0.9 million, respectively is further limited to $113,000 per year due to a change of ownership in 2000, as defined by Section 382 of the Internal Revenue Code of 1986, as amended.
The expected expiry dates of these losses are as follows:
|
|
|
Federal
|
|
|
State
|
|
|
|
|
NOL’s
|
|
|
NOL’s
|
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
2013- 2015
|
|
|
$
|
113
|
|
|
$
|
113
|
|
2016- 2020
|
|
|
|
791
|
|
|
|
791
|
|
2021- 2032
|
|
|
|
8,742
|
|
|
|
16,940
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
9,646
|
|
|
$
|
17,844
|
|
In addition US subsidiaries has alternative minimum tax credit carry forwards of approximately $0.3 million that are available to reduce future U.S. federal regular income taxes, over an indefinite period. They also have general business credit carry forwards of approximately $0.3 million that are available to offset future U.S. federal income taxes.
The valuation allowance at December 31, 2012 was approximately $18.8 million. The valuation allowance for deferred tax assets as of December 31, 2011 and December 31, 2010 was $16.4 million and $12.3 million respectively. The net change in the total valuation allowance was an increase of $2.4 million during 2012 and an increase of $4.1 million during 2011.
The valuation allowances at December 31, 2012 and December 31, 2011 were primarily related to tax losses and tax credits carried forward that, in the judgment of management, are not more likely than not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment.
The Company has not recognized a deferred tax liability for the undistributed earnings of foreign subsidiaries that arose in 2012 and prior years as the Company considers these earnings to be indefinitely reinvested.
A reconciliation of the beginning and ending amount of total unrecognized tax benefits is as follows:
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Gross amount of unrecognized tax benefits at start of year
|
|
$
|
6,543
|
|
|
$
|
8,566
|
|
|
$
|
15,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase related to prior year tax positions
|
|
|
1,167
|
|
|
|
304
|
|
|
|
189
|
|
Decrease related to prior year tax positions
|
|
|
-
|
|
|
|
(36
|
)
|
|
|
(3,861
|
)
|
Increase related to current year tax positions
|
|
|
1,473
|
|
|
|
482
|
|
|
|
-
|
|
Settlements
|
|
|
(98
|
)
|
|
|
-
|
|
|
|
(289
|
)
|
Lapse of statute of limitations
|
|
|
(1,896
|
)
|
|
|
(2,773
|
)
|
|
|
(3,328
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross amount of unrecognized tax benefits at end of year
|
|
$
|
7,189
|
|
|
$
|
6,543
|
|
|
$
|
8,566
|
|
The relevant statute of limitations for gross unrealized tax benefits totaling $3.5 million could potentially expire during 2013.
Included in the balance of total unrecognized tax benefits at December 31, 2012 there were net potential benefits of $7.2 million, which if recognized, would affect the effective rate on income tax from continuing operations. The balance of total unrecognized tax benefits at December 31, 2011 and December 31, 2010 included net potential benefits which, if recognized, would affect the effective rate of income tax from continuing operations of $6.5 million and $8.1 million respectively.
Interest and penalties recognized as a net benefit during the year ended December 31, 2012 amounted to $0.1 million (2011: $0.4million) and are included within the provision for income taxes. Total accrued interest and penalties as of December 31, 2012 and December 31, 2011 were $1.1 million and $1.2 million respectively and are included in the closing income tax liabilities at those dates.
Our major tax jurisdictions are the United States and Ireland. We may potentially be subjected to tax audits in all our major jurisdictions. In the United States tax periods open to audit include the years December 31, 2009, December 31, 2010, December 31, 2011 and December 31, 2012. In Ireland tax periods open to audit include the years ended December 31, 2008, December 31, 2009, December 31, 2010, December 31, 2011 and December 31, 2012. During such audits, local tax authorities may challenge the positions taken by us in tax returns.
14. Restructuring and other items
Restructuring and other items recognized during the year ended December 31, 2012 comprise:
|
|
Year Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Restructuring charges
|
|
$
|
4,525
|
|
|
|
9,817
|
|
|
|
-
|
|
Other items
|
|
|
1,111
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net charge
|
|
$
|
5,636
|
|
|
$
|
9,817
|
|
|
|
-
|
|
Restructuring Charges
Restructuring charges of $4.5 million were recorded during year ended December 31, 2012 (inclusive of the release of $0.1 million relating to the 2011 Restructuring Plans). During the year ended December 31, 2012 the Company completed a review of its operations to improve resource utilization throughout the business. This review resulted in the adoption of a restructuring plan, to include resource rationalizations in certain areas of the business and a re-organization of available office space at the Company’s Philadelphia facility. A restructuring charge of $4.6 million was recognized during the year ended December 31, 2012; $3.4 million in respect of resource rationalizations and $1.2 million in respect of lease termination and exit costs.
Details of the movement in this Restructuring Plan recognized during the year ended December 31, 2012 are as follows:
|
|
Workforce
|
|
|
Office
|
|
|
|
|
|
|
Reductions
|
|
|
Consolidations
|
|
|
Total
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Initial provision recognized
|
|
$
|
3,394
|
|
|
$
|
1,250
|
|
|
$
|
4,644
|
|
Cash payments
|
|
|
(3,030
|
)
|
|
|
(824
|
)
|
|
|
(3,854
|
)
|
Foreign exchange movement
|
|
|
(4
|
)
|
|
|
-
|
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision at December 31, 2012
|
|
$
|
360
|
|
|
$
|
426
|
|
|
$
|
786
|
|
Prior Period Restructuring Charges
During the three months ended March 31, 2011 the Company commenced a review of its operations to improve resource utilization within the business and better align resources to current and future growth opportunities of the business. This review resulted in the adoption of an initial restructuring plan (the “Q1 2011 Plan”), which resulted in the closure of the Company’s facility in Edinburgh, United Kingdom and resource rationalizations in certain of the more mature markets in which it operates. A restructuring charge of $5.0 million was recognized in respect of this plan during the three months ended March 31, 2011, $1.0 million in respect of lease termination and exit costs associated with the closure of the Edinburgh facility and $4.0 million in respect of workforce reductions. $3.5 million of costs recognized under the Q1 2011 Plan related to the clinical research segment, while $1.5 million related to the central laboratory business.
During the three months ended September 30, 2011 the Company implemented a further restructuring plan (the “Q3 2011 Plan”) which resulted in the relocation of the Company’s facility in Maryland, USA; and further resource rationalizations. A restructuring charge of $4.8 million was recognized in respect of this plan during the three months ended September 30, 2011, $0.9 million in respect of lease termination and exit costs associated with the closure of the existing Maryland facility and $3.9 million in respect of workforce reductions. All costs recognized under the Q3 2011 Plan related to the clinical research segment.
Details of the movement in the 2011 Restructuring Plans recognized during the years ended December 31, 2011 and December 31, 2012 are as follows:
|
|
Workforce
|
|
|
Office
|
|
|
|
|
|
|
Reductions
|
|
|
Consolidations
|
|
|
Total
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Q1 Plan - initial provision recognized
|
|
$
|
3,956
|
|
|
$
|
1,046
|
|
|
$
|
5,002
|
|
Q3 Plan - initial provision recognized
|
|
|
3,880
|
|
|
|
935
|
|
|
|
4,815
|
|
Total provision recognized
|
|
$
|
7,836
|
|
|
$
|
1,981
|
|
|
$
|
9,817
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash payments
|
|
|
(5,438
|
)
|
|
|
(251
|
)
|
|
|
(5,689
|
)
|
Property, plant and equipment write-off
|
|
|
-
|
|
|
|
(55
|
)
|
|
|
(55
|
)
|
Foreign exchange movement
|
|
|
(164
|
)
|
|
|
(35
|
)
|
|
|
(199
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision at December 31, 2011
|
|
$
|
2,234
|
|
|
$
|
1,640
|
|
|
$
|
3,874
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash payments
|
|
|
(2,146
|
)
|
|
|
(1,203
|
)
|
|
|
(3,349
|
)
|
Amounts released
|
|
|
(32
|
)
|
|
|
(95
|
)
|
|
|
(127
|
)
|
Property, plant and equipment write-off
|
|
|
-
|
|
|
|
(263
|
)
|
|
|
(263
|
)
|
Foreign exchange movement
|
|
|
(20
|
)
|
|
|
25
|
|
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision at December 31, 2012
|
|
$
|
36
|
|
|
$
|
104
|
|
|
$
|
140
|
|
Other Items
On September 30, 2011 Mr. Peter Gray, retired as Chief Executive Officer (“CEO”) of the Company, in accordance with the provisions of his service agreement, which was terminable on twelve months notice by either party. On October 1, 2011 Mr. Gray was appointed Vice Chairman of the Board. On June 11, 2012 the Company entered into an agreement with Mr. Gray whereby Mr. Gray’s employment and directorship of ICON plc and other ICON group companies would terminate on July 19, 2012. Under the terms of this agreement Mr. Gray would be entitled to be paid €160,000 ($200,000) in lieu of the balance of his notice period and to receive a discretionary bonus of €194,000 ($243,000) in respect of 2012. In addition, under the agreement Mr. Gray’s unvested share options would vest on the date of termination of his employment. The Company has recognized a share-based compensation charge of $738,000 in respect of these options during the year ended December 31, 2012, $620,000 of which was recognized within restructuring and other non-recurring items during the three months ended June 30, 2012.
15. Provision for Doubtful Debts
The Company does business with most major international pharmaceutical companies. Provision for doubtful debts at December 31, 2012 comprises:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Opening provision
|
|
$
|
5,526
|
|
|
$
|
3,284
|
|
Amounts used during the year
|
|
|
(756
|
)
|
|
|
(945
|
)
|
Amounts provided during the year
|
|
|
382
|
|
|
|
4,190
|
|
Amounts released during the year
|
|
|
(105
|
)
|
|
|
(1,003
|
)
|
|
|
|
|
|
|
|
|
|
Closing provision
|
|
$
|
5,047
|
|
|
$
|
5,526
|
|
16. Commitments and Contingencies
Litigation
The Company is not party to any litigation or other legal proceedings that the Company believes could reasonably be expected to have a material adverse effect on the Company's business, results of operations and financial condition.
Operating Leases
The Company has several non-cancelable operating leases, primarily for facilities, that expire over the next 10 years. These leases generally contain renewal options and require the Company to pay all executory costs such as maintenance and insurance. The Company recognized $52.5 million, $52.2 million and $46.0 million in rental expense for the years ended December 31, 2012, December 31, 2011 and December 31, 2010 respectively. Future minimum rental commitments for operating leases with non-cancelable terms in excess of one year are as follows:
|
|
Minimum rental payments
|
|
|
|
(in thousands)
|
|
2013
|
|
$
|
40,412
|
|
2014
|
|
|
31,252
|
|
2015
|
|
|
24,827
|
|
2016
|
|
|
20,474
|
|
2017
|
|
|
14,694
|
|
Thereafter
|
|
|
32,267
|
|
|
|
|
|
|
Total
|
|
$
|
163,926
|
|
17. Business Segment Information
The Company is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. It specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. The Company has the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. The Company has expanded predominately through internal growth, together with a number of strategic acquisitions to enhance its expertise and capabilities in certain areas of the clinical development process. The Company also provides laboratory services through its central laboratory business, which includes the Company’s central laboratories located in Dublin, New York, India, Singapore and China.
The Company determines and presents operating segments based on the information that is internally provided to the Chief Executive Officer and Chief Financial Officer, who together are considered the Company’s chief operating decision maker, in accordance with FASB ASC 280-10
Disclosures about Segments of an Enterprises and Related Information
. The Company has determined that it has two reportable segments, its Clinical Research segment and Central Laboratory segment.
The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Finland, Denmark, Belgium, Switzerland, Poland, Czech Republic, Lithuania, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa.
Segment information as at December 31, 2012 and December 31, 2011 and for the years ended December 31, 2012, December 31, 2011 and December 31, 2010 is as follows:
a) The distribution of net revenue by geographical area was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Ireland
|
|
$
|
171,977
|
|
|
$
|
88,869
|
|
|
$
|
128,790
|
|
Rest of Europe
|
|
|
338,537
|
|
|
|
348,492
|
|
|
|
292,567
|
|
U.S.
|
|
|
471,700
|
|
|
|
393,957
|
|
|
|
381,196
|
|
Other
|
|
|
132,792
|
|
|
|
114,411
|
|
|
|
97,491
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,115,006
|
|
|
$
|
945,729
|
|
|
$
|
900,044
|
|
b)
|
The distribution of net revenue by business segment was as follows:
|
|
|
|
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
87,467
|
|
|
$
|
71,549
|
|
|
$
|
63,813
|
|
Clinical research
|
|
|
1,027,539
|
|
|
|
874,180
|
|
|
|
836,231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,115,006
|
|
|
$
|
945,729
|
|
|
$
|
900,044
|
|
c)
|
The distribution of income from operations by geographical area was as follows:
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2012
|
|
|
2012
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including
Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
11,733
|
|
|
$
|
(2,074
|
)
|
|
$
|
9,659
|
|
Rest of Europe
|
|
|
29,786
|
|
|
|
(546
|
)
|
|
|
29,240
|
|
U.S.
|
|
|
23,687
|
|
|
|
(2,651
|
)
|
|
|
21,036
|
|
Other
|
|
|
8,447
|
|
|
|
(365
|
)
|
|
|
8,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
73,653
|
|
|
$
|
(5,636
|
)
|
|
$
|
68,017
|
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2011
|
|
|
2011
|
|
|
2011
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
(33,139
|
)
|
|
$
|
(1,564
|
)
|
|
$
|
(34,703
|
)
|
Rest of Europe
|
|
|
35,175
|
|
|
|
(3,000
|
)
|
|
|
32,175
|
|
U.S.
|
|
|
30,127
|
|
|
|
(5,253
|
)
|
|
|
24,874
|
|
Other
|
|
|
7,097
|
|
|
|
-
|
|
|
|
7,097
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
39,260
|
|
|
$
|
(9,817
|
)
|
|
$
|
29,443
|
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2010
|
|
|
2010
|
|
|
2010
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
36,636
|
|
|
|
-
|
|
|
$
|
36,636
|
|
Rest of Europe
|
|
|
24,212
|
|
|
|
-
|
|
|
|
24,212
|
|
U.S.
|
|
|
25,017
|
|
|
|
-
|
|
|
|
25,017
|
|
Other
|
|
|
6,230
|
|
|
|
-
|
|
|
|
6,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
92,095
|
|
|
|
-
|
|
|
$
|
92,095
|
|
d)
|
The distribution of income from operations by business segment was as follows:
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2012
|
|
|
2012
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
4,059
|
|
|
$
|
(158
|
)
|
|
$
|
3,901
|
|
Clinical research
|
|
|
69,594
|
|
|
|
(5,478
|
)
|
|
|
64,116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
73,653
|
|
|
$
|
(5,636
|
)
|
|
$
|
68,017
|
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2011
|
|
|
2011
|
|
|
2011
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
Central laboratory
|
|
$
|
(661
|
)
|
|
$
|
(1,545
|
)
|
|
$
|
(2,206
|
)
|
Clinical research
|
|
|
39,921
|
|
|
|
(8,272
|
)
|
|
|
31,649
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
39,260
|
|
|
$
|
(9,817
|
)
|
|
$
|
29,443
|
|
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2010
|
|
|
2010
|
|
|
2010
|
|
|
|
Excluding Restructuring
and other
items, net
|
|
|
Restructuring
and other
items, net
|
|
|
Including Restructuring
and other
items, net
|
|
|
|
(in thousands)
|
|
Central laboratory
|
|
$
|
(12,759
|
)
|
|
|
-
|
|
|
$
|
(12,759
|
)
|
Clinical research
|
|
|
104,854
|
|
|
|
-
|
|
|
|
104,854
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
92,095
|
|
|
|
-
|
|
|
$
|
92,095
|
|
e)
|
The distribution of property, plant and equipment, net, by geographical area was as follows:
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
110,369
|
|
|
$
|
109,953
|
|
Rest of Europe
|
|
|
16,115
|
|
|
|
16,419
|
|
U.S.
|
|
|
32,400
|
|
|
|
33,086
|
|
Other
|
|
|
9,489
|
|
|
|
9,003
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
168,373
|
|
|
$
|
168,461
|
|
f)
|
The distribution of property, plant and equipment, net, by business segment was as follows:
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Central laboratory
|
|
$
|
17,138
|
|
|
$
|
18,292
|
|
Clinical research
|
|
|
151,235
|
|
|
|
150,169
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
168,373
|
|
|
$
|
168,461
|
|
g) The distribution of depreciation and amortization by geographical area was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
17,885
|
|
|
$
|
15,192
|
|
|
$
|
11,840
|
|
Rest of Europe
|
|
|
7,211
|
|
|
|
7,057
|
|
|
|
5,543
|
|
U.S.
|
|
|
13,865
|
|
|
|
12,427
|
|
|
|
12,422
|
|
Other
|
|
|
3,862
|
|
|
|
4,006
|
|
|
|
4,068
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
42,823
|
|
|
$
|
38,682
|
|
|
$
|
33,873
|
|
h) The distribution of depreciation and amortization by business segment was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
4,142
|
|
|
$
|
3,721
|
|
|
$
|
4,888
|
|
Clinical research
|
|
|
38,681
|
|
|
|
34,961
|
|
|
|
28,985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
42,823
|
|
|
$
|
38,682
|
|
|
$
|
33,873
|
|
i) The distribution of total assets by geographical area was as follows:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
476,159
|
|
|
$
|
414,510
|
|
Rest of Europe
|
|
|
236,305
|
|
|
|
216,313
|
|
U.S.
|
|
|
437,756
|
|
|
|
355,577
|
|
Other
|
|
|
51,888
|
|
|
|
41,117
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,202,108
|
|
|
$
|
1,027,517
|
|
j) The distribution of total assets by business segment was as follows:
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Central laboratory
|
|
$
|
73,304
|
|
|
$
|
54,361
|
|
Clinical research
|
|
|
1,128,804
|
|
|
|
973,156
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,202,108
|
|
|
$
|
1,027,517
|
|
k) The distribution of capital expenditures by geographical area was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
12,406
|
|
|
$
|
16,987
|
|
|
$
|
16,095
|
|
Rest of Europe
|
|
|
2,506
|
|
|
|
4,795
|
|
|
|
5,869
|
|
U.S.
|
|
|
13,389
|
|
|
|
10,222
|
|
|
|
5,852
|
|
Other
|
|
|
4,725
|
|
|
|
4,001
|
|
|
|
3,777
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
33,026
|
|
|
$
|
36,005
|
|
|
$
|
31,593
|
|
l) The distribution of capital expenditures by business segment was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
2,375
|
|
|
$
|
1,449
|
|
|
$
|
3,991
|
|
Clinical research
|
|
|
30,651
|
|
|
|
34,556
|
|
|
|
27,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
33,026
|
|
|
$
|
36,005
|
|
|
$
|
31,593
|
|
m) The following table sets forth the clients which represented 10% or more of the Company's net revenue in each of the periods set out below.
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
Client A
|
|
|
18
|
%
|
|
|
*
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Client B
|
|
|
12
|
%
|
|
|
13
|
%
|
|
|
*
|
|
* Net revenue did not exceed 10%.
n) The distribution of interest income by geographical area was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
464
|
|
|
$
|
762
|
|
|
$
|
1,277
|
|
Rest of Europe
|
|
|
661
|
|
|
|
364
|
|
|
|
406
|
|
U.S.
|
|
|
3
|
|
|
|
18
|
|
|
|
22
|
|
Other
|
|
|
23
|
|
|
|
50
|
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,151
|
|
|
$
|
1,194
|
|
|
$
|
1,761
|
|
o) The distribution of interest income by business segment was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
3
|
|
|
$
|
18
|
|
|
$
|
20
|
|
Clinical research
|
|
|
1,148
|
|
|
|
1,176
|
|
|
|
1,741
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
1,151
|
|
|
$
|
1,194
|
|
|
$
|
1,761
|
|
p) The distribution of the tax charge by geographical area was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
Ireland
|
|
$
|
1,216
|
|
|
$
|
(3,475
|
)
|
|
$
|
5,310
|
|
Rest of Europe
|
|
|
3,298
|
|
|
|
657
|
|
|
|
(1,606
|
)
|
U.S.
|
|
|
3,669
|
|
|
|
4,656
|
|
|
|
(593
|
)
|
Other
|
|
|
3,618
|
|
|
|
4,277
|
|
|
|
2,542
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
11,801
|
|
|
$
|
6,115
|
|
|
$
|
5,653
|
|
q) The distribution of the tax charge by business segment was as follows:
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Central laboratory
|
|
$
|
(3,169
|
)
|
|
$
|
(175
|
)
|
|
$
|
(2,858
|
)
|
Clinical research
|
|
|
14,970
|
|
|
|
6,290
|
|
|
|
8,511
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
11,801
|
|
|
$
|
6,115
|
|
|
$
|
5,653
|
|
18. Supplemental Disclosure of Cash Flow Information
|
|
Year ended
|
|
|
|
December
|
|
|
December
|
|
|
December
|
|
|
|
2012
|
|
|
2011
|
|
|
2010
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash interest on acquisition consideration payable*
|
|
$
|
940
|
|
|
$
|
743
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
602
|
|
|
$
|
388
|
|
|
$
|
833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
$
|
18,475
|
|
|
$
|
22,723
|
|
|
$
|
14,634
|
|
* recorded within interest expense
19. Accumulated Other Comprehensive Income
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2012
|
|
|
2011
|
|
|
|
(in thousands)
|
|
Currency translation adjustments
|
|
$
|
12,103
|
|
|
$
|
7,609
|
|
Currency impact on long term funding
|
|
|
(18,931
|
)
|
|
|
(20,913
|
)
|
Tax on currency impact on long term funding
|
|
|
1,184
|
|
|
|
1,540
|
|
Actuarial loss on defined benefit pension plan (note 9)
|
|
|
(3,371
|
)
|
|
|
(4,060
|
)
|
Unrealised capital gain/(loss) – investments (note 3)
|
|
|
239
|
|
|
|
(622
|
)
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
(8,776
|
)
|
|
$
|
(16,446
|
)
|
20. Impact of New Accounting Pronouncements
In July 2012, the FASB issued ASU No. 2012-02, Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment. ASU 2012-02 allows an organization to first assess qualitative factors to determine whether it is necessary to perform the quantitative impairment test for indefinite-lived intangible assets. An organization that elects to perform a qualitative assessment is required to perform the quantitative test for indefinite-lived intangible asset if it is more likely than not that the asset is impaired. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company does not expect the adoption of ASU 2012-02 to have a material impact on the financial statements.
In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210
): Disclosures about Offsetting Assets and Liabilities
. ASU 2011-11 requires an entity to disclose information about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on its financial position, and to allow investors to better compare financial statements prepared under U.S. GAAP with financial statements prepared under International Financial Reporting Standards (IFRS). ASU 2011-11 is effective retrospectively for fiscal years beginning after January 1, 2013. The Company does not expect the adoption of ASU 2011-11 to have a material impact on the financial statements.
In September 2011, the FASB issued ASU No. 2011-08 Intangibles - Goodwill and Other (Topic 350):
Testing Goodwill for Impairment
. ASU 2011-08 permits an entity to make a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount before applying the two-step goodwill impairment test. If an entity concludes it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, it need not perform the two-step impairment test. ASU 2011- 08 is effective for fiscal years beginning after December 15, 2011. The Company does not expect the adoption of ASU 2011-08 to have a material impact on the financial statements.
In June 2011, the FASB issued ASU No. 2011-05, Comprehensive Income (Topic 220):
Presentation of Comprehensive Income.
ASU 2011-05 permits an entity to present the components of net income and comprehensive income in either one or two consecutive financial statements. The ASU eliminates the option in U.S. GAAP to present other comprehensive income in the statement of changes in equity. An entity should apply the ASU retrospectively. ASU 2011-05 is effective for fiscal years ending after December 15, 2012. In December 2011, the FASB decided to defer the effective date of those changes in ASU 2011-05 that relate only to the presentation of reclassification adjustments in the statement of income by issuing ASU 2011-12, Comprehensive Income (Topic 220):
Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive income in Accounting Standards Update 2011-05.
The Company does not expect the adoption of ASU 2011-05 to have a material impact on the financial statements.
In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement (Topic 820):
Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.
ASU 2011-04 provides guidance about how fair value should be applied where it already is required or permitted under IFRS or U.S. GAAP. For U.S. GAAP, most of the changes are clarifications of existing guidance or wording changes to align with IFRS. ASU 2011- 04 is effective prospectively for interim and annual periods beginning after December 15, 2011. The Company does not expect the adoption of ASU 2011-04 to have a material impact on the financial statements.
21. Related Parties
On July 19, 2012, Mr. Peter Gray retired as a Director and employee of the Company. The Company subsequently entered into an agreement with Integritum Limited, a company controlled by Mr. Gray, for the provision of consultancy services for a period of two years from August 1, 2012, at an agreed fee of €265,000 ($350,000) per annum.
On December 31, 2009, Dr. John Climax retired as Chairman of the Board of the Company. From January 2010 he has held the position as an outside director of the Company. The Company entered into an agreement with Rotrua Limited, a company controlled by Dr. Climax for the provision of consultancy services for a period of three years from January 1, 2010, at an agreed fee of €262,500 ($346,000) per annum. The consultancy agreement expired in December 2012. The agreement provided that the Company would provide during the term of the agreement permanent disability and life insurance coverage for Dr. Climax and medical insurance cover for himself and his dependants.
22. Subsequent Events
Acquisition of the Clinical Trial Services Division of Cross Country Healthcare, Inc.
On February 15, 2013 the Company acquired the clinical trial services division of Cross Country Healthcare Inc. for an initial cash consideration of $51.9 million. Further consideration of up to $3.75 million may become payable if certain performance milestones are achieved during the period ended December 31, 2013. Cross Country Healthcare’s Clinical Trial Services Division’s services include contract staffing, permanent placement and functional service provision. The division also includes AKOS, a leading US and EU provider of pharmacovigilance and drug safety services. ClinForce and Assent will be combined with ICON’s FSP division, DOCS, creating a leader in global resourcing and FSP, while AKOS will enhance the services offered by ICON’s medical and safety services team.
The following table summarizes the Company’s provisional estimates of the fair values of the assets acquired and the liabilities assumed:
|
|
February 15
|
|
|
|
2013
|
|
|
|
(in thousands)
|
|
Property, plant and equipment
|
|
$
|
367
|
|
Cash and cash equivalents
|
|
|
939
|
|
Accounts receivable
|
|
|
11,614
|
|
Prepayments and other current assets
|
|
|
442
|
|
Income taxes receivable
|
|
|
2,646
|
|
Accounts payable
|
|
|
(306
|
)
|
Other liabilities
|
|
|
(2,380
|
)
|
Non-current other liabilities
|
|
|
(156
|
)
|
|
|
|
|
|
Total
|
|
$
|
13,166
|
|
It is anticipated that goodwill arising from the acquisition of the clinical trial services division of Cross County Healthcare Inc. will comprise an established workforce with experience in the clinical research industry, thereby allowing the Company to enhance its capabilities in global resourcing and FSP and also medical and safety services. Other intangible assets are expected to comprise of customer relationships.
SIGNATURES
The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.
|
|
ICON plc
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Brendan Brennan
|
Date March 6, 2013
|
|
Brendan Brennan
|
|
|
Chief Financial Officer
|
INDEX TO EXHIBITS
Exhibit
Number
|
|
Title
|
|
|
|
3.1*
|
|
Memorandum and Articles of Association of the Company (Amended as of December 17, 2012).
|
|
|
|
10.1*
|
|
Office Space Lease, dated November 20, 2012, between ICON Clinical Research SARLand MS Capitole SCI.
|
|
|
|
12.1*
|
|
Section 302 certifications.
|
|
|
|
12.2*
|
|
Section 906 certifications.
|
|
|
|
21.1
|
|
List of Subsidiaries (incorporated by reference to Item 4 of Form 20-F filed herewith).
|
|
|
|
23.1*
|
|
Consent of KPMG, Independent Registered Public Accounting Firm
|
|
|
|
101.1*
|
|
Interactive Data Files (XBRL – Related Documents)
|
* Filed herewith
ICON (NASDAQ:ICLR)
過去 株価チャート
から 6 2024 まで 7 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 7 2023 まで 7 2024